

## ***CURRICULUM VITAE***

May 1, 2024

**JESSE ROMAN, MD, ATSF, FACCP, FACP, FSSCI**

Ludwig Kind Professor of Medicine  
Professor, Pharmacology & Experimental Therapeutics  
CEO, Jane & Leonard Korman Respiratory Institute of  
Jefferson Health and National Jewish Health  
Director, Division of Pulmonary, Allergy & Critical Care  
Enterprise Leader, Respiratory Medicine, Jefferson Health  
Thomas Jefferson University, Philadelphia, PA  
Medical Director, Jefferson/National Jewish Health Respiratory  
Therapy Training Program



Editor-In-Chief, American Journal of the Medical Sciences  
Treasurer & Executive Committee Member, American Thoracic Society

### **Education**

1976-79 BS, General Sciences, University of Puerto Rico, San Juan, PR  
1979-83 MD, University of Puerto Rico School of Medicine, San Juan, PR

### **Postgraduate Training and Fellowship Appointments**

1983-86 Internal Medicine Internship & Residency, San Juan VAMC, PR  
1986-89 Pulmonary / Critical Care Medicine Fellowship  
Washington Univ. Sch of Medicine, St. Louis, MO  
1989-91 Postdoctoral Research Training, Washington Univ. Sch of Medicine  
St. Louis, MO (John A. McDonald, MD, PhD, mentor)

### **Military or Government Service**

1983-86 Resident at San Juan VA Medical Center, San Juan, Puerto Rico  
1986-87 Fellow at St. Louis VA Medical Center, St. Louis, Missouri  
2009-17 Staff physician at Atlanta VA Medical Center, Atlanta, Georgia  
2009-18 Staff physician at Louisville VA Medical Center, Louisville, Kentucky

### **Faculty Appointments**

1989-91 Instructor in Medicine, Washington Univ., St. Louis, MO  
1991-97 Assistant Professor of Medicine, Emory University, Atlanta, GA  
1997-03 Tenured Associate Professor of Medicine, Emory University, Atlanta, GA  
2003-09 Tenured Professor of Medicine, Emory University, Atlanta, GA  
2009-18 Tenured Professor of Medicine (University of Louisville, primary appointment)  
2009-18 University of Louisville Distinguished University Scholar

2010-2018 Secondary appointment in Pharmacology & Toxicology (UofL, secondary)  
 2018-pres Professor, Department of Medicine, University of Louisville, KY (*Gratis*)  
 2018-pres Ludwig Kind Endowed Professor of Medicine, Thomas Jefferson University  
 2018-pres Professor of Pharmacology & Experimental Therapeutics, Thomas Jefferson Univ.

**Prior hospital, administrative, and other appointments**

1991-99 Medical Director, Respiratory Therapy, Atlanta VAMC, GA  
 1991-94 Assistant Chief, Pulmonary & Crit. Care Sect., Atlanta VAMC, GA  
 1994-00 Chief, Pulmonary & Critical Care Section, Atlanta VAMC, GA  
 1997-00 Associate Director for Research, Pulmonary Division, Emory University  
 1998-01 Associate Director for Research, Atlanta Sarcoidosis Center  
 2002-05 Director, Emory Adult Cystic Fibrosis Program  
 2004 Interim Section Chief, Pulmonary/CCM, Emory Univ. Hospital  
 2002-07 Director, The Emory Interstitial Lung Disease Center  
 2005-07 Co-Director, Aerodigestive / Lung Cancer Program  
 2007-09 Associate VP & Center Director, Emory Center for Respiratory Health  
 2007-09 Director, Respiratory Care & PFT Lab, Emory Northlake Hospital  
 2007-09 Associate Director for Research, Interstitial Lung Disease Program  
 2002-09 Director, Division of Pulmonary, Allergy & Critical Care Med  
 2009-17 Chief of Medicine, University of Louisville Hospital  
 2009-17 Chair of Medicine, University of Louisville, Louisville, KY  
 2009-17 President & Board Chairman, University Medical Associates, PSC  
 2009-14 President, University Medical Foundation  
 2009-13 Board Member, University Physician Associates, PSC  
 2009-13 Member, Executive Committee, University Physician Associates  
 2009-14 Member, Council School of Medicine, University of Louisville  
 2009-2011 Member, Board of Passport Healthcare  
 2010-14 Secretary, University Physician Associates, PSC  
 2010-17 Secretary-Treasurer, UofL Medical School Fund, Inc.  
 2011-17 Member, Executive Committee, Univ. of Louisville Physicians

**Prior hospital, administrative, and other appointments (continuation)**

2011-14 Interim Senior Associate Dean for Clinical Research, UofL  
 2012-17 Secretary, University of Louisville Physicians, PSC  
 2012-17 Faculty, Graduate Research Training Program, UofL  
 2013-17 Chief, UofL Division of Pulmonary, CCM, Sleep Medicine  
 2014-15 Director, Pulmonary Function Laboratory, UofL Outpatient Center  
 2017 Physician Engagement Taskforce, ULH/UL/KOH Transition  
 2018-2022 Director, Pulmonary & Critical Care Fellowship Program (TJU)

**Specialty Certification**

1986 American Board of Internal Medicine (Specialty)  
 1989 Board of Pulmonary Disease (Subspecialty)

## Licensures

1984	Diplomate, National Board of Medical Examiners
1984	Puerto Rico Board of Medical Examiners (expired)
1986	State Missouri Board of Medical Examiners, #R8G32 (expired)
1992	State Georgia Board of Medical Examiners, #037059 (expired)
2009-pres	State Kentucky Board of Medical Licensure, #43402
2015-17	Most recent Advanced Cardiac Life Support Recertification (ACLS)
2015-17	Most recent Basic Cardiac Life Support Recertification (BCLS)
2018-pres	State Pennsylvania Licensing, #MD464010

## Awards, Honors, Membership in Honorary Societies

1979	<i>Magna Cum Laude</i> , General Science, University of Puerto Rico, PR
1988	NRSA Fellowship, National Heart, Lung, and Blood Institute, NIH
1988	American Lung Association Research Fellowship, Am Lung Association
1989	<i>Minority Travel Award</i> , American Society for Cell Biology
1990	<i>Biomedical Research Support Award</i> , Washington Univ., St. Louis, MO
1990	<i>Minority Medical Faculty Development Award</i> , R W Johnson Foundation
1991	Department of Veterans Affairs Research Advisory Group Award
1991	<i>Young Faculty Award</i> , Am Fed of Clin Research, Southern Section
1992	American Lung Association Research Award
1992	Elected Member, Society of Experimental and Biological Medicine
1992	Grant-in-Aid, American Heart Association
1994	Elected Member, Southern Society Clinical Investigation
1995	<i>Tinsley R. Harrison Award</i> (for best 1995 paper in Am J Med Sci)
1995	<i>Fellow</i> , American College of Chest Physicians
1995	Listed in Marquis Who's Who in America
1995	Listed in Sterling's Who's Who in America
1998	<i>Established Investigator Award</i> , American Heart Association
2001	<i>President</i> , Georgia Thoracic Society

## Awards, Honors, Membership in Honorary Societies (continuation)

2002	<i>Fellow</i> , The Woodruff Leadership Academy (WLA), First Class
2004	<i>Mentorship Award</i> , J. Willis Hurst Internal Medicine Residency Program
2004	<i>Outstanding Team Award</i> for clinical service at the VA Medical Center
2003-pres	Listed yearly in <i>Best Doctors in America</i> since 2003
2006	<i>Silver Pear Mentoring Award</i> for Faculty Mentorship, Emory DOM
2009	One of two finalists for <i>Secretary-Treasurer</i> of American Thoracic Society
2009-10	<i>President</i> , Southern Society for Clinical Investigation
2010, 11, 12	Named " <i>One Of The Most Influential Health Care Business Leaders In Greater Louisville</i> ", Business First, Louisville, KY
2011	<i>Fellow</i> , American College of Physicians
2011	<i>Fight for Life Award</i> , American Lung Association (with Rodney Folz)
2011	Elected, faculty member of <i>Alpha Omega Alpha</i> Honor Medical Society
2012	<i>Presidential Commendation</i> ; Research and Finance, American Thoracic Society

- 2012, 14 Named in *America's Top Physicians*  
2012-pres *Top Doctor*, Castle Connolly and US News & World Report  
2012, 18-20 Named in *Top Doctors*, Louisville Magazine  
2013 *Tinsley R. Harrison Award* (for best 2012 paper in Am J Med Sci to Viranuj Sueblinvong; Roman was senior author and mentor)  
2013-15 *Partner in Healthcare*, Business First, Louisville, KY (designates most influential healthcare business leaders in the community)  
2014 President's *Supervisor of the Year Award*, University of Louisville  
2014 *Founders Medal*, Southern Society for Clinical Investigation  
2014 *Presidential Commendation*, Health Equality, American Thoracic Society  
2015 President's *Outstanding Scholarship, Research, and Creative Activity Award for Career Achievement*, University of Louisville  
2016 *Key To Our Success Award*, Hermansky Pudlak Syndrome Network  
2017 *Top Doctor*, Hermansky Pudlak Syndrome Network  
2019 *AL DIA Top Doctors Award*, for a distinguished medical career, Philadelphia, PA  
2019 *World of Difference Award*, (with Drs. de Jesus, Rivera, Egozcue and Roman). Hermansky Pudlak Syndrome Network Annual Meeting, Long Island, NY  
2019-pres *Castle Connolly Top Doctors*, Philadelphia Magazine  
2021 *SKCM Student Scholarship Honoree* (related to Algernon B. Jackson Scholarship)  
2023 Named *Fellow* of the American Thoracic Society (ATSF)  
2022-25 *Treasurer*, American Thoracic Society  
2023 *William J. Martin II Distinguished Achievement Award*, ATS-PAR  
2023 *SKMC Dean's Team Award for Innovation: Interstitial Lung Disease Program* (with Dr. Ross Summer and others)  
2024 *Above & Beyond Award*, Hermansky Pudlak Syndrome Network

### **Membership in Professional and Scientific Societies**

Association of Professors of Medicine

Member, Board of Directors (2013-2015); Secretary-Treasurer (2014-17)

Member, Robert H. Williams Award Selection Committee (2012-17)

### **Membership in Professional and Scientific Societies (continuation)**

Southern Society for Clinical Investigation (Fellow)

Editor, Am J Med Sci and Officer (2017-2021; re-elected for 2021-2026)

Member, Publications, Finance, Mentoring, Development Committees (2023- )

Member, External Advisory Committee, (2010-17); Abstract reviewer (2010-pres)

Chair, Fund Raising Committee (2011-17)

Membership Committee (2006-09; 2012; Chair from 2012-17)

Chair, Nominations Committee (2010-11)

Past President (2010), President (2009), President-Elect (2008)

Councilor (2003-2008)

Reviewer, Young Investigator Awards (2006-08) and abstracts (2012-pres)

Alliance for Academic Internal Medicine

Member, Finance Committee (2014-17); Member, Diversity Committee (2010-17)

American Thoracic Society (Fellow)

Treasurer & Executive Committee Member, American Thoracic Society (2022-25)  
Chair, Finance Committee (2022-pres)  
Funds for the Future Committee (2022-23)  
Nominations Committee (2020-pres); Awards Committee (2018-pres)  
Chair (2015-18), Vice-Chair (2013-1015), Health Equality Committee  
Member, Board of Directors, American Thoracic Society (2012 – 14)  
Chair, Respiratory Cell & Molecular Biology Assembly (2012 - 14)  
Reviewer, ATS GEMSSTAR grant applications.  
Chair-Elect, Respiratory Cell & Molecular Biology Assembly (2011- 2012)  
Chair, Task Force on Research Development, ATS Research Foundation (2012-13)  
Chair, Scientific Advisory Committee (2010-12); Chair of study sections  
Member, Steering Committee, Division Director's Group (2008-09;10-12)  
ATS Foundation Research Dinner Committee (2011)  
One of two final nominees for ATS Secretary-Treasurer (2009)  
Member, Steering Committee, Division Director's Group (2008-09)  
Member, Executive Committee RCMB Assembly (2008-09)  
Member, Scientific Advisory Committee (2008-09; 2009-10)  
Chair, Planning Committee of RCMB Assembly (2008-09; 2009-10)  
Minority Travel Award Subcommittee (2007-13)  
Highlighted in *Who's Who in ATS*, July issue, 2007  
ATS International Conference Committee (2005-07)  
Program Chair-Elect, RCMB Assembly (2005-06), Chair (2006-07)  
ATS Program Review Subcommittee (2003-04)  
The Veterans's Research Fellowship Committee (2003-04)  
Planning Committee (1998-01; 07-08)  
Research Advocacy Committee (2001-05, 07-09)  
Nominating Committee (2002-04; 2015-2016)  
National Scientific Review Committee (1999-00)  
RCMB Assembly Program Committee (2002-05; 2010-2012)

**Membership in Professional and Scientific Societies (continuation)**

American Thoracic Society (continuation)

RCMB Assembly Planning Committee (2002-05; 07-08)  
ATS Revenue Development Committee (2003-04)  
Membership Committee (1995-97; Chair 1997)

American Lung Association

Board Member, ALA Midland States (2012-2017)  
Mission Committee, ALA Midland States (Vice Chair, 2013-14; Chair, 2014-pres)

Pulmonary Fibrosis Foundation

Chair, Medical Advisory Committee, Pulmonary Fibrosis Foundation (2014-17)  
Chair, Research Advisory Committee (2011-14)  
Reviewer, Scientific Poster Session during PFF Summit (2011, 2013, 2015-2017)

PFF Grant Application reviewer (member, scientific review committee) (2011-pres)

American College of Chest Physicians (Fellow)  
Editorial Board, CHEST (2006-2019)  
Grant Reviewer, CHEST Foundation Awards, (2013-2019)  
Co-chair, Cultural Diversity Subcommittee (1996-97)  
Fellow (2011-pres)

Society for Critical Care Medicine (2021-pres)  
Collaborative Committee (2022-pres)  
Respiratory Care Section (2022-pres)

PF Warriors  
Member, Medical Advisory Committee (2023-pres)

Association of Pulmonary & Critical Care Medicine Program Directors  
Member (2018-22)

Alpha Omega Alpha Honorary Medical Society (2011-22)

American College of Physicians (Fellow; 2011-pres)

Louisville Innominate Society  
Member (2010-17); President (2017)

Georgia Chapter American Lung Association:  
Past-President (03-04); President (01-03); President-Elect (1999-01)  
Secretary (1997-99)  
Personnel Committee (2003-04)  
Executive Committee (1996-99; 2003-04)  
Finance Committee (2003-04); Chair, Sci. Rev. Committee (1996-97, 99-01)

Society Memberships prior to 2001:  
American Society for Matrix Biology (until 2007)  
American Society for Cell Biology (until 2000)  
American Association for the Advancement of Science (until 2000)  
Society for Experimental Biology and Medicine (until 2000)  
Cardiopulmonary Council of the American Heart Association (until 1997)  
American Federation of Medical Research (1995-2000)  
Kentucky Medical Association (2010-13)  
Greater Louisville Medical Society (2009-13)

### **Editorial Positions / Efforts**

2017-pres     Editor-In-Chief, *American Journal of Medical Sciences*  
2020-21     Lead Co-Editor, American Thoracic Society Interstitial Lung Disease (ILD)  
Primers: <https://www.thoracic.org/education-center/ild/primer.html>

- Solomon et al. Connective Tissue Disease-ILD, released 2021.
  - Kurkarni et al. Pulmonary Fibrosing-ILD, released 2021.
  - Evans et al. Hypersensitivity Pneumonitis, released 2022.
  - Sharp et al. Sarcoidosis, expected release in 2024.
- 2021-22 Guest editor, CHEST Physician supplement on Progressive Fibrosing ILDs. [https://cdn.mdedge.com/files/s3fspublic/bipi\\_supplement\\_to\\_chest\\_physician\\_may2021\\_final.pdf](https://cdn.mdedge.com/files/s3fspublic/bipi_supplement_to_chest_physician_may2021_final.pdf)
- 2009-pres Member, Editorial Board of *American J of Respiratory & Crit Care Med*
- 2017-pres Member, Editorial Board, *UofL Journal of Infectious Diseases*
- 2006-2019 Member, Editorial Board of *CHEST*
- 2014-18 Member, Editorial Board, *Austin J of Pulmonary & Respiratory Medicine*
- 2014-18 Member, Editorial Board, *Austin – Critical Care Journal*
- 2012-14 Member, Editorial Board, *Air & Water Borne Diseases*
- 2011 Guest Editor, Special Issue, Idiopathic Pulmonary Fibrosis, *Am J Med Sci*
- 2011 Co-Editor, Special Issue, PPAR $\gamma$  in lung biology. *PPAR Research*
- 2010-12 Member, Editorial Board of *Thoracic Cancer*
- 2008-13 Member, Editorial Board of *Clinical and Translational Science*
- 2008-12 Member, Editorial Board of *The Chinese Journal of Lung Cancer*
- 1998 Assistant Editor, American Journal of Medical Sciences
- 1997 Guest Co-Editor, Issue on Cellular Mechanisms of Lung Development, *Experimental Lung Research*, volume 23, number 2, March-April.
- 2007-13 Member, Editorial Board of *The Open Biology Journal*,
- 2007 Co-Editor, Special issue, PPARs-lung biology & disease, *PPAR Research*

*Manuscript Reviewer (ad hoc)*

- American Journal of Respiratory Cell and Molecular Biology  
 American Journal of Respiratory and Critical Care Medicine (editorial board member)  
 American Journal of Physiology (Lung Cell and Molecular Physiology)  
 Chest (editorial board member)  
 American Journal of Physiology (Cell Physiology)  
 American Journal Pathology

*Manuscript Reviewer (ad hoc) (continuation)*

- American Journal of the Medical Sciences (Editor-In-Chief)  
 Other: Journal of Clinical Investigation, Journal of Immunology, PLoS ONE, The Int J of Biochemistry & Cell Biology, Cancer Res, Journal of Invest Medicine, Lung Exp Res, Blood, Alcohol, Histochemical J, J of Cell Physiol, Tuberculosis, Anatom Record, Microbes and Infection, British J Pharmacology, British Med Journal, Respir Res, Dev Biol, Experimental Cell Research, American Journal of Transplantation, Cancer, Wound Repair and Regeneration, Journal of Cellular Biochemistry, Thorax, Journal of Applied Physiology, Journal Lab & Clinical Medicine

**Administrative / Academic Committees a Thomas Jefferson University**

- 2023-pres Medical Director, Respiratory Therapy Program
- 2018-21 Member, Cancer Screening Program Committee
- 2018-pres Lung Transplantation Initiative Committee
- 2018-20 Member, Respiratory Therapy Advisory Group, Thomas Jefferson University

2020-pres Member, COVID-19 Clinical Task Force  
2022-pres Clinical Steering Committee Member, Specialty Care Pavilion  
2022-pres Member, New Honickman Center Change Champion Network

### **Major Teaching and Clinical Responsibilities at Thomas Jefferson University**

2018-2022 Program Director, Pulmonary & Critical Care Fellowship Program  
2018-pres Member, Interstitial Lung Disease Program Clinical and Research program

### **Lectures by Invitation**

May 2024 Panelist, Post Graduate Course: A primer on health equity research for clinical, translational, and basic scientists. ATS Meeting, San Diego, CA.

May 2024 Speaker, Lung fibrosis and lung transplantation in HPS. HPS Program, San Juan, PR.

Feb 2024 Organizer and speaker, Session on Strategies for Successful Careers in Academic Medicine. SRM, Southern Society for Clinical Investigation, New Orleans, LA

Feb 2024 Speaker, two lectures: 1) Progressive Pulmonary Fibrosis, and 2) Familial Pulmonary Fibrosis. Respir Update – Post-MECOR Meeting, Bangalore and New Delhi, India.

Nov 2023 Speaker and Panelist, Familial IPF and Hermansky Pudlak Syndrome (HPS). IPF Summit, Pulmonary Fibrosis Foundation, Orlando, FL.

Sep 2023 Speaker, Genetics of IPF and implications for Latino community. 11<sup>th</sup> Annual Respiratory Congress, San Juan, Puerto Rico.

May 2023 Speaker #1, Association of circulating metabolites with disease severity and mortality in patients with idiopathic pulmonary fibrosis (IPF): data from the IPF-PRO Registry.  
Speaker #2: My Story. American Thoracic Society Meeting, Washington D.C.

### **Lectures by Invitation (continuation)**

Feb 2023 Speaker, Grand Rounds: Aging and lung fibrosis. University of Alabama, Birmingham, AL.

Jan 2023 Speaker, Update on idiopathic pulmonary fibrosis. First Winter Congress on Pulmonary Disorders, San Juan, Puerto Rico.

Dec 2022 Speaker, Progressive Pulmonary Fibrosis. Medical Grand Rounds San Juan VA Medical Center, University of Puerto Rico, San Juan, Puerto Rico.

Nov 2022 Speaker, Progressive-fibrosing interstitial lung disease (PF-ILD). 22<sup>nd</sup> Annual Convention of Puerto Rican Pulmonary Society. Rio Grande, Puerto Rico.



- Nov 2022 Speaker, Academic Medicine – the more it changes, the more it stays the same. Ohio State University, Columbus, OH.
- Oct 2022 Mentor and Speaker, Young Investigators Forum. National Jewish Health, Denver, CO.
- May 2022 Speaker, A career as a physician scientist – From medicine to humanism. Diversity Forum, American Thoracic Society (ATS) Meeting, San Francisco, CA, USA.
- May 2022 Lecturer: “Addressing disparities in lung disease – the Puerto Rico experience.” ATS Public Advisory Roundtable (PAR) Symposium. ATS Meeting San Francisco, CA.
- May 2022 Lecturer: Aging and lung remodeling. Accomplished Scientist Seminar. National Jewish Health, Denver, CO.
- Mar 2022 Panelist, Healthcare and Advocacy (Mar 5), Latino Medical Students Association (LMSA) Annual Meeting, Philadelphia, PA; Judge for Poster presentations (Mar 4)
- Mar 2022 Lecturer: “Nicotinic receptors and alcohol-related tissue injury”. National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD.
- Aug 2021 Workshop co-leader and speaker: 1) Aging, senescence and IPF. 2) Novel tools and models for studying IPF. Virtual IPF Summit.
- Nov 2020 Panelist/speaker, Drug-induced ILD. BI Advisory Board (virtual meeting).
- Nov 2020 Panelist, Virtual Discussion on Lung Cancer. Medicina y Salud Publica
- Jul 2020 Panelist, Real World Data from Patients with IPF. ATS / BI, a virtual symposium.
- Sep 2020 Speaker and panelist, The early and accurate diagnosis and treatment of IPF and PF-ILD. Respiratory Institutes national webinar.
- Lectures by Invitation (continuation)**
- Nov 2019 Speaker, Roland Ingram Memorial Lecture, Division of Pulmonary, Allergy and CCM, Emory University, Atlanta, GA
- Nov 2019 Speaker, Fundamentals of IPF: Navigating the patient journey. Toms River, NJ.
- Oct 2019 Speaker, Systemic sclerosis interstitial lung disease: a multidisciplinary approach to diagnosis, treatment and longitudinal management. 2019 CHEST Meeting, NO, LA.
- Oct 2019 Speaker, ‘A career in health: mentoring, science and heart’. Esperanza College, PA.
- Sep 2019 Speaker, Interstitial Lung Disease; Symposium titled: ‘The next level in pulmonary care. The France Foundation. Philadelphia, PA

- Sep 2019 Speaker, Grand Rounds titled: Interstitial Lung Disease. Abington Hospital, PA.
- May 2019 Panelist on “How to lead teams”, Members in Transition and Training Committee. Center for Career Development. Annual Int Am Thorac Soc meeting, Dallas, TX.
- Feb 2019 Speaker, Pathways for navigating ILD and IPF. Program by Natl. Jewish Health, Philadelphia, PA.
- Aug 2018 Speaker, ILD Classification & Research. Seventh Annual Respiratory Congress & First Pulmonary Hypertension PR Summit, Isla Verde, Puerto Rico.
- May 2018 Speaker, Redox stress & lung remodeling in HIV. ATS Meeting, San Diego, CA.
- May 2018 Panelist, ‘Hints and tips on leadership in medicine’. Center for Career Development at the annual ATS Meeting, San Diego, CA.
- Apr 2018 Speaker, Pulmonary Fibrosis. HPS Education Day, San Juan, PR.
- Apr 2018 Participant, IPF Collaborative Design Meeting, OptumLabs, Boston, MA.
- Mar 2018 Speaker, Pulmonary fibrosis in Puerto Rico. Annual Hermansky-Pudlak Network Meeting, Long Island, NY.
- Sep 2017 Speaker, Diagnosis and management of pulmonary fibrosis. 58<sup>th</sup> Annual Convention of University of Puerto Rico Alumni Association. San Juan, PR.
- Aug 2017 Speaker, Novel insights in idiopathic pulmonary fibrosis. 6<sup>th</sup> Respiratory Congress, Coalition of Asthma and Other Chronic Respiratory Conditions. San Juan, PR.
- Jun 2017 Speaker, Pulmonary Fibrosis in Hermansky Pudlak Syndrome. Symposium on Explaining Hermansky Pudlak Syndrome for Patients. San Juan, PR
- Lectures by Invitation (continuation)**
- May 2017 Speaker, Year In Review, Health Equality. International American Thoracic Society Meeting in Washington DC.
- May 2017 Speaker, Sc17a11 and redox stress in aging lung fibroblasts. International American Thoracic Society Meeting in Washington DC.
- Mar 2017 Speaker on: 1) *Sarcoidosis*, 2) *Idiopathic Pulmonary Fibrosis*, 3) *Connective Tissue-Related Interstitial Lung Disorders*, and 4) *Environmental factors and lung injury/repair*. 10<sup>th</sup> Seminary of the International Association of Pneumology & Tisiology of Santa Catarina, Florianopolis, Brazil.

- Mar 2017 Speaker on: “Puerto Rico Center for Pulmonary Fibrosis” during the Hermansky Pudlak Syndrome Network Meeting, Long Island, NY.
- Jan 2017 Speaker on “*Pulmonary Fibrosis-diagnosis, management and new insights*”. Grand Rounds, Department of Medicine, University of Puerto Rico, San Juan, Puerto Rico, and at Ponce Sciences University, Ponce, Puerto Rico
- May 2016 Co-Chair, Workshop on Respiratory Health in Migrants and Refugees to be held in conjunction with American Thoracic Society Meeting in Washington DC.
- Aug 2016 Lecture on “*Pulmonary Fibrosis*” delivered during the 5<sup>th</sup> Respiratory Congress, San Juan, Puerto Rico. Lecture on *Idiopathic Pulmonary Fibrosis* delivered at Caribbean VA Medical Center and the San Juan Hospital as well. San Juan, Puerto Rico.
- May 2016 Panelist, “How to successfully compete for an academic job: What division directors want and do not want in candidates”. MITT Committee; to be presented during the 2016 International American Thoracic Society Meeting, San Francisco, CA.
- May 2016 Speaker: Redox potential and tissue remodeling in HIV. Session during the 2016 International American Thoracic Society Meeting, San Francisco, CA.
- May 2016 Co-chair, Respiratory Health in Migrant Populations. Mini-symposium during the 2016 International American Thoracic Society Meeting, San Francisco, CA.
- Mar 2016 Participant, Hermansky Pudlak Syndrome Network Scientific Session. Held during annual meeting, Long Island, NY
- Feb 2016 Speaker, Chairs-Residents Meeting. Lecture: Preparing faculty and trainees for the new academic model. Annual Southern Societies Meeting, New Orleans, LA
- Feb 2016 Lecturer at 1) Municipal Hospital, University of Puerto Rico (San Juan); 2) Auxilio Mutuo Hospital (San Juan), and 3) Mayaguez Medical Center, Ponce School of Medicine(Mayaguez). Lecture: Pulmonary Fibrosis. San Juan and Mayaguez, PR.
- Lectures by Invitation (continuation)**
- Feb 2016 Lecturer to the CATO Society of Louisville. Lecture: Pulmonary Fibrosis: From Science and Medicine to Humanism. Louisville, KY.
- Jan 2016 Lecturer at the Skin Winter Meeting. Lectures: 1) Sarcoidosis and 2) Advances in Internal Medicine. Park City, UT.
- Nov 2015 Abstract reviewer, plenary session panel co-leader, and faculty. Pulmonary Fibrosis Foundation Summit. Washington DC.
- Aug 2015 Speaker, Internal Medicine Grand Rounds. Medical University of South Carolina, SC.

- May 2015 Session co-chair and participant, NIH/ATS Workshop on Health Equality. Denver, Colorado (held in conjunction with ATS meeting).
- May 2015 Speaker, Fibrosis and Cancer: Crossroads or Merging Traffic. Scientific Symposium. American Thoracic Society Meeting, Denver, CO.
- Apr 2015 Keynote Speaker, Lung Transitional Remodeling: Implications for lung health and disease. Pulmonary Research Day, Washington University, St. Louis, MO
- Mar 2015 Participant, Hermansky Pudlac Syndrome Network Annual Meeting, Long Island, NY
- Dec 2014 Speaker, Dr. John McClement Grand Rounds, New York University Langone Medical Center, New York, NY.
- Nov 2014 Speaker, 20th Annual Pulmonary Evening Grand Rounds. Lecture: Mechanisms of action of new anti-fibrotic drugs. St. Lukes Hospital, St. Louis, MO.
- June 2014 Speaker, 2014 Sunnyside Guild Grand Rounds (Named Lecture). Lecture: Nicotinic receptors in lung health and disease. Implications for asthma, injury, cancer & aging.
- May 2014 Speaker, Meet the Professor Seminar: Career Strategies for junior investigators. American Thoracic Society, San Diego, CA.
- May 2014 Speaker, *Aging, redox stress, and transitional remodeling of lung extracellular matrices*. In Symposium: Cellular and Molecular Determinants of the Aging Lung. American Thoracic Society, San Diego, CA.
- May 2014 Featured Speaker, *Aging and ECM – contributions to lung disease*; for the 2014 Scientific Breakthrough Session. American Thoracic Society, San Diego, CA.
- May 2014 Facilitation: Poster Discussion Session B29 – Its what's outside that matters: lung extracellular matrix. American Thoracic Society, San Diego, CA.

**Lectures by Invitation (continuation)**

- Apr 2014 Moderator, Speaker, and Co-Chair: Fibrosis Across Species Workshop. Louisville, KY
- Dec 2013 Chief Fellow Visiting Professor, Lecture: Lung tissue remodeling – implications for health and disease. The Ohio State University, OH
- Nov 2013 Speaker, Simposio sobre EPOC (Symposium on COPD). Lecture: Genes, epigenetics and nicotinic receptors in COPD. University of Zaragoza, Zaragoza, Spain
- Oct 2013 Plenary Speaker, Munich Lung Conference on Lung Aging – Molecular mechanisms and clinical relevance. Lecture: ECM remodeling in the aging lung. German Center for Lung Research, Munich, Germany.

- Jun 2013 Speaker and Visiting Professor, Lecture: Transitional Remodeling – an overarching hypothesis of pre-disease states in lung. Texas Tech, Lubbock, TX
- May 2013 Speaker: Inflammation, Matrix, and Cancer Progression. Symposium on Immune cells, inflammation and cancer. American Thoracic Society, Philadelphia, PA
- May 2013 Speaker: Role of Cys/CySS redox potential in aging and in idiopathic pulmonary fibrosis. American Thoracic Society, Philadelphia, PA.
- Apr 2013 Speaker and Visiting Professor, Grand Rounds, Department of Medicine Research Day, University of Mississippi, Jackson, MS.
- Nov 2012 Speaker, Louisville Innominate Society, Lecture: Bailey Asford – A soldier, a scientist, a pioneer. Louisville, KY
- Nov 2012 Participant, Workshop on Strategic Planning of IPF research. Lecture: Aging matrix and oxidant stress in lung. Sponsored by The Lung Branch of NHLBI, National Institutes of Health, Bethesda, Maryland.
- Oct 2012 Speaker, Mouse Healthspan: Why Lifespan Is No Longer Enough. Lecture: Pulmonary function in aging. 2012 San Antonio Nathan Shock Center Conference on Aging. San Antonio, TX
- Jan 2012 Speaker – Papper Lecture/Grand Rounds, Lecture: Transitional remodeling in lung. University of Oklahoma, Oklahoma
- Nov 2011 Speaker, Air Quality and Health Panel, Festival of Faiths. Lecture: Biomass burning and global health. Louisville, KY.
- Sep 2011 Speaker, Hermansky-Pudlak Scientific Meeting, Lecture: TGF $\beta$  in lung fibrosis. National Institutes of Health Workshop, Bethesda, MD.

**Lectures by Invitation (continuation)**

- Sep 2011 Speaker, Update in Lung Disease Symposium, Lecture #1: Idiopathic Pulmonary Fibrosis; Lecture #2: Connective tissue related interstitial lung disease. University of Michigan, Ann Arbor, MI.
- June 2011 Speaker: Nicotine-induced fibronectin: a marker of disease susceptibility. Aspen Lung Conference, Aspen, CO.
- Sept 2011 Visiting Professor, University of Michigan. 2011 Update in Pulmonary and Critical Care. Speaker: 1) Idiopathic Pulmonary Fibrosis and 2) Connective tissue related interstitial lung disease, Ann Arbor, MI.

- May 2011 Co-Chair and Speaker, Symposium on Prenatal exposures and their impact on adult lung disease. To be presented during the 2011 International ATS Meeting, Denver, CO.
- May 2011 Lead Facilitator, Thematic Poster Session on Novel Therapeutics in Pulmonary Fibrosis. 2011 Annual American Thoracic Society Meeting, Denver, CO
- Feb 2011 Speaker and Co-Chair, Workshop on Career Development; Lecture: *Careers in Academic Medicine*; Annual Meeting of Southern Society for Clinical Investigation, New Orleans, LA.
- Jan 2011 Visiting Professor, Grand Rounds Lecture: Subclinical Lung Tissue Remodeling – A biomarker of disease susceptibility. Louisiana State University, New Orleans, LA.
- Dec 2010 *William H. Anderson, MD, Memorial Pulmonary Lecture*; Idiopathic Pulmonary Fibrosis. Norton Healthcare Internal Medicine Update. Louisville, KY.
- May 2010 Co-Chair, Mini-symposium on *Translational Research In Interstitial Lung Disease*. To be presented during the 2010 International ATS Meeting, New Orleans, LA.
- May 2010 Speaker, Post-Graduate Course - *Pro and Con Session on Critical Care Models*. American Thoracic Society Meeting, New Orleans, LA.
- May 2010 Facilitator, Session on *Fibroblast matrix, cytoskeleton, and migration*. American Thoracic Society Meeting, New Orleans, LA.
- May 2010 Speaker, IPFnet session, *Ancillary studies of the IPFnet*. American Thoracic Society Meeting, New Orleans, LA.
- May 2010 Speaker, Symposium: *Matrix production and remodeling in lung development and disease*. Lecture: *Extracellular matrix and lung development*. American Thoracic Society Meeting, New Orleans, LA.

**Lectures by Invitation (continuation)**

- May 2010 Co-chair and speaker, Symposium: *Nicotinic acetylcholine receptors in lung health and disease*. Lecture: *Nicotinic receptors and lung tissue remodeling*. American Thoracic Society Meeting, New Orleans, LA.
- May 2010 Speaker, Symposium: *PPARs and lung disorders*. Lecture: *Roles of PPAR $\gamma$  and PPAR $\beta/\delta$  in lung cancer*. American Thoracic Society Meeting, New Orleans, LA.
- May 2010 Speaker, 2010 Pulmonary Care Symposium. Kentucky ALA, Bowling Green, KY.
- Jul 2009 Visiting Professor, Lecture: *Tumor cell-stromal interactions in lung cancer* Zhongshan Hospital, Fudan University, Shanghai, PR China.

- Jul 2009 Keynote Lecture: *Tumor cell-stromal interactions in lung cancer*. The 8<sup>th</sup> Chinese National Conference on Tumor Metastasis, Tianjin, PR China
- May 2009 Co-Chair and Speaker, Symposium on *Targeting tumor microenvironment in lung cancer*, American Thoracic Society, San Diego, CA
- May 2009 Co-Chair, Mini-symposium on *Lung Tumorigenesis: Insights from Animal Models*, American Thoracic Society, San Diego, CA
- May 2009 Facilitator, Thematic Poster Session: *Pulmonary Fibrosis - The Fibroblast*, to be held during the *American Thoracic Society, San Diego, CA*
- Dec 2008 Invited Participant, *Cell-based therapies in lung disease*. Athersys, Atlanta, GA.
- Oct 2008 Visiting Professor, Lecture: *Mechanisms of lung fibrosis*. Northwestern University, Chicago, IL.
- Aug 2008 Speaker, Lecture: *Presentation skills*. National IDEA Symposium, Washington, DC.
- Jul 2008 Lecture: *Interstitial Lung Disease*. Georgia Lung Associates, Austell, GA.
- May 2008 Facilitator for Thematic Poster Presentation: *Interstitial Lung Disease-Mechanisms of Action*; Facilitator for Thematic Poster Presentation: *Lung Fibrosis*; American Thoracic Society International Meeting, Montreal, Canada
- Feb 2008 Lecturer, Emory Mini Medical School. Lecture: *Respiratory Health: How the lungs work and stay well*. Emory University, Atlanta, GA.
- Apr 2008 Visiting Professor, Lecture: *Subclinical states of lung tissue remodeling: implications for health and disease*. UCLA, Los Angeles, CA.

#### **Lectures by Invitation (continuation)**

- Mar 2008 Visiting Professor, Lectures: 1) *The clinical scientist and translational research* (Clinical Research Center), 2) *Pre-clinical states of lung tissue remodeling: implications for lung health and disease* (Grand Rounds University Hospital); 3) *Role of tumor cell-stromal interactions in lung cancer* (Grand Rounds in San Juan VA Medical Center). University of Puerto Rico School of Medicine, San Juan, PR.
- Feb 2008 Visiting Professor, Lecture: *Pre-clinical state of lung tissue remodeling: implications for lung health and disease*. Tulane University, New Orleans, LA.
- Feb 2008 Speaker, Southern Society for Clinical Investigation. Lecture: *Tissue remodeling in lung inflammation, injury and repair, and cancer*. New Orleans, MI

- Oct 2007 Participant/Speaker, IPF Canine/Human Conference, Lafayette, IN.
- May 2007 Speaker, Session on NHLBI IPF Clinical Trials Network – Status of Patient Studies and Future Plans. Lecture: *Clinical Trials: the best strategy for finding a cure for IPF*. International American Thoracic Soc Conf to be held in San Francisco, CA.
- May 2007 Speaker, Symposium on The biology of nicotine: Newly recognized roles in lung disease. Lecture: *Nicotine and nicotinic acetylcholine receptor-mediated signals in lung disease*. Facilitator, Session on Acute and Chronic Lung Injury. International American Thoracic Society Conference to be held in San Francisco, CA.
- May 2007 Visiting Professor, University of Nebraska, Omaha. Lecture for Division Grand Rounds: Tumor cell-stromal interactions in lung cancer. VA Research Week Keynote Speaker: *Regulation of lung tissue remodeling by nicotine and ethanol: Implications for lung function in health and disease*. Grand Rounds: *Idiopathic Pulmonary Fibrosis and related disorders*.
- Apr 2007 Visiting Professor, University of Pennsylvania. Lecture: *Lung tissue remodeling in pre-clinical states. Mechanisms of action and implications for lung disease*.
- Apr 2007 Speaker, Symposium on PPAR $\gamma$ : a novel molecular target in lung disease. Lecture: *PPAR $\gamma$  and lung cancer*. Experimental Biology Meeting 2007 to be held in Washington DC.
- Mar 2007 Speaker, Aerodigestive and Lung Cancer Symposium, Winship Cancer Institute, Emory. Lecture: *Tumor cell-stromal interactions in lung cancer pathobiology*.
- Jan 2007 Elkin Lecture: *The Matrix Reloaded: How the lung matrix contributes to lung cancer*. Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
- Oct 2006 Visiting Professor, University of Tennessee – Memphis. Lecture: *Connective tissue related fibrosing lung disease: clinical presentation, treatment, and novel findings*.
- Lectures by Invitation (continuation)**
- Jul 2006 Speaker, Institutional Development Award (IDeA) Program Symposium. Career Development Program; Lecture: *Presentation Skills*. To be held in Washington, DC.
- Jun 2006 Speaker, 12<sup>th</sup> International Course on Advancements in Pulmonary and Critical Care Medicine, Lima, Peru. Lectures: (1) *Idiopathic Pulmonary Fibrosis: Novel therapies*. (2) *Connective tissue disease related interstitial lung disease*. (3) *Chronic alcohol abuse and susceptibility to acute lung injury via activation of tissue remodeling*. (4) *Tobacco exposure and lung development*. (5) *Tissue remodeling in chronic rejection after lung transplantation*. (6) *Tumor cell-stromal interactions in the pathogenesis of lung cancer*. (7) *Session discussant: Clinical cases of lung disease*.



- May 2006 Speaker, *Aberrant signaling in fibrosing lung disease*. American Thoracic Society, San Diego, CA.
- Apr 2006 Visiting Professor, Lecture: *Consequences of subclinical lung tissue remodeling*, Mount Sinai Hospital, New York, NY
- Mar 2006 Speaker, *Faces of Tuberculosis Patients Seen by the Health Care Provider*, World TB Day, Center for Disease Control and Prevention, Atlanta, GA
- May 2005 Co-Chair, Symposium: *Targeting Lung Cancer*. American Thoracic Society International Meeting, San Diego, CA. Speaker: *Targeting lung matrix: role of integrins and extracellular matrices in lung cancer*.
- May 2005 Visiting Professor, Lecture: *COPD*; Palm Beach VA, Palm Beach, FL
- Oct 2004 Visiting Professor, Lecture: *Control of lung inflammation by extracellular matrices*. Wyeth, Cambridge, MA.
- Sept 2004 Speaker: *Tissue Remodeling: A key process in pulmonary tuberculosis*. Working Group on the Genetics of Tuberculosis. NHLBI, NIH, Bethesda, Maryland.
- Sept 2004 Speaker: Destin Pulmonary/CCM Conference. Lecture: *Collagen vascular disease and interstitial lung disease*. Destin, Florida.
- Aug 2004 Visiting Professor, University of Minnesota, Lecture: *Nicotine-induced modulation of fibronectin expression: implications for lung development, injury/repair, and carcinogenesis*. Minneapolis, Minnesota.
- May 2004 Lecture: *Matrix, integrins and lung cancer*. Symposium to be held at American Thoracic Society Meeting, Orlando, FL.
- May 2004 Meet-the-Professor Seminar: *Regulation of inflammation by extracellular matrices*. American Thoracic Society Meeting, Orlando, FL.
- Lectures by Invitation (continuation)**
- Aug 2003 Lecturer, Matrix Metalloproteinases in Lung Disease. Symposium: Research Advancements in Lung Disease. Sponsored by Emory University, Destin, FL, 2002
- Jun 2003 Visiting Professor, University of South California; Lecture: Tissue remodeling in the lung – Control of fibronectin gene expression.
- June 2003 Speaker, *Asthma: Pitfalls in Diagnosis and Management*. Symposium on Asthma and COPD, sponsored by GlaxoWellcome and Intellyst, Atlanta, GA
- May 2003 Session facilitator, Thematic Poster Session on *Smoking, COPD, oxidants and immune mechanisms*, American Thoracic Society Meeting, Seattle, GA.

- Nov 2002 Speaker, Regulation of fibronectin expression in lung fibroblasts. Department of Medicine Research Conference, Emory University, Atlanta, GA.
- Aug 2002 Lecturer, Molecular targets in Idiopathic Pulmonary Fibrosis. Symposium: Lung Disease. Chair: Session on Interstitial Lung Diseases. Sponsored by Emory University, Destin, FL, 2002 (scheduled)
- May 2002 Lecturer, *Induction of Tissue Remodeling Genes by M. tuberculosis*. 2002 Annual International Meeting of the American Thoracic Society, Atlanta, GA.
- May 2002 Meet-the-Professor Seminar, *Lung destruction in mycobacteria infection*. 2002 Annual International Meeting of the American Thoracic Society, Atlanta, GA
- May 2002 Meet-the-Professor Seminar, *Cellular mechanisms of lung development*. 2002 Annual International Meeting of the American Thoracic Society, Atlanta, GA
- Mar 2002 Lecturer, *New insights in the pathophysiology of asthma: Implications for management*. Chateau Elan, Georgia. Mini-symposium on Asthma (sponsored by AstraZeneca).
- Nov 2001 Lecturer, *Inflammation and tissue remodeling in the lung: Lessons for IPF*. Tampa Pulmonary Group, Tampa, FL.
- Oct 2001 Lecturer, *Regulation of fibronectin gene transcription in fibroblasts via nicotinic acetylcholine receptors: Implications for acute lung injury*. Meeting on Lung Injury and Repair, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
- Oct 2001 Lecturer, *Strategies for the development of a national center for minority affairs and cultural diversity*. Northwestern University, Chicago, IL.
- Jul 2001 Speaker, *Lung Disease: Inflammation and Beyond*. Sponsored by the Georgia Thoracic Society and AstraZeneca, Ritz Carlton Hotel, Atlanta, GA.
- Lectures by Invitation (continuation)**
- Jul 2001 Visiting Professor, Saint Louis University School of Medicine, Saint Louis, MO
- May 2001 Speaker, *Nicotine acetylcholine receptors and fibronectin expression in lung*. Mini-symposium on Cell-Matrix Interactions, Annual American Thoracic Society Meeting, San Francisco, CA.
- May 2001 Lecturer, *Pathophysiology of obstructive airways disease*. Symposium on Asthma and COPD, Sponsored by Emory University and the Georgia Thoracic Society, Atlanta, GA
- Jan 2001 Lecture: *Pulmonary Fibrosis: Novel links between inflammation and tissue remodeling*. Visiting Professor, Pulmonary, Allergy, and Critical Care Division, University of Pittsburgh, PA.

- Aug 2000 Lecturer, *Control of inflammation in COPD and Mechanical ventilation in COPD*. Symposium on Advances in Pulmonary Medicine, Sponsored by Emory University, Sandestin, FL.
- Jun 2000 Speaker, *Gelatinases in Sarcoidosis*. Annual Thomas L. Petty Lung Conference, Aspen, CO. Topic: Pulmonary Fibrosis.
- Oct 1999 Visiting Professor, National Institute of Environmental Health Sciences, Research Triangle, NC. Lecture: *Tissue remodeling in lung injury and repair*.
- Sep 1999 Participant and small group leader, Workshop on *Fibrin turnover in lung inflammation and neoplasia*. Sponsored by the NHLBI, National Institutes of Health, Washington, D.C.
- Aug 1999 Invited Speaker, *Idiopathic Pulmonary Fibrosis: Role of tissue remodeling and Asthma: A review*. Symposium on Advances in Pulmonary Medicine, Sponsored by Emory University, Sandestin, FL.
- Apr 1999 Invited Speaker, *Tissue remodeling in lung transplantation*. Symposium on Lung Transplantation, International American Thoracic Society Meeting, San Diego, CA.
- Apr 1999 Invited Speaker, *Mechanisms of  $\alpha5\beta1$  integrin expression in monocytes by lipopolysaccharide*. Symposium on Lung Inflammation, International American Thoracic Society Meeting, San Diego, CA.
- Nov 1998 Tobacco Lung Disease Conference, Sponsored by the Georgia Thoracic Society, Atlanta, GA. Invited Speaker: *Long term oxygen therapy*.
- Sep 1998 Visiting Professor, Denver VA Medical Center and National Jewish Research and Medical Center. Denver, CO. Lecture: *Tissue remodeling and inflammation in lung disease*.

**Lectures by Invitation (continuation)**

- May 1998 Invited Speaker, *The History of Pulmonary Medicine*. Annual Meeting of the Puerto Rico Chapter of the Alpha Omega Alpha Medical Honor Society, San Juan, PR.
- Apr 1998 Visiting Professor, Michael Reese Hospital and Medical Center, Chicago, IL. Grand Rounds: *Mechanisms of tissue remodeling during lung injury*.
- Sep 1997 Visiting Professor, National Respiratory Diseases Institute, Mexico City, Mexico. Lecture: *Progression to fibrosis in granulomatous lung disease*.
- Sep 1997 Visiting Professor, University of Puerto Rico School of Medicine, San Juan, Puerto Rico. Grand Rounds: 1) *New insights in matrix deposition in fibrotic lung diseases* (San Juan VAMC), 2) *Tuberculosis: Mechanisms of granuloma formation* (University

- Hospital), and 3) *Matrix deposition and degradation in mammalian lung development* (Clinical Research Center).
- Apr 1996 Session Co-Chairman and Speaker, *Matrices and matrix receptors in lung morphogenesis*. Session on Cell-Matrix Interactions in Lung Development, Experimental Biology Meeting, Washington, DC
- May 1995 Co-Chairman and Speaker, *Sarcoidosis: today and tomorrow*. Symposium: Effects of Sarcoidosis on Minorities. American Thoracic Society, Boston, MA (May) and American College of Chest Physicians, New York, NY (Oct).
- Nov 1994 Invited Speaker, *Cellular stress and strain: effects on lung development and morphology*. NIH workshop on Chaotic questions: from theory to bedside applications, Baltimore, MD
- Oct 1994 Invited Speaker, *Role of extracellular matrices in control of the inflammatory response that characterizes tuberculosis infection*. Pulmonary Symposium: Molecular Biology and Immunology of Mycobacterial Infection. Woods Hole, MA
- Oct 1994 Invited Speaker, *Extracellular matrices and integrins in inflammation*. American College of Rheumatology, Latin American Study Group, Minneapolis, MN
- May 1994 Invited Speaker, *Extracellular matrix components, inflammation and fibrosis in lung repair*. Symposium: Angiogenesis and lung remodeling. American Thoracic Society, Boston, MA
- Mar 1994 Invited Speaker, *Fibronectin and pulmonary tuberculosis*. Workshop on Tuberculosis, NHLBI, NIH, Bethesda, MD
- Oct 1993 Invited Participant, *Fourth Consensus Conference on Long Term Oxygen Therapy*, Washington, DC

**Lectures by Invitation (continuation)**

- Aug 1993 Invited Speaker, *Mechanisms of lung development*. Pediatric Research Conference, Egleston Children's Hospital, Emory University, Atlanta, GA
- May 1993 Invited Speaker, *Epithelial-mesenchymal interactions in lung development*. American Thoracic Society Meeting, San Francisco, CA
- Apr 1993 Invited Speaker, *Extracellular matrices modulate the production of IL-1 $\beta$  and IL-1ra in human mononuclear cells*. Symposium of Integrins and Cell Signaling, University of North Carolina, Chapel Hill, NC

- Mar 1993 Invited Speaker, Mexican Congress on Thoracic Medicine, I. *Role of integrin receptors in granulomatous inflammation*. II. *Alpha-1-antitrypsin deficiency: potentiation of inflammation by extracellular matrices*. Ixtapa, Mexico
- Oct 1992 Invited Speaker, *Role of parabronchial smooth muscle cells in lung development*. Symposium: Lung Cell Biology-Lung Development, Woods Hole, Massachusetts.
- Sept 1992 Invited Speaker, *Integrins in lung development and inflammation*, NIH Workshop on Cell Adhesion Molecules in Lung, Washington, DC
- Jun 1992 Invited Participant, NIH Minisymposium on *Molecular Embryology and Lung Development*, Seattle, WA
- May 1992 Invited Speaker, *Education and Behavioral Research Initiatives*. Minisymposium on Respiratory Health in Minorities, Am Thor Soc Meeting, Miami, FL
- Sep 1991 Invited Speaker, *Initiatives in Research and Training for Minorities*. NIH Workshop on Respiratory Health of Minorities, Bethesda, MD
- May 1990 Invited Lecture, *Extracellular Matrices in Lung Development*. Special Session on Lung Cell and Molecular Biology, American Society of Cell Biology, San Diego, CA
- Mar 1989 Invited Lecture, *Cellular Processes in Lung Injury and Repair*. Interstitial Lung Disease Symposium, American Federation of Clinical Research, Chicago, IL
- Jul 1989 Invited Speaker, *Fibronectin in lung branching morphogenesis*. Aspen Lung Conference, Aspen, CO.

**Organizing roles in scientific meetings**

**Sessions as Chair, Co-Chair, Moderator, or Facilitator:**

- Mar 2023 Chair, Session on “New Interventions in HPS”, Hermansky Pudlak Syndrome Network Annual Meeting, Long Island, NY

**Organizing roles in scientific meetings**

**Sessions as Chair, Co-Chair, Moderator, or Facilitator (continuation):**

- Feb 2023 Faculty and Organizer, Program on ‘Successful Careers in Academic Medicine’, & 2024 Southern Regional Meeting, New Orleans, LA.
- Oct 2022 Faculty, 18<sup>th</sup> Annual Respiratory Disease Young Investigator’s Forum, National Jewish Health, Denver, CO.
- Mar 2020 Lead Judge, Poster Session, Hermansky Pudlak Syndrome Network, Long Island, NY (cancelled due to Coronavirus pandemic).

- May 2019 Session Co Chair, Session on “Barriers to inclusion of minorities in research”. ATS/NIH Workshop on Enhancing Minority Recruitment & Retention in Clinical Studies. International American Thoracic Society Meeting, Dallas, TX.
- Mar 2019 Facilitator, Poster Session. HPS Clinical Research Programs and Science. Meeting of the Minds. Hermansky Pudlak Syndrome Network Annual Meeting, Long Island, NY
- Nov 2017 Chair, Session 5A: Therapeutics. Pulmonary Fibrosis Found. Summit, Nashville, TN.
- May 2017 Co-Chair, Joint ATS/ERS Workshop on Respiratory Health of Migrant and Refugee Populations; 2017 International Am Thoracic Society Meeting, Washington DC.
- May 2017 Facilitator, Session on Translational research in COPD. Poster session held during the 2017 International American Thoracic Society Meeting, Washington DC.
- May 2016 Co-chair, Respiratory Health in Migrant Populations. Mini-symposium during the 2016 International American Thoracic Society Meeting, San Francisco, CA.
- May 2023 Co-Chair, Patients and Experts Symposium on Patient Access to Care. Sponsored by the Public Advisory Roundtable, American Thoracic Society Meeting, Washington D.C.
- May 2015 Co-Chair, Session on The Next Frontier: Personalized Medicine to Solve Respiratory Health Disparities. In ATS/NHLBI Workshop on Addressing Respiratory Health Equality in the U.S. International American Thoracic Society Meeting, Denver, CO.
- May 2015 Facilitator, Poster Discussion Session: Aging – The Common Denominator. International American Thoracic Society Meeting, Denver, CO.
- May 2015 Facilitator, Thematic Poster Session: Magical Mysteries of IPF. International American Thoracic Society Meeting, Denver, CO.
- Mar 2015 Chair, Workshop: PILOT -Navigating the new era of IPF: Collaborative patient care. University of Louisville, Louisville, KY

**Organizing roles in scientific meetings**

**Sessions as Chair, Co-Chair, Moderator, or Facilitator (continuation):**

- Oct 2014 Chair, Session on Aging Lung Cells and Repair. 2014 Pittsburgh-Munich International Lung Conference - Aging and Lung Disease: Clinical Impact and Cellular and Molecular Pathways, University Club in Pittsburgh, Pennsylvania.
- Sep 2014 Facilitator, Poster discussion session: Clinical Research related to IPF. International Colloquium on Lung and Airway Fibrosis. Mont Tremblant, QC, Canada.

- May 2014 Facilitator, Thematic Poster Presentation: Diamonds are forever but new treatment for interstitial lung disease can't wait. International American Thoracic Society Meeting, San Diego, CA.
- May 2014 Panel Participant: Careers for Junior Investigators. International American Thoracic Society Meeting, San Diego, CA.
- Apr 2014 Co-Chair, Workshop on Fibrosis Across Species Meeting, Louisville, KY
- Dec 2013 Co-Chair, Presentation of Best Poster Science, Pulmonary Fibrosis Summit 2013, Pulmonary Fibrosis Foundation Meeting, La Jolla, CA.
- May 2013 Co-Chair, Session on: A Hitchhiker's Guide to Mechanobiology: How Matrix-Cytoskeleton Interactions Drive Cell Behavior. International American Thoracic Society Meeting, Philadelphia, PA.
- May 2013 Facilitator, The influence of matrix on lung repair and remodeling (D40). Thematic Poster Presentation. International American Thoracic Society Meeting, Philadelphia, PA.
- May 2012 Co-Chair, Session on Pulmonary Research at the VA. International American Thoracic Society Meeting, San Francisco, CA.
- May 2012 Co-Chair, Cigarette smoke, alcohol, and oxidative stress responses of the lung – poster discussion session. American Thoracic Society Meeting, San Francisco, CA.
- May 2012 Facilitator, Session on Pulmonary Vices: Cigarette smoke, alcohol, and oxidative stress responses of the lung. International American Thoracic Society Meeting, San Francisco, CA.
- Mar 2012 Group Leader, Session on Resolution of Injury – What defines normal wound healing following an injury. In ATS-sponsored meeting on Fibrosis Across Organ Systems, Denver, CO.
- Sep 2011 Chair, Session on Fibroblasts and Extracellular Matrix in Lung Fibrosis. During Hermansky-Pudlak Scientific Meeting, National Institutes of Health, Bethesda, MD.
- Organizing roles in scientific meetings**  
**Sessions as Chair, Co-Chair, Moderator, or Facilitator (continuation):**
- May 2011 Co-Chair, Symposium on *Prenatal exposures and their impact on adult lung disease*. To be presented during the 2011 International American Thoracic Society Meeting, Denver, CO.
- May 2011 Lead Facilitator, Thematic Poster Session on *Novel Therapeutics in Pulmonary Fibrosis*. 2011 Annual American Thoracic Society Meeting, Denver, CO

- Feb 2011 Co-Chair, *Career Development Workshop*. Annual Southern Society for Clinical Investigation Meeting, New Orleans, LA.
- May 2010 Co-Chair, Symposium on *Nicotine and nicotinic receptors in lung health and disease*. Presented during the 2010 International American Thoracic Society Meeting, New Orleans, LA.
- May 2010 Co-Chair, Mini-symposium on *Translational Research In Interstitial Lung Disease*. Presented during the 2010 International American Thoracic Society Meeting, New Orleans, LA.
- Feb 2010 Moderator, Plenary Session, Southern Society for Clinical Investigation, Idiopathic Pulmonary Fibrosis: dealing with an orphan disease. Southern Regional Meeting, New Orleans. (This activity continues yearly)
- Feb 2010 Moderator: Joint Plenary Session, SSCI and SS-AFMR, Sickle Cell Disease – From bed to bedside. Southern Regional Meeting, New Orleans.
- Feb 2010 Moderator, Lung Club Session of the Southern Society for Clinical Investigation, Southern Regional Meeting, New Orleans.
- Jul 2009 Co-Chair, Symposium on Cancer Metastasis, The 8th Chinese National Conference on Tumor Metastasis, Tianjin, P. R. China.
- May 2009 Co-Chair, Symposium on Targeting tumor microenvironment in lung cancer, American Thoracic Society, San Diego, CA
- May 2009 Co-Chair, Mini-symposium on Lung Tumorigenesis: Insights from Animal Models, American Thoracic Society, San Diego, CA
- Feb 2008 Co-Chair, Southern Lung Club Meeting, Annual Southern Societies and SSCI Meeting, New Orleans, LA
- May 2006 Co-Chair, Session on *Novel biomarkers and mechanisms of lung carcinogenesis*. American Thoracic Society International Conference, San Diego, CA

**Organizing roles in scientific meetings**

**Sessions as Chair, Co-Chair, Moderator, or Facilitator (continuation):**

- Feb 2007 Co-Chair, Southern Lung Club Meeting and Co-Chair of Session on Pulmonary and Critical Care; Annual Meeting of the Southern Society for Clinical Investigation, New Orleans, LA
- Feb 2006 Co-chair, Southern Lung Club Meeting, Annual Meeting of the Southern Society of Clinical Investigation, New Orleans, LA.



- May 2005 Co-Chair, Symposium, *Targeting Lung Cancer*. American Thoracic Society Meeting, San Diego, CA.
- May 2005 Co-Chair, Mini-symposium, *Translating lung cancer – from mice to humans*. American Thoracic Society Meeting, San Diego, CA.
- May 2005 Co-Chair, Poster-Discussion, Mechanisms of fibroblast survival and proliferation. American Thoracic Society Meeting, San Diego, CA.
- May 2004 Chair, Symposium, *At the interface of injury and repair: matrix, cellular and developmental paradigms for (re)modeling in lung disease*. Lecture: Matrix, integrins and lung carcinogenesis. American Thoracic Society Meeting, Orlando, FL.
- May 2003 Co-Chair, Minisymposium on *Molecular Basis of Pulmonary Fibrosis*, American Thoracic Society Annual Meeting, Seattle, WA.
- Apr 1998 Chairman, Postgraduate Course on Planning a Career in Pulmonary/Critical Care Medicine; American Thoracic Society Annual Meeting, Chicago, IL
- Apr 1998 Chairman, Poster Discussion Session on Nitric oxide, oxidants, and diffuse lung injury; American Thoracic Society Annual Meeting, Chicago, IL.
- Apr 1998 Chairman, Poster Discussion Session on Airway epithelial growth and differentiation. American Thoracic Society Annual Meeting, Chicago.
- Apr 1997 Co-Chair, Minisymposium: Immunologic Diseases of the Lung. Georgia Lung Association/GA Thor Soc Annual Meeting, Atlanta, GA.
- Oct 1996 Co-Chair, Session on Clinical & sociocultural impact of tobacco on minorities: Is this a biological or social problem? XVIII World Congress on Disease of the Chest/ACCP International Scientific Assembly, San Francisco, CA.
- Jun 1996 Co-Chair, Minisymposium: *Asthma: new insights into airway biology, physiology, and management*. Georgia Lung Assoc/GA Thor Soc Annual Meeting, Atlanta, GA

### **Organizing roles in scientific meetings**

#### **Sessions as Chair, Co-Chair, Moderator, or Facilitator (continuation):**

- Apr 1996 Co-Chairman and Speaker, *Matrices and matrix receptors in lung morphogenesis*. Session on Cell-Matrix Interactions in Lung Development, Experimental Biology Meeting, Washington, DC
- Sep 1996 Co-Chairman, Mini-symposium: *Frontiers in Pulmonary Medicine*. Emory University, Atlanta, GA.

- Oct 1995 Co-Chair and Speaker, *Sarcoidosis: today and tomorrow*. Symposium: Effects of Sarcoidosis on Minorities. American College of Chest Physicians, New York, NY.
- Jan 1992 Chairman, *Pulmonary Subspecialty II*, 1992 American Federation of Clinical Research Southern Section Meeting, New Orleans, LA
- May 1991 Chairman, *Interstitial Lung Disease*. Am Thoracic Society Meeting, Anaheim, CA

**Organizing roles in scientific meetings - Administrative Positions:**

- 2017-pres Officer, Southern Society for Clinical Investigation
- 2017 Member, Organizing Committee, Pulmonary Fibrosis Foundation Summit, 2017.
- 2016 Member, Organizing Committee, G.P. Herzig Symposium on Hematologic Malignancies and BMT, Louisville, KY (April)
- 2015 Member, Organizing Committee, Pulmonary Fibrosis Foundation Summit, Washington DC.
- 2014 Co-Chair, Organizing Committee, Fibrosis Across Species Meeting, Louisville, KY
- 2009-12 Member, Planning Committee, Southern Regional Meeting
- 2009 Judge, Research Louisville, Louisville, KY
- 2008-10 Chair, Planning Committee, Respiratory Cell Molecular Biology Assembly, ATS
- 2007-10 Chair, Education Committee of the IPFNET, NIH/NHLBI
- 2007-08 Planning Committee, Respiratory Cell Molecular Biology Assembly, ATS
- 2006-10 Co-organizer, Lung Club Session, Annual SSCI Meeting
- 2005-07 American Thoracic Society International Conference Committee

**2003 Organizing roles in scientific meetings - Administrative Positions (continuation):**

- 2005-07 Program Chair-Elect and Chair, RCMB Assembly, American Thoracic Society
- 2003-08 Councilor, Southern Society for Clinical Investigation
- 2002-05 Program Committee, Respiratory Cell Molecular Biology Assembly, ATS
- 1996-97 Co-Chair, Cultural diversity subcommittee, American College of Chest Physicians

## Bibliography

### Peer-reviewed publications

1. **Roman J**, LaChance R, Broekelmann TJ, Roberts CJ, Wayner EA, Carter WG, McDonald JA. The fibronectin receptor is organized by extracellular matrix fibronectin: Implications for oncogenic transformation and for cell recognition of fibronectin matrices. *J Cell Biol* 108:2529-43, 1989.
2. **Roman J**, Little, C, McDonald JA. Potential role of RGD-binding integrins in mammalian lung branching morphogenesis. *Development* 112:551-8, 1991.
3. **Roman J**, McDonald JA. Expression of fibronectin, fibronectin receptor  $\alpha 5\beta 1$  and  $\alpha$ -smooth muscle actin during heart and lung development. *Am J Resp Cell Mol Biol* 6:472-480, 1992.
4. Rosen, GD, Sanes, JR, LaChance, R, Cunningham, JM, **Roman, J**, Dean, D. Regulation of VLA 4/VCAM-1 during muscle differentiation. *Cell* 69:1107-1119, 1992.
5. Pacifici R, Basilico C, **Roman J**, Sutter M, Santoro SA, McCracken R. Collagen-induced release of interleukin 1 from human blood mononuclear cells. Potentiation by fibronectin binding to the  $\alpha 5\beta 1$  integrin. *J Clin Invest* 89:61-67, 1992.
6. Porrás-Reyes, BH, Lewis, WL, **Roman, J**, Simchowicz, L, Mustoe, TA. Enhancement of wound healing by the alkaloid taspine defining mechanism of action. *Proc Soc Exp Biol Med* 203:18-25, 1993.
7. **Roman J**, McDonald JA. Fibulin's organization into the extracellular matrix of fetal lung fibroblasts is dependent on fibronectin matrix assembly. *Am J Resp Cell Mol Biol* 8:538-545, 1993.
8. Aguayo, SM, Richardson CL, **Roman J**. Severe extrapulmonary thoracic restriction caused by morphea, a form of localized scleroderma. *Chest* 104:1304-1305, 1993.
9. Perez, RL, **Roman, J**, Staton, GW, Hunter, R. Extravascular coagulation and fibrinolysis in murine lung granulomatous inflammation induced by the mycobacterial cord factor trehalose-6,6'-dimycolate. *Am J Resp Crit Care Med.* 149:510-518, 1994.
10. Aguayo, SM, Schuyler, WE, Murtagh, JJ, **Roman, J**. Regulation of lung branching morphogenesis by bombesin-like peptides and neutral endopeptidase. *Am J Resp Cell Mol Biol* 10:635-642, 1994.
11. Pacifici, R., **Roman J**, Kimble, R., Civitelli, R., Brownfield, CM, and Bizarri, C. Ligand binding to monocyte  $\alpha 5\beta 1$  integrin activates the  $\alpha 2\beta 1$  receptor via the  $\alpha 5$  subunit cytoplasmic domain and protein kinase C. *J Immunol* 153:2222-2233, 1994.

12. **Roman, J** and Jones, S. Congenital absence of the left pulmonary artery with ipsilateral emphysema and adenocarcinoma. *Am J Med Sci* 309:188-190, 1995.
13. **Roman, J.** Effects of calcium channel blockade on mammalian lung branching morphogenesis. *Exp. Lung Res.* 21:489-502, 1995.
14. Perez, RL and **Roman, J.** Fibrin enhances the expression of interleukin-1 $\beta$  in human peripheral blood mononuclear cells: Implications for pulmonary inflammation. *J Immunol* 154:1879-1887, 1995.
15. **Roman, J,** Jeon, YJ, Gal, T, Perez, RL. Distribution of extracellular matrices, matrix receptors and transforming growth factor- $\beta$ 1 in clinical and experimental granulomatous lung inflammation. *Am J Med Sci* 309:124-133, 1995. (Tinsley Harrison Award for best 1995 paper in the *Am J Med Sci*).
16. Chalasani, N, **Roman, J,** Jurado, R. Chronic salicylate intoxication presenting as the systemic inflammatory response syndrome. *Southern Med J* 89:479-482, 1996.
17. Graves, K. and **Roman, J.** Fibronectin modulates the expression of interleukin-1 $\beta$  and its receptor antagonist in human mononuclear cells. *Am J Physiol (Lung & Molecular Physiology)* 271:L61-L69, 1996.
18. Lois, M. and **Roman, J,** Holland, W, Agudelo, C. The diagnostic dilemma of coexisting Sjogren's Syndrome and Sarcoidosis in the lung. *Arthritis and Rheumatism*, 28:31-40, 1998.
19. Ritzenthaler, J and **Roman, J.** Differential effects of protein kinase C inhibitors on fibronectin-induced interleukin-1 $\beta$  gene transcription, protein synthesis and secretion in human monocytic cells. *Immunology*, 95:264-271, 1998.
12. **Roman, J,** Shuyler, W, McDonald, JA, Roser, S. Heparin prevents mammalian lung branching morphogenesis. Potential role of parabronchial smooth muscle cells. *Am J Med Sci*, 316:368-378, 1998.
21. Rivera-Marrero, C, Burroughs, MA, Mase, RA, Vannberg, FO, Leimback, DL, **Roman, J,** Murtagh, JJ. Identification of genes differentially expressed in Mycobacterium tuberculosis by differential display PCR. *Microbial Pathogenesis*, 25:307-316, 1998.
22. Perez, R, Ritzenthaler, J, and **Roman, J.** Transcriptional regulation of the IL-1 $\beta$  promoter via fibrinogen engagement of CD18 integrin receptor. *Am J Respir Cell Mol Biol*, 20:1059-1066, 1999.
23. **Roman, J,** Ritzenthaler, J, Perez, R, Roser, S. Differential modes of regulation of interleukin-1 $\beta$  expression by extracellular matrices. *Immunology*, 98:228-237, 1999.

24. Lois, M, Brown, LA, Moss, M, **Roman, J**, Guidot, D. Ethanol induces the expression of matrix metalloproteinases in rat lungs. *Am J Respir & Crit Care Med*, 160:1354-1360, 1999.
25. Iqbal, F, Michaelson, J, Thaler, L, Rubin, J, **Roman, J**, Nanes, MS. Declining bone mass in men with chronic obstructive pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function. *Chest*, 116:1616-1624, 1999.
26. Boles, B, Ritzenthaler, J, Birkenmeier, T, **Roman, J**. Expression of fibronectin  $\alpha 5\beta 1$  integrins during phorbol ester-induced U937 differentiation: Effects on  $\alpha 5$  gene transcription. *Am J Physiol*, 278:L703-712, 2000.
27. Perez, RL, **Roman, J**, Roser, S, Litte, C, Olsen, M, Indrigo, J, Hunter, J, Actor, JK. Cytokine message and protein expression during lung granuloma formation and resolution induced by the mycobacterial cord factor trehalose-6,6'-dimycolate. *J Interf & Cytokine Res* 20:795-804, 2000.
28. **Roman, J**, Ritzenthaler, J, Fenton, M. Regulation of IL-1 $\beta$  gene transcription by fibronectin in human monocytic cells. Role of protein kinase C and AP-1. *Cytokine*, 12:1581-1596, 2000.
29. Rivera-Marrero, C, Schuyler, W, **Roman, J**. Induction of MMP-9 mediated gelatinolytic activity in human monocytic cells by cell wall components of *M. tuberculosis*. *Microbial Pathogenesis*, 29:231-244, 2000.
30. Ritzenthaler, JD and **Roman, J**. Interleukin-1 $\beta$  gene transcription in U937 cells is modulated by type I collagen and cytoskeletal integrity via distinct signaling pathways. *J Interf & Cytokine Res*, 21:105-116, 2000.
31. Rivera-Marrero, CA, Ritzenthaler, JD, **Roman, J**, Moremen, KW. Molecular cloning and expression of an  $\alpha$ -mannosidase gene in *Mycobacterium tuberculosis*. *Microbial Pathogenesis* 30:9-18, 2001.
32. Dillard, DG, Gal, AA, **Roman, J**, White, S, Jacobs, I. Transforming Growth Factor and neutralizing antibodies in subglottic stenosis. *Ann Oto, Rhino, Laryng*, 110:393-400, 2001.
33. Michaelson, J, Ritzenthaler, JD, **Roman, J**. Regulation of serum-induced fibronectin expression by protein kinases, cytoskeletal integrity, and CREB. *Am J Physiol*, 282:L291-301, 2002.
34. Rivera-Marrero, CA, Schuyler S, Roser, S, Ritzenthaler, JD, Newburn, SA, **Roman, J**. *M. tuberculosis* induction of matrix metalloproteinase-9: the role of mannose and receptor-mediated mechanisms. *Am J Physiol*, 282:L546-555, 2002.

35. Rivera-Marrero, C.A., Newburn, S.A., **Roman, J**, Ritzenthaler, J., and R.D. Cummings (2001). Cloning and expression of a novel glycolipid sulfotransferase in *Mycobacterium tuberculosis*. *Microbiology*, 148:783-792, 2002.
36. Calnek DS, Mazzella L, Roser S, **Roman J**, Hart CM. Peroxisome proliferators-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. *Arterioscler Thromb Vasc Biol*, 23:52-57, 2003.
37. Bechara RI, Brown LAS, Eaton DC, **Roman J**, Guidot DM. Chronic Ethanol Ingestion Increases Expression of the Angiotensin II Type 2 (AT2) Receptor and Enhances Tumor Necrosis Factor-alpha- and Angiotensin II-Induced Cytotoxicity Via AT2 Signaling in Rat Alveolar Epithelial Cells. *Alcohol Clin Exp Res*. 27:1006-1014, 2003.
38. Han S, Sidell N, Fisher PB, **Roman J**. Upregulation of p21 gene expression by peroxisome proliferator-activated receptor gamma (PPAR $\gamma$ ) in human lung cancer cells. *Clinical Cancer Research*. 10:1911-1919, 2004.
39. Holtzcalw JD, Jack D, Aguayo SM, Eckman JR, **Roman J**, Hsu LL. Enhanced pulmonary and systemic response to endotoxin in transgenic sickle mice. *Am J Respir Crit Care Med*, 169:687-695, 2004.
40. Han S, **Roman J**. Suppression of prostaglandin E2 receptor subtype EP2 by PPAR $\gamma$  ligands inhibits human lung carcinoma cell growth. *Biochem Biophys Res Comm*, 314:1093-1099, 2004.
41. Jarmuz T, Roser S, Rivera H, Gal A, **Roman J**. Transforming growth factor- $\beta$ 1, myofibroblasts, and tracheal injury: Potential role of gastro-esophageal reflux. *Ann Oto Rhino Laryn*, 113:488-497, 2004.
42. Han S, Sidell N, Roser-Page S, **Roman J**. Fibronectin stimulates human lung carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) gene expression. *Int J Cancer*, 111:322-331, 2004.
43. **Roman J**, Ritzenthaler JD, Boles B, Lois M, Roser-Page S. Lipopolysaccharide induces the expression of fibronectin  $\alpha$ 5 $\beta$ 1 integrin receptors on human monocytic cells in a Protein Kinase C-dependent fashion. *Am J Physiol*, 287:L239-L249, 2004.
44. Bechara RI, Brown LAS, **Roman J**, Joshi PC, Guidot DM. Transforming growth factor  $\beta$ 1 expression and activation is increased in the alcoholic rat lung. *Am J Respir Crit Care Med*, 170:188-194, 2004.
45. Walia B, Castaneda FE, Wang L, Kolachala V, Bajaj R, **Roman J**, Merlin D, Gewirtz AT, Sitaraman SV. Polarized fibronectin secretion induced by adenosine regulates bacterial-epithelial interactions in human intestinal epithelial cells. *Biochem J*, 382:589-596, 2004.

46. **Roman J**, Ritzenthaler JD, Gil-Acosta A, Rivera HN, Roser-Page S. Nicotine and fibronectin expression in lung fibroblasts: Implications for tobacco-related lung tissue remodeling. *FASEB J*, 18:1436-1438, 2004.
47. Ramirez AM, Takagawa S, Sekosan M, Jaffe A, Varga J, **Roman J**. Smad3 deficiency ameliorates experimental obliterative bronchiolitis in a heterotopic tracheal transplantation model. *Am J Pathol*, 165:1223-1232, 2004.
48. Rivera-Marrero-CA, Stewart J, Shafer WM, **Roman J**. The down-regulation of cathepsin G in THP-1 monocytes after infection with *M. tuberculosis* is associated with increased intracellular survival of bacilli. *Infection and Immunity*, vol 72, 1512-1521, 2004.
49. Han S, Sidell N, **Roman J**. Fibronectin stimulates human lung carcinoma cell proliferation by suppressing p21 gene expression via signals involving Erk- and Rho kinase. *Cancer Letters*, 219:71-81, 2005.
50. Tomic R, Lassiter CC, Ritzenthaler JD, Rivera HN, **Roman J**. Anti-tissue remodeling effects of corticosteroids: Fluticasone propionate inhibits fibronectin expression in fibroblasts. *CHEST* 127:257-265, 2005.
51. **Roman J**, Ritzenthaler JD, Bechara R, Brown LA, Guidot DM. Ethanol stimulates fibronectin expression through protein kinase-dependent signals that activate CREB. *Am J Physiol*, 288:L975-L987, 2005.
52. Mora AL, Woods CR, Garcia A, Xu J, Rojas M, Speck S, **Roman J**, Brigham KL, Stecenko AA. Lung infection with gamma herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice. *Am J Physiol*, 289:L7111-L721, 2005.
53. Rojas M, Xu J, Mora A, **Roman J**, Brigham KL. Bone Marrow Derived Mesenchymal Stem Cells in Repair of the Injured Lung. *Am J Respir Cell Mol Biol*, 33:145-152, 2005.
54. Ramadan B and **Roman J**. *Rhodococcus equi* causing progressive cavitory pneumonia in an AIDS patient. *J Critical Illness*, 61-63, 2005.
55. Castaneda FE, Walia B, Vijay-Kumar M, Patel NR, Roser S, Kolachala VL, Rojas M, Wang L, Oprea G, Pallavi G, Gewirtz AT, **Roman J**, Merlin D, Sitaraman SV. Targeted deletion of MMP-9 attenuates experimental colitis in mice. *Gastroenterology*, 129:1991-2008, 2005.
56. Joshi PC, Applewhite L, Ritzenthaler JD, **Roman J**, Fernandez AL, Eaton DC, Brown LAS, Guidot DM. Chronic ethanol ingestion in rats decreases granulocyte/macrophage colony-stimulating factor receptor expression and downstream signaling in the alveolar macrophage. *J Immunol*, 175:6837-45, 2005.

57. **Roman J**, Rivera HN, Roser-Page, S, Sitaraman SV, Ritzenthaler JD. Adenosine induces fibronectin expression in lung epithelial cells: Implications for airway remodeling. *Am J Physiol*, 290:L317-L325, 2006.
58. Han S and **Roman J**. COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals. *Lung Cancer* 51:283-296, 2006.
59. Han SW, Khuri F, **Roman J**. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of the Akt/mTOR/S6K and inactivation of LKB1/AMPK signal pathways. *Cancer Research*, 66:315-323, 2006.
60. Stewart JN, Rivera HN, Russell K, Quinn FD, **Roman J**, Rivera-Marrero, C.A. Increased pathology in lungs of mice after infection with  $\alpha$ -crystallin mutant of Mycobacterium tuberculosis: changes in cathepsin proteases and certain cytokines. *Microbiology*, 152:233-244, 2006.
61. Han S and **Roman J**. Rosiglitazone suppresses human lung carcinoma cell growth through PPAR $\gamma$ -dependent and -independent signal pathways. *Molecular Cancer Therapeutics*, 5:430-437, 2006.
62. Han S and **Roman J**. Fibronectin induces cell proliferation and inhibits apoptosis in human bronchial epithelial cells: Pro-oncogenic effects mediated by PI3-Kinase and NF- $\kappa$ B. *Oncogene*, 25:4341-4349, 2006.
63. Ramirez A, **Roman J**. Myofibroblast transdifferentiation in obliterative bronchiolitis: TGF $\beta$  signaling through Smad3-dependent and -independent pathways. *Am J Transplantation*, 6:2080-2088, 2006.
64. Mora AL, Torres-Gonzalez E, Rojas M, Corredor C, Ritzenthaler J, Xu J, **Roman J**, Brigham KL, Stecenko A. Activation of Alveolar Macrophages via the Alternative Pathway in Herpesvirus-Induced Lung Fibrosis. *Am J Respir Cell Mol Biol*, 35:466-473, 2006.
65. Joshi PV, Applewhite LD, Mitchell P, Fernainy K, **Roman J**, Eaton DC, Guidot DM. GM-CSF receptor expression and signaling is decreased in lung of ethanol-fed rats. *Am J Physiol*, 291:L1150-L1158, 2006.
66. Ramadan B, Perez RL, **Roman J**. Polydipsia, polyuria, and pneumothorax in a young woman with diffuse cystic lung lesions. *J Respir Dis* 27:472-476, 2006.
67. Burnham EL, Ritzenthaler JD, Moss M, **Roman J**. Evidence for activation of tissue remodeling in lung in the setting of chronic alcohol abuse. *Alcoholism: Clinical and Experimental Research*, 31:675-683, 2007.
68. Perez, RL, Kimani AP, King, TE, Aguayo SM, **Roman J**. Bronchoalveolar Lavage Fluid D dimer Levels are Higher and more Prevalent in Black Patients with Pulmonary Sarcoidosis. *Respiration*, 74:297-303, 2007.



69. Garg P, Ravi A, Patel N, **Roman J**, Gerwitz AT, Merlin D, Sitaraman SV. Matrix metalloproteinase-9 (MMP-9) regulates MUC-2 expression through its effect on goblet cell differentiation. *Gastroenterology*, 132:1877-1889, 2007.
70. Mora AL, Torres-Gonzalez E, Rojas M, Xu J, Ritzenthaler JD, Speck SH, **Roman J**, Brigham KL, Stecenko A. Control of virus reactivation arrests pulmonary herpesvirus induced fibrosis in IFN $\gamma$ R deficient mice. *Am J Respir Crit Care Med*, 175:1139-1150, 2007.
71. Han SW, Zheng Y, **Roman J**. Rosiglitazone, an agonist of peroxisome proliferator activated receptors gamma (PPAR $\gamma$ ), inhibits non-small cell carcinoma cell proliferation in part through activation of TSC2. *PPAR Research*, 2007, 2007, 29632.
72. Brown LAS, Ritzenthaler JD, Guidot DM, **Roman J**. Alveolar type II cells from ethanol-fed rats produce a fibronectin-enriched extracellular matrix that promotes monocyte activation. *Alcohol*, 41:317-324, 2007.
73. Wongtrakool C, Roser S, Rivera H, **Roman J**. Nicotine alters lung branching morphogenesis through the  $\alpha$ 7 nicotinic acetylcholine receptor. *Am J Physiol*, 293:L611-L618, 2007.
74. Zheng Y, Ritzenthaler JD, **Roman J**, Han SW. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. *Am J Respir Cell Mol Biol*, 37:681-690, 2007.
75. Ramirez A, Ramadan B, Ritzenthaler JD, Rivera HN, Jones DP, **Roman J**. Extracellular cysteine/cystine redox potential controls lung fibroblast proliferation and matrix expression through upregulation of transforming growth factor-beta. *Am J Physiol*, 293:L972-981, 2007.
76. Kolachala VL, Bajaj R, Wang L, Yan Y, Ritzenthaler JD, Gewirtz AT, **Roman J**, Merlin D, Sitaraman SV. Epithelial-derived fibronectin: Expression, signaling and function in intestinal inflammation. *J Biol Chem*, 282:32965-73, 2007.
77. Holguin F, Ramadan B, Gal AA, **Roman J**. Prognostic Factors for Hospital Mortality and ICU admission in Patients with ANCA-Related Pulmonary Vasculitis. *Am J Med Sci*, 336:321-326, 2008.
78. Ramirez A, Nunley A, Ritzenthaler JR, Roman J. Activation of tissue remodeling precedes obliterative bronchiolitis in lung transplant recipients. *Biomarker Insights*, 3:351-359, 2008.
79. Wongtrakool C and **Roman J**. Role of apoptosis in lung branching morphogenesis. *Exp Lung Res*, 34:481-499, 2008.

80. Iyer SS, Ramirez AM, Ritzenthaler JD, Torres-Gonzalez E, Roser-Page S, Mora AL, Brigham KL, Jones DP, **Roman J**, Rojas M. Oxidation of extracellular cysteine/cystine redox state in bleomycin-induced lung fibrosis. *Am J Physiol*, 296:L37-45, 2008.
81. Zheng Y, Ritzenthaler JD, Sun X, **Roman J**, Han S. Prostaglandin E2 increases human lung carcinoma cell growth through induction of ILK: the involvement of EP4 and Sp1. *Cancer Res*, 69:896-904, 2009.
82. Han SW, Sun X-J, Ritzenthaler JD, **Roman J**. Fish oil inhibits human lung carcinoma cell growth through suppressing ILK. *Mol Can Res*, 7:108-117, 2009.
83. Sun X-J, Zheng Y, Ritzenthaler JD, **Roman J**, S.W. Han. Rosiglitazone inhibits human lung carcinoma cell growth by inhibiting alpha 4 nicotinic acetylcholine receptor through activation of ERK and p38 MAPK, and via induction of p53. *Mol Can Ther*, 8:110-118, 2009.
84. Mitchell PO, Jensen JS, Ritzenthaler JD, **Roman J**, Pelaez A, Guidot DM. Alcohol primes the airway for increased interleukin-13 signaling. *Alcohol Clin Exp Res*, 33:505-513, 2009.
85. Iyer S, Accardi C, Blanco R, Ziegler TR, Rojas M, **Roman J**, Jones DP. Cysteine redox potential determines pro-inflammatory IL-1 $\beta$  levels. *PLoS One*, 4(3):e5017. Epub 2009.
86. Sun X, Ritzenthaler JD, Zhong X, Zheng Y, **Roman J**, Han SW. Nicotine stimulates PPAR $\beta/\delta$  expression in human lung carcinoma cells through activation of PI3-K/mTOR and suppression of AP-2a. *Cancer Res*, 69:6445-6453, 2009.
87. Pozharskaya V, Torres-Gonzalez E, Rojas M, Gal A, Amin M, Dollar S, **Roman J**, Stecenko AA, Mora A. Twist: a regulator of epithelial-mesenchymal transition in lung fibrosis. *PLoS One Oct 23*;4(10):e7559s, 2009.
88. Ramirez AM, Wongtrakool C, Welch T, Steinmeyer A, Zugel U, **Roman J**. Vitamin D inhibition of pro-fibrotic effects of transforming growth factor  $\beta$ 1 in lung fibroblasts and epithelial cells. *J Steroid Biochem Mol Biol*, 118:142-150, 2010.
89. Koval MH, Roser-Page S, **Roman J**. Extracellular matrix influences alveolar epithelial claudin expression and barrier function. *Am J Respir Cell Mol Biol*, 42:172-180, 2010.
90. Lofton M, Yang S, Roser-Page S, **Roman J**, Murthy N, Barker T. PK3 polyketals: a new biocompatible polymer for lung therapeutic delivery. *Biomaterials*, 31:810-817, 2010.
91. **Roman J**, Ritzenthaler JD, Roser SD, Han S.  $\alpha$ 5 $\beta$ 1 integrin expression is essential for tumor progression in experimental lung cancer. *Am J Respir Cell Mol Biol*, 43:684-691, 2010.

92. Li P, Xiao HD, Xu J, Ong FS, Kwon M, **Roman J**, Gal A, Berstein KE, Fuchs S. Angiotensin-Converting Enzyme N-Terminal Inactivation Alleviates Bleomycin-Induced Lung Injury. *Am J Pathol*, 177:1113-1121, 2010.
93. White ES, Sagana RL, Booth AJ, Yan M, Cornett AM, Bloomheart CA, Tsui JL, Wilke CA, Moore BB, Ritzenthaler JD, **Roman J**, Muro AF. Control of fibroblast fibronectin expression and alternative splicing via PI3K/AKT/mTOR pathway. *Exp Cell Res*, 316:2644-2653, 2010.
94. Fioret D, Perez RL, **Roman J**. A case of progressive lung fibrosis. *Am J Med Sci*, 341:428-430, 2011.
95. Mehta AJ, Joshi PC, Fan X, Brown LA, Ritzenthaler JD, **Roman J**, Guidot DM. Zinc supplementation restores PU.1 and Nrf2 nuclear binding in alveolar macrophages and improves redox potential balance and bacterial clearance in the lungs of alcohol-fed rats. *Alcohol Clin Exp Res*, 35:1519-28, 2011.
96. Deng Z, Cheng Z, Xiang X, Yan J, Zhuang X, Liu C, Jiang H, Ju S, Zhang L, Grizzle W, Mobley J, **Roman J**, Miller D, Zhang HG. Tumor cell cross talk with tumor-associated leukocytes leads to induction of tumor exosomal fibronectin and promotes tumor progression. *Am J Pathol*, 180:390-8, 2011.
97. Sueblinvong V, Neujahr DC, Roser-Page S, Ritzenthaler J, Guidot DM, Rojas M, **Roman J**. Predisposition to disrepair in the aged lung. *Am J Med Sci*, 344:41-51, 2012 (Tinsley Harrison Award for best 2012 paper in the *Am J Med Sci*)
98. Wongtrakool CW, Hyde D, **Roman J**, Spindel E. Prenatal nicotine exposure alters lung function and airway geometry through  $\alpha 7$  nicotinic receptors. *Am J Respir Cell Mol Biol*, 46:695-702, 2012.
99. Wongtrakool CW, Grooms K, Ping, X-d, Rivera H, Ward W, Roser-Page S, **Roman J**, Brown LA, and Gauthier T. Nicotine exposure promotes M2 activation in neonatal mice alveolar macrophages. *Ped Research*, 73:147-1453, 2012.
100. Ramirez A, Ballard EN, **Roman J**. TGF $\beta$ 1 controls PPAR $\gamma$  expression, transcriptional potential, and activity, in part, through Smad3 signaling in murine lung fibroblasts. *PPAR Research*, ID 375876, 2012.
101. Ritzenthaler JD, Roser-Page S, Guidot, DM, **Roman J**. Nicotinic Acetylcholine Receptors are Sensors for Ethanol in Lung Fibroblasts. *Alcoholism: Clinical and Experimental Research*, 37:914-923, 2013.
102. Puthalapattu S, **Roman J**, Perez RL, Bhadriraju S, Ioachimescu O. Sleep apnea and other sleep disorders: survey in individuals with Idiopathic Pulmonary Fibrosis. *J Sleep Disorders & Therapy*, 2:210. Doi: 10.4172/2167-0277.1000120

103. Sueblinvong V, Neveu WA, Neujahr DC, Mills ST, Rojas M, **Roman J**, Guidot DM. Aging promotes pro-fibrotic matrix production and increases fibrocyte recruitment during acute lung injury. *Adv Biosci Biotechnol* 5:19-30, 2014.
104. Zhong XR, Fan Y, Ritzenthaler JD, Zhang WJ, Wang K, Zhou QH, **Roman J**. Novel link between prostaglandin E2 (PGE2) and cholinergic signaling in lung cancer: the role of c-Jun in PGE2-induced  $\alpha 7$  nicotinic acetylcholine receptor expression and tumor cell proliferation. *Thor Cancer* 6:488-500, 2015.
105. Jin S, Merchant ML, Ritzenthaler JD, McLeish KR, Lederer ED, Lentsch AB, **Roman J**, Klein JB, Rane MJ. Baclofen, a GABABR agonist, ameliorates immune-complex mediated acute lung injury by modulating pro-inflammatory mediators. *PLoS One*, 10(4):e0121637, 2015. PMID 25848767.
106. Song N, Liu J, Shaheen S, Du L, Proctor M, **Roman J**, Yu J. Vagotomy attenuates pulmonary fibrosis in mice. *Scientific Reports*, 2015; 5:13419. Doi:101038/srep13419
107. Woolery K, Mohamed M, Linger R, Dobrinsky K, **Roman J**, Kruk P. BARCA1185delAG mutation enhances interleukin-1b expression in ovarian surface epithelial cells. *BioMed Research International*, 2015:652017, 2015 doi:101155/2015/652017.
108. Massey V, Poole L, Siow D; Torres-Gonzalez E, Warne N, Schmid R; Ritzenthaler JD, **Roman J**, Arteel G. Chronic alcohol exposure enhances lipopolysaccharide-induced lung injury in mice: potential role of systemic tumor necrosis factor alpha. *Alcoholism: Clinical and Experimental Research*, 39:1978-1988, 2015.
109. Beier JJ, Guo L, Joshi-Barve S, Ritzenthaler JD, **Roman J**, Arteel GE. Fibrin-mediated integrin signaling plays a critical role in hepatic regeneration after partial hepatectomy in mice. *Annals of Hepatology*, 15:762-772, 2016.
110. Fioret D, Mannino D, **Roman J**. In-hospital mortality, length of stay, and charges related to pulmonary fibrosis in the U.S. between 1993 and 2008. *Pulmonary Crit Care Med* 1:doi:10.15761/PCCM.1000104. 2016
111. El-Kersh K, Guardiola J, Cavallazzi R, Wienkem TL, **Roman J**, Saad M. Open and closed models of intensive care units have different influences on infectious complications in a tertiary care center: A retrospective analysis. *Am J Infection Control*, 44:1744-1746, 2016.
112. Watson WH, Burke T, Zelko IN, Torres-Gonzalez E, Ritzenthaler JD, **Roman J**. Differential regulation of the extracellular cysteine/cystine redox state (EhCySS) by lung fibroblasts from young and old mice. *Oxidative Medicine & Cellular Longevity*, 2016;2016:1561305. doi: 10.1155/2016/1561305.
113. Zelko IN, Zhu JX, Ritzenthaler JD, **Roman J**. Pulmonary hypertension and vascular remodeling in mice exposed to crystalline silica. *Respiratory Research*, Nov 28;17(1):160, 2016.

114. Liu J, Song N, Guardiola J, **Roman J**, Yu Jerry. Slowly adapting sensory units have more receptors in large airways than in small airways in rabbits. *Frontiers in Physiology (Respiratory Physiology)*, 2016 Dec 9;7:588. doi: 10.3389/fphys.2016.00588.
115. Collard HR, Richeldi L, Dong SK, Taniguchi H, Tschoepe I, Luisetti M, **Roman J**, Tino G, Schlenker-Herzeg R, Hallmann C, du Bois RM. Acute exacerbations in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. *Eur Respir J*, 49(5). Pii. 1601339. [Doi:10.1183/13993003.01339-2016], 2017.
116. Poole LG, Massey VL, Siow DL, Torres-Gonzales E, Warner NL, Luyendyk JP, Ritzenthaler JD, **Roman J**, Arteel G. Plasminogen activator inhibitor-1 is critical in alcohol-enhanced acute lung injury in mice. *Am J Respir Cell Mol Biol*, 57:35-323, 2017.
117. Vicary G, Ritzenthaler JD, Panchabhai TS, Torres-Gonzalez E, **Roman J**. Nicotine stimulates collagen type I expression in lung via  $\alpha 7$  nicotinic acetylcholine receptors. *Respiratory Research*, 18(1):115. [doi: 10.1186/s12931-017-0596-8], 2017.
118. Suliman S, Al Harash A, Roberts WN, Perez RL, **Roman J**. Scleroderma-related interstitial lung disease. *Respir Med Case Rep*. 22:109-112, 2017.
119. **Roman J**, Zhu J, Ritzenthaler JD, Zelko IN. Epigenetic regulation of EC-SOD expression in aging lung fibroblasts: role of histone acetylation. *Free Radical Biology & Medicine*. 112:212-223, 2017.
120. Morello-Gearhart A, Cavallazzi R, Peyrani P, Wiemken TL, Furmanek S, Reyes-Vega A, Gauhar U, Rivas-Perez H, **Roman J**, Ramirez JA, Fernandez-Botran R. Lung cytokines and systemic inflammation in patients with COPD. *The UofL Journal of Respiratory Infections*. 1:zodd/ 4, Article 4. DOI:10.18297/jri/vol1/iss4/4, 2017.
121. Zheng Y, Ritzenthaler JD, Burke TJ, Otero J, **Roman J**, Watson WH. Age-dependent oxidation of extracellular oxidation of Cysteine/Cystine redox state (Eh Cys/CySS) in mouse lung fibroblasts is mediated by a decline in Slc7a11 expression. *Free Radical & Medicine*, 118:13-22, 2018.
122. Zelko IN, Zhu J, **Roman J**. Role of SOD3 in silica-related lung fibrosis and pulmonary vascular remodeling. *Respir Res*, Nov 20;19(1):221. doi: 10.1186/s12931-018-0933-6. 2018.
123. Poole LG, Beier JI, Torres-Gonzalez E, Schlueter CF, Hudson SV, Artis A, Warner NL, Nguyen-Ho CT, Dolin CE, Ritzenthaler JD, Hoyle GW, **Roman J**, Arteel G. Chronic + binge alcohol exposure promotes inflammation and alters airway mechanics in the lung. *Alcohol*, 2018, Nov 13. pii: S0741-8329(18)30080-6. doi: 10.1016/j.alcohol.2018.10.008, 2018.

124. Zelko IN, Zhu J, **Roman J**. Maternal undernutrition during pregnancy alters the epigenetic landscape and the expression of endothelial function genes in male progeny. *Nutrition Res*, 61:53-63, 2019.
125. Gualdoni J, Ritzenthaler JD, Elkhawas I, Bauldoff G, Nunley D, **Roman J**. Aspiration of gastrointestinal material and induction of fibronectin expression in lung transplant recipients: Implications for early airway remodeling. *OBM Transplantation*, accepted, 2019.
126. Summer R, Krishna R, Schriener D, Cuevas-Mora K, Sales D, Para R, **Roman J**, Nieweld C, Gochuico BR, Romero F. Matrix metalloproteinase activity in the lung is increased in Hermansky Pudlak Syndrome. *Orphanet Journal of Rare Diseases*, 14(1):162. 2019; doi: 10.1186/s13023-019-1143-0.
127. Watson W, Ritzenthaler JD, Peyrani P, Wiemken T, Furmanek S, Reyes Vega A, Burke T, Zheng Y, Ramirez J, **Roman J**. Plasma cysteine/cystine and glutathione/glutathione disulfide redox potentials in HIV and COPD patients. *Free Radical Biology and Medicine*, 143:55-61, 2019.
128. Todd JL, Neely M, Overton R, Durham K, Gulati M, Huang H, **Roman J**, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. *Respir Res*, 2019. 20(1):227. doi: 10.1186/s12931-019-1190-z.
129. Fernandez-Botran R, Reyes Vega A, Gacia Y, Tirumala CT, Srisailam PK, Raghuram A, Peyrani P, Furmanek S, Tella MA, Ritzenthaler JD, **Roman J**, Ramirez JA. The elevated systemic cytokine levels in HIV patients are not associated with an elevated pulmonary cytokine environment. *Cytokine*, 2019. Oct 23;126:154874. doi: 10.1016/j.cyto.2019.154874
130. Greenwell J, Torres-Gonzalez E, Ritzenthaler JD, Watson W, **Roman J**. Impact of sex, age and diet on the cysteine/cystine and glutathione/glutathione disulfide plasma redox couples in mice. *J Nutritional Biochemistry*, 84:108431, 2020. doi: 10.1016/j.jnutbio.2020.108431.
131. Gualdoni J, Ritzenthaler J, Burlen J, Stocker A, Abell T, **Roman J**, Nunley DR. Gastrointestinal reflux and microaspiration in lung transplant recipients: the utility of a single esophageal manometry and pH probe monitoring study. *Transplant Proc* 52: 977-981, 2020.
132. Zheng Y, Merchant ML, Burke T, Ritzenthaler JD, Gaweda A, **Roman J**, Watson WH, Li M, Benz F. Redox states of protein cysteines in pathways of protein turnover and cytoskeleton dynamics are changed with aging and reversed by Slc7a11 restoration in mouse lung fibroblasts. *Oxidative Med & Cellul Longevity* 2020 Jun 7;2020:2468986. doi: 10.1155/2020/2468986.

133. Flamenbaum M, **Roman J**. Endemic and emerging coronavirus pulmonary infections. *Am J Med Sci*. 2020 Jun 12:S0002-9629(20)30255-X. doi: 10.1016/j.amjms.2020.06.013.
134. Greenwell JC, Torres-Gonzalez E, Ritzenthaler JD, **Roman J**. Interplay between aging, lung inflammation/remodeling, and fibronectin EDA in lung cancer progression. *Cancer Biology & Therapy*. 21:1109-1118, 2020.
135. Fonseca M, Summer R, **Roman J**. Acute exacerbation of interstitial lung disease as a sequela of COVID-19 pneumonia. *Am J Med Sci*. 361:126-129, 2021.
136. Shaghghi H, para R, Tran C, **Roman J**, Ojeda-Lassalle Y, Romero F, Summer R. Glutamine restores mitochondrial respiration in bleomycin-injured epithelial cells. *Free Radical Biology and Medicine*. 176:335-344, 2021.
137. Todd JL, Neely ML, Overton R, Mulder H, **Roman J**, Lasky JA, de Andrade JA, Huang H, Leonard TB, Hesslinger C, Noth I, Belperio J, Flaherty KR, Palmer SM. Association of circulating proteins with death or lung transplantation in patients with idiopathic pulmonary fibrosis in the IPF-PRO Registry cohort. *Lung*. 2022; 200:11-18. Doi: 10.1007/s00408-021-00505-y.
138. Ritzenthaler JD, Torres-Gonzalez E, Zheng Y, Zelko IN, van Berkel V, Nunley DR, Kidane B, Halayko AJ, Summer R, Watson WH, **Roman J**. The pro-fibrotic and senescence phenotype of old lung fibroblasts is reversed or ameliorated by genetic and pharmacological manipulation of Slc7a11 expression. *Am J Physiol – LCMB*, 2022; 322:L449-L461.
139. Zhao J, Metra B, George G, **Roman J**, Mallon J, Sundaram B, Li M, Summer R. Mortality among patients with SARS-CoV-2 and different interstitial lung disease subtypes: a multicenter cohort study. *Annals ATS*, 19:1435-1437, 2022.
140. Watson WH, Ritzenthaler JD, Torres-Gonzalez E, Arteel GE, **Roman J**. Mice lacking  $\alpha 4$  nicotinic acetylcholine receptors are protected against alcohol-associated liver injury. *Alcoholism: Clin Exp Res*, 46:1371-1383, 2022.
141. Greenwell JC, Torres E, Ritzenthaler JD, **Roman J**. Fibroblast-derived conditioned media promotes lung cancer progression. *Am J Med Sciences*, 365:189-197. 2023
142. Peljto AL, Blumhagen RZ, Walts AD, Cardwell J, Powers J, Corte TJ... **Roman J**..., Schwartz DA. Idiopathic pulmonary fibrosis is associated with common genetic variants and limited rare variants. *Am J Respir Crit Care Med*. 207:1194-1202, 2023.
143. Nunley DR, Gualdoni J, Ritzenthaler JD, Bauldoff GS, Howsare M, Reynolds KG, van Berkel V, **Roman J**. Evaluation of donor lungs for transplantation: the efficacy of screening bronchoscopy for detecting donor aspiration and its relationship to the resulting allograft function in corresponding recipients. *Transplantation Proceedings*, S0041-1345(23)00394-9, 2023.

144. Zhao J, Fares J, George G, Maheu A, Loizidis G, **Roman J**, Kramer D, Li M, Summer R. Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis. *Respirology*. 2023; doi:10.1111/resp.14563 (online ahead of print).
145. Summer R, Todd JL, Neely ML, Lobo LJ, Namen A, Newby K, Shfazand S, Suliman S, H C, Kellre S, Leonard TB, Palmer SM, Ilkayeva O, Muehlbauer M, Newgard CB, **Roman J**. Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. *Respiratory Research*, 25:58, 2024.

**Manuscripts related to participation in multicenter clinical trials (corporate authorship or not necessarily recognized by author):**

**Clinical trials related to the NHLBI Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet).** **Roman J** was an IPFnet investigator, served as Site PI at Emory University and later at the University of Louisville, served on the IPFnet steering committee, co-chaired the IPFnet Publications Committee, and participated in study design, patient recruitment, data interpretation, and manuscript preparation and review of the trials sponsored through this program including the Sildenafil trial, ACE, and PANTHER.

1. National Heart, Lung, and Blood Institute **Idiopathic Pulmonary Fibrosis Clinical Research Network**. A randomized, controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. *N Eng J Med*, 363:620-628, 2010.
2. National Heart, Lung and Blood Institute **Idiopathic Pulmonary Fibrosis Clinical Research Network**, Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, Azathioprine and N-acetylcysteine for pulmonary fibrosis. *N Engl J Med*, 366(21):1968-1977, 2012.
3. Noth I, Anstrom K, Clavert S, de Andrade J, Flagerty K, Kaner R, Olman M, for the **IPF Clinical Research Network**. A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*, 186:88-95, 2012.
4. Swigris JJ, Han MK, Vij R, Noth E, Eisenstein EL, Anstrom KJ, Brown KK, Fairclough D. UCSD Shortness of Breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. *Respir Med*, 106:1447-1455, 2012. (*based on the STEP trial of the IPFnet.*)
5. Han MK, Bach DS, Hagan P, Yow E, Flaherty K, Toews GB, Anstrom KJ, Martinez FJ, for the IPFnet. Sildenafil preserves exercise capacity in IPF patients with right ventricular dysfunction. *Chest* 143:1699-1708, 2013.
6. Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C, **IPFnet investigators**. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. *Respir Res*. Jul 13;14:73. Doi: 10.1186/1465-9921-14-73, 2013.



7. Lee JS, Collards HR, Anstrom KJ, Martinez FJ, Noth Im Roberts RS, Yow E, Raghu G, for the **IPFnet Investigators**. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomized controlled trials. *Lancet Respir Med*, 1:369-376, 2013.
8. Swigris JJ, Streiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS; **IPFnet Investigators**. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. *Respir Med*. 2014 Jan;108(1):181-8. doi: 10.1016/j.rmed.2013.12.009. Epub 2013 Dec 24.
9. **IPF Clinical Research Network**, Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. *NEJM* 370:2093-2101, 2014.
10. De Andrade J, Schwartz M, Collard HR, Gentry-Bumpass, Colby T, Lynch D, Kaner RJ,; **IPFnet Investigators**. The idiopathic pulmonary fibrosis clinical research network (IPFnet): Diagnostic and adjudication processes. *Chest* 148:1034-1042, 2015.
11. Oldham JM, Ma SF, Martinez FJ, Anstrom KJ, Raghu G, Schwartz DA, Valenzi E, Witt L, Lee DC, Vij R, Huang Y, Streck ME, Noth I; **IPFnet investigators**. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 192:1472-1482, 2015.
12. Salisbury ML, Lynch DA, van Beek EJ, Kazerooni EA, Guo J, Xia M, Murray S, Anstrom KJ, Yow E, Martinez FJ, Hoffman EA, Flagerty KR; **IPFnet investigators**. Idiopathic pulmonary fibrosis: The association between the adaptive multiple features method and fibrosis outcomes. *Am J Respir Crit Care Med*. 195:921-929, 2017.
13. Yagihashi K, Huckleberry J, Colby TV, Tazelaar HD, Zach J, Sundaram B, Pipavath S, Schwarz MI, Lynch DA, **IPFnet Investigators**. Radiographic-pathologic discordance in biopsy-proven usual interstitial pneumonia. *Eur Respir J*. 47:1189-1197, 2016.
14. Durham MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE Jr, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, Martinez FJ, **IPFnet Investigators**. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. *Lancet Respir Med*. 3:388-396, 2015.
15. Collard HR, Brown KK, Martinez FJ, Raghu G, Roberts RS, Anstrom KJ; **IPFnet investigators**. Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. *Chest*. 146:1256-1262, 2014.

**Clinical trials related to INSPIRE, CAPACITY, INPULSIS, SENSICIS and other clinical trials:**

16. King TE, Albera C, Bradford WZ, et al., for the **Inspire Study Group**. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (**INSPIRE**): a

- multicentre, randomized, placebo-controlled trial. *Lancet*, 374 (9685):222-228, 2009. **Roman J** was member of Inspire Study Group (collaborator) and participated in patient recruitment as site PI.
17. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr., Lancaster L, Sahn SA, Szwarberg J, Valeyre D, du Bois RM, for the CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. *Lancet* 377:1760-1769, 2011. **Roman J** was a member of the CAPACITY Study Group (collaborator) and participated in patient recruitment as Site PI.
  18. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, Flaherty KR, Frankel S, Oddis CV, Denton CP, Fisher A, Kowal-Bielecka OM, LeSage D, Merkel PA, Phillips K, Pittrow D, Swigriss J, Antoniou K, Baughman RP, Castelino FV, Christmann RB, Christopher-Stine L, Collard HR, Cottin V, Danoff S, Highland KB, Hummers L, Shah AA, Kim D, Lynch DA, Miller FW, Proudman SM, Richeldi L, Ryu JH, Sandorfi N, Sarver C, Wells AU, Strand V, Matteson EL, Brown KK, Seibold JR. Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. *Thorax* doi:10.1136/thoraxjnl-2013-204202, 2014. **Roman J** was a “Contributor Delphi Co-Author” in the publication. He assisted with survey responses, among other duties.
  19. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceq R, Disse B, Collard HR; **IMPULSIS TRIAL INVESTIGATORS**. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *NEJM* 370:2071-2082, 2014. **Roman J** was a member of the IMPULSIS TRIAL INVESTIGATORS and chaired the Adjudication Committee of this trial.
  20. Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group. Reconciling healthcare professional and patient perspective in the development of disease activity and response criteria in connective tissue disease-related interstitial lung disease. *J Rheumatol* 41:792-798, 2014. **Roman J** was a “Contributor Delphi Co-Author” in the publication. He assisted with survey responses, among other duties.
  21. Wilkes DS, Chew T, Flaherty KR, Frye S, Gibson KF, Kaminski N, Klemsz MJ, Lange W, Noth I, Rothaar K. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. *Eur Respir J* 45:1393-1402, 2015. **Roman J** assisted with patient recruitment as site PI and clinical trial investigator for this project.
  22. Distler O, Highland KB, Gahlemann M, Azuma A, Fisher A, Mayes MD, Rahgu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; **SENCIS Trial Investigators**. Nintedanib for systemic sclerosis-associated interstitial lung disease. **Dr. Roman** assisted in patient recruitment and was site PI and clinical trial investigator for this project.

23. Allanore Y, Khanna D, Smith V, Aringer M, Hoffmann-Vold, A-M, Kuwana M, Merkel PA, Stock C, Sambevski S, Denton CP. Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease. *Rheumatology (Oxford)*. 63:639-647, 2024. **Dr. Roman** assisted in patient recruitment and was site PI and clinical trial investigator for this project.

**Manuscripts related to participation in patient registry-related research (corporate authorship or not necessarily recognized by author) – IPF-PRO and ILD-PRO. Roman J** serves as an IPF-PRO and IPF-ILD investigator. He served as Site PI for this registry at the University of Louisville and later at the Thomas Jefferson University. He serves on the steering committee and participated in study design, patient recruitment, data interpretation, and manuscript approval.

1. Kim HJ, Snyder LD, Adgunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Streck ME and The **IPF-PRO Registry Investigators**. Hospitalizations in patients with idiopathic pulmonary fibrosis. *Respir Res*. 2021; 22: 257.
2. De Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conocenti CS, Snyder LD; **IPF-PRO Investigators**. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. *Respir Res*. 2022; 23(1):3.

#### **Selected abstracts and papers presented at scientific meetings since 2018 (from over 200)**

1. Gualdoni J, Ritzenthaler JD, Burlen J, Abell T, **Roman J**, Nunley DR. Gastroesophageal reflux and associated microaspiration in lung transplant recipients. Presented during the International American Thoracic Society meeting in May 2018 (San Diego).
2. Ritzenthaler JD, Watson WH, Peyrani P, Wiemken T, Burke TJ, Zheng Y, Ramirez JA, **Roman J**. Redox states of cysteine/cystine and glutathione/glutathione disulfide in plasma and bronchoalveolar lavage fluid in HIV-infected patients with COPD. Presented during the International American Thoracic Society meeting in May 2018 (San Diego).
3. Gualdoni J, Ritzenthaler JD, Elkhawas I, Bauldoff GS, Nunley DR, **Roman J**. Aspiration of gastrointestinal material induces fibronectin promoter luciferase activity – Implications for early airway remodeling in the allograft of lung transplant recipients. Presented during the International American Thoracic Society meeting in May 2018 (San Diego).
4. Ritzenthaler JD, Watson WH, Zheng Y, Burke TJ, Torres-Gonzalez E, Arteel G, **Roman J**. role of  $\alpha 4$  nicotinic acetylcholine receptors in regulation of fibronectin expression and redox state in lung fibroblasts. Presented during the International American Thoracic Society meeting in May 2018 (San Diego).

5. Ritzenthaler JD, Zhang Y, Burke TJ, Otero J, **Roman J**, Watson WH. Alterations in the expression of Slc7a11 in murine lung fibroblast responsible for aging-dependent oxidation of cysteine/Cystine redox state (Eh cys/CySS). Presented during the International American Thoracic Society meeting in May 2018 (San Diego).
6. Suliman SA, Ritzenthaler JD, Peyrani P, Wiemken T, Burke TJ, Zheng Y, Ramirez JA, Watson WH, **Roman J**. Redox states of thiol disulfide couples and markers of extracellular matrix remodeling in bronchoalveolar lavage fluid of HIV-infected subjects with COPD. Presented during the International American Thoracic Society meeting in May 2018 (San Diego).
7. McAllister R, Torres-Gonzalez E, Ritzenthaler JD, Hoyle GW, **Roman J**. Perinatal nicotine exposure along with early life Influenza A 2009 pandemic H1N1 (Swine Flu) infection leads to lung dysfunction in adulthood. Presented during the International American Thoracic Society meeting in May 2018 (San Diego).
8. Greenwell J, Torres-Gonzalez E, Ritzenthaler JD, **Roman J**. Fibronectin EDA is essential for bleomycin-induced augmentation of pulmonary metastasis in aging mice. Presented during the International American Thoracic Society meeting in May 2018 (San Diego).
9. Gualdoni J, Ritzenthaler JD, Burlen J, Abell T, **Roman J**, Nunley DR. Gastroesophageal reflux and microaspiration in lung transplant recipients: The utility of a single esophageal manometry and pH probe monitoring test. Presented at CHEST, San Antonio, Oct 2018.
10. Culver DA, Yow E, Neely ML, Belperio JA, Bender S, de Andrade JA, **Roman J**, Whelan T, Palmer S, Conoscenti CS, on behalf of the IPF-PRO Registry Investigators. Presented at CHEST, San Antonio, Oct 2018.
11. Todd JL, Durham K, Overton R, Neely ML, Belperio JA, Gulati M, Huang HJ, **Roman J**, Newby K, Noth I, Vinisko R, Liu Y, Hesslinger C, Leonard T, Flaherty KR, Palmer SM. Peripheral Blood Proteomic Profiling to Distinguish Disease Biomarkers in the Multicenter IPF-PRO Registry Cohort. Presented at ATS Meeting, Dallas, May 2019.
12. Todd JL, Neely ML, Overton R, Gulati M, Huang HJ, **Roman J**, Flaherty KR, Vinisko R, Hesslinger C, Leonard T, Noth I, Palmer SM, Belperio JA. Association of Circulating Proteins with Disease Specific Measures in the Multicenter IPF-PRO Registry Cohort. Presented at ATS Meeting, Dallas, May 2019.
13. Arocho G, Gonzalez S, Atencio X, **Roman J**, Roman R, Carrero M. Description and characterization of patients evaluated at the Center for Pulmonary Fibrosis in Mayaguez Medical Center. Presented at ATS Meeting, Dallas, May 2019.

14. Ritzenthaler J, Torres-Gonzalez E, Arteel GE, **Roman J**. The In Vivo Effects of Alcohol in Lung are at Least Partially Mediated Through the Alpha 4 Nicotinic Acetylcholine Receptor. American Thoracic Society International Conference, May 2019, Dallas, TX
15. **Roman J**, Torres-Gonzalez E, Ritzenthaler JD, Watson WH, Romero F, Summer RS. Hermansky-Pudlak Syndrom-1 (HPS-1) lung fibroblasts show a profibrotic phenotype characterized by decreased Slc7a11, a phenotype shared by aging and IPF lungs. To be presented at the 2023 International Conference of the American Thoracic Society, Washington, DC.
16. **Roman J**, Ritzenthaler JD, Torres-Gonzalez E, Watson WH. Role of a4 nicotinic acetylcholine receptors (a4 nAChRs) in lipopolysaccharide-induced lung injury. To be presented at the 2023 International Conference of the American Thoracic Society, Washington, DC.
17. Mallozzi M, Pena DE, **Roman J**, Most JF. The use of biologics in a real-world setting reduces hospitalizations. To be presented at the 2023 International Conference of the American Thoracic Society, Washington, DC.
18. **Roman J**, Ritzenthaler JD, Torres-Gonzalez E. Embryologic origins of obstructive lung disease: perinatal nicotine exposure promotes expression of tissue remodeling genes in lung. To be presented at the 2023 International Conference of the American Thoracic Society, Washington, DC.
19. Fares J, Zhao J, George G, Maheu A, Loizidis G, **Roman J**, Kramer DR, Li M, Summer RS. Racial and ethnic disparities in antifibrotic therapy in IPF. To be presented at the 2023 International Conference of the American Thoracic Society, Washington, DC.
20. Summer RS, Todd JL, Neely ML, ....., and **Roman J**. Association of circulating metabolites with disease severity and mortality in patients with IPF: data from the IPF-PRO Registry. To be presented at the 2023 International Conference of the American Thoracic Society, Washington, DC.

### **Editorials, reviews, chapters**

#### **Review articles:**

1. **Roman J**, McDonald JA. Lung extracellular matrix: Physiology and pathophysiology. *Hosp Pract* 25:125-40, 1990.
2. **Roman, J**, McDonald, JA. Cellular processes in lung repair. *Chest*, 100:245-248, 1991.

3. Limper AH, **Roman J**. Fibronectin: A versatile matrix protein with roles in pulmonary development, repair, and infection. *Chest* 101:1663-1673, 1992.
4. SM Aguayo, JC Flowers, JG Ford, KF Gibson, JH Jackson, JS Lwebuga-Mukasa, **J Roman**, JM Samet, AV Thomas, RC Young. NHLBI Working Group Report: Respiratory diseases disproportionately affecting minorities. *Chest* 108:1380-1392, 1995.
5. **Roman, J**. Extracellular matrix and lung inflammation. *Immunologic Research* , 15:163-178, 1996.
6. **Roman, J**. Fibronectin and fibronectin receptors in lung development. *Exp. Lung Res*, 23:147-159, 1997.
7. Lois, M, **Roman, J**, Honig, E. Using  $\beta$ -blockers for CHF in patients with COPD. *J Respir Dis*, 20:31-43, 1998.
8. Michaelson, J, Aguayo, SM, **Roman, J**. Idiopathic Pulmonary Fibrosis: A practical approach for diagnosis and management. *Chest* 20:788-794, 2000.
9. **Roman, J**. Indications for lung biopsy in Idiopathic Pulmonary Fibrosis. Harrison's Online (Editor: E. Braunwald).
10. Guidot DM and **Roman J**. Chronic ethanol ingestion increases susceptibility to acute lung injury: role of oxidative stress and tissue remodeling. *Chest*. 122:309S-314S. 2002.
11. Perez RL, Rivera-Marrero CA, **Roman J**. Pulmonary granulomatous inflammation: From Sarcoidosis to Tuberculosis. *Seminars in Respiratory Medicine* (requested review) 18:23-32, 2003.
12. **Roman, J** and Perez, RL. COPD in veterans. Requested Review. *Clinical Cornerstones* 5:37-44, 2003.
13. Han SW and **Roman J**. Extracellular matrix and aberrant signaling in lung carcinoma: Role of fibronectin in control of lung carcinoma cell proliferation, apoptosis and resistance to therapy. *Current Signal Transduction Therapy*. 2:1-10, 2007.
14. Han SW and **Roman J**. PPAR $\gamma$ : A novel target for cancer therapies? *Anti-Cancer Drugs*, 18:237-244, 2007
15. Keshamouni VG, Han SW, **Roman J**. Peroxisome proliferator activated receptors in lung cancer. *PPAR Research*, ID 90289 (doi:10.1155/2007/90289), Hindawi Publishing Corporation, 2007; 2007:90289.
16. Standiford TJ and **Roman J**. PPARs in lung biology and disease. *PPAR Res* 2007; 2007:28765.

17. **Roman J.** PPAR $\gamma$  in lung cancer biology: Implications for therapy. *J Invest Med.* 56:528-533, 2008.
18. Collard HR, BB Moore, KR Flaherty, KK Brown, RJ Kaner, TE King, JA Lasky, JE Loyd, I Noth, MA Olman, G Raghu, **J Roman**, JH Ryu, DA Zisman, GW Hunninghake, TV Colby, JJ Egan, DM Hansell, T Johkoh, N Kaminski, DS Kim, Y Kondoh, DA Lynch, J Müller-Quernheim, JL Myers, AG Nicholson, M Selman, GB Toews, AU Wells, FJ Martinez with the IPFNet Investigators. Pulmonary Perspective: Acute exacerbations of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*, 176:636-643, 2007.
19. Blanquicett C, **Roman J**, Hart CM. Thiazolidinediones as anti-cancer agents. *Cancer Therapy*, 6A:25-34, 2008.
20. Ritzenthaler JD, Han SW, **Roman J.** Stimulation of lung carcinoma cell growth by fibronectin-integrin signaling. *Mol Biosystems*, 4:1160-1169, 2008 (highlighted in RSC's Chemical Biology Research Articles).
21. Hart CM, **Roman J**, Reddy R, Sime PJ. PPAR $\gamma$ : A novel molecular target in lung disease. *J Investig Med*, 56:515-517, 2008.
22. Han SW and **Roman J.** Activated PPAR $\gamma$  targets surface and intracellular signals that inhibit the proliferation of lung carcinoma cells. *PPAR Research*, 2008;2008:254108.
23. Wongtrakool C and **Roman J.** Tobacco smoke exposure, nicotine and the embryologic origins of asthma. *Current Respiratory Medicine Reviews*. May; 5(2): 96-104, 2009.
24. Han S and **Roman J.** Targeting Apoptotic Signaling Pathways in Human Lung Cancer. *Curr Cancer Drug Targets*. 10:566-574, 2010.
25. Fioret D, Perez RL, Roman J. Management of Idiopathic Pulmonary Fibrosis. *Am J Med Sciences*, 341:450-453, 2011.
26. Thannickal VJ, Henke C, Horowitz JC, Noble P, **Roman J**, Sime P, Zhou Y, Wells RG, White ES, Tschumperlin D. Matrix Biology of Idiopathic Pulmonary Fibrosis: A Summary from a National Heart, Lung and Blood Institute Workshop. *Am J Pathol*, 184:1643-1651, 2014.
27. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Cosgrove GP, Deterding R, Doyle R, Flaherty KJ, Garcia CK, Hagood JS, Henke CA, Herzog E, Hogaboam CM, Horwitz JC, King TE, Loyd JE, Lawson WE, Marsh CB, Noble PW, Noth I, Sheppard D, Olsson J, Ortiz LA, O'Riordan TG, Oury TD, Sisson TH, Raghu G, **Roman J**, Sime PJ, Tschumperlin D, Violette SM, Weaver TE, Wells TG, White ES, Kaminski N, Martinez FJ, Wynn TA, Thannickal VJ, Eu JP. NHLBI Workshop Summary – Future directions in Idiopathic Pulmonary Fibrosis Research. *Am J Respir Crit Care Med*, 189:214-222, 2014.

28. William H. Goodson III, WH, Lowe L, Carpenter DO, Gilbertson M, Ali AM, Lopez de Cerain Salsamendi A, Lasfar A, CarneroA, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen A-K, Berg, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglolle C, Dong C, Mondello C, Hsu C-W, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown D et al. , Edward Ratovitski<sup>31</sup>, Elizabeth P. Ryan<sup>30</sup>, Emanuela Corsini<sup>32</sup>, Emilio Rojas<sup>33</sup>, Eun-Yi, Raju J, ..., **Roman J**, Wise JP, ..., Chen Z, Hu Z. Assessing the Carcinogenic Potential of Low Dose Exposures to Chemical Mixtures in the Environment: The Challenge Ahead. *Carcinogenesis* 36: Suppl 1:S254-96, 2015
29. Casey SC, Vaccri M, Al-Mulla F, Al-Temaimi R, Amedei A, Barcellos-Hoff MH, ..., **Roman J**, Roy R, Ryan EP... The effect of environmental chemicals on the tumor microenvironment. *Carcinogenesis* 36 Suppl 1:S160-83, 2015.
30. Massey VL, Beier JI, Ritzenthaler JD, **Roman J**, Arteel G. Potential role of the gut/liver/lung axis in alcohol-induced tissue pathology. *Biomolecules* 5:2477-2503,2015.
31. Williams K and **Roman J**. Studying human respiratory disease in animals – Role of induced and naturally-occurring models. *Journal of Pathology* 238:220-232, 2016
32. White ES, Borok Z, Brown K, Eickelberg O, Guenther A, Jenkins G, Kolb M, Martinez FJ, **Roman J**, Sime P. Future directions in pulmonary fibrosis research – an official ATS Research Statement. *Annals of Am Thor Soc*, 2016, 193:792-800, 2016.
33. Watson WH, Ritzenthaler JD, **Roman J**. Lung extracellular matrix and redox regulation. *Redox Biol* 8:305-315, 2016.
34. Vicary GW, Vergne Y, Santiago-Cornier A, Young LR, **Roman J**. Pulmonary fibrosis in Hermansky Pudlak Syndrome. *Annals of Am Thor Soc*, 13:1839-1846, 2016.
35. Vicary GW and **Roman J**. Targeting the mammalian target of rapamycin (mTOR) in lung cancer. *Am J Med Sci*, 352:507-516, 2016.
36. Holguin F, Moughrabieh MA, Ojeda V, Patel SR, Peyrani P, Pinedo M, Celedon JC, Douglas IS, Upson DJ, **Roman J**. Respiratory health in migrant populations – a crisis overlooked. *Annals of Am Thoracic Soc*, 14:153-159, 2017.
37. Bagnato G, Roberts NW, **Roman J**, Gangemi S. A systematic review of overlapping microRNA patterns in systemic sclerosis and idiopathic pulmonary fibrosis. *Eur Respir J*, 2017, May 17;26(144). pii: 160125. doi: 10.1183/16000617.0125-2016.
38. Presti R, Flores S, Palmer B, Atkinson J, Lesko, C, Lau B, Fontenot A, Roman J, McDyer J, Twig III H. Mechanisms underlying HIV associated non-infectious lung disease. *CHEST*, 152:1053-1060, 2017.
39. Kolb M, Bondue B, Pesci A, Miyazaki Y, Song JW, Bhatt NY, Huggins JT, Oldham JM, Padilla ML, **Roman J**, Shapera S. Acute exacerbations of progressive-fibrosing



- interstitial lung disease. *Eur Respir Rev.* 27(150). Pii: 180071. doi: 10.1183/16000617.0071-2018, 2018.
40. **Roman J.** El albinismo y la fibrosis pulmonary (Albinism and pulmonary fibrosis). *Medicina y Salud Publica* LXXIII 14-18, 2019.
  41. Culver DA, Behr J, Belperio JA, Corte TJ, de Andrade JA, Flaherty KR, Gulati M, Huie TJ, Lancaster LH, Roman J, Ryerson CJ, Kim HJ. Patient registries in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2019; 200:160-167
  42. Hilton R, Summer R, **Roman J**, Sundaram B, George G. E-cigarettes and vaping associated lung injury: a case series and brief review. *Am J Med Sci*, 359:137-139, 2020.
  43. Pandit P, Perez RL, **Roman J.** Sex-related differences in interstitial lung disease. *Am J Med Sci.* 2020 Apr 25:S0002-9629(20)30154-3. doi: 10.1016/j.amjms.2020.04.023.
  44. Venkata-Subramani M, Nunley D, **Roman J.** Donor factors and risk of primary graft dysfunction and mortality post lung transplantation – A proposed conceptual framework. *Clinical Transplantation*, Sep 13:e14480, 2021.
  45. **Roman J.** Fibroblasts – Warriors at the intersection of wound healing and tissue disrepair (requested review). *Biomolecules*, 13(6)945, 2023
  46. Howard-Anderson JR, Gewin L, Rocky D, Krousel-Wood M, **Roman J.** Strategies for developing a successful career in academic medicine. *Am J Med Sci*, 367:15-27, 2024.
  47. Pulmonary manifestations of alpha1 antitrypsin deficiency. *Am J Med Sci*, accepted.

**Symposium contributions, editorials, commentaries, position papers, and letters:**

1. **Roman, J.** Protein kinases and cytoskeletal integrity modulate the expression of fibronectin by affecting cyclic AMP binding element. In the proceedings of the Aspen Lung Conference on Pulmonary Fibrosis. *Chest* 120:19S-20S, 2001.
2. **Roman, J.** Increased gelatinolytic activity in sarcoidosis. In the proceedings of the Aspen Lung Conference on Pulmonary Fibrosis. *Chest* 120, 2001.
3. **Roman J** and Galis Z. Sarcoidosis: Activation of tissue remodeling in sarcoid granulomas. *Hum Pathol* Requested Editorial, 33:1155-1156, 2002.
4. Han S, Sidell N, Fisher PB, **Roman J.** Ligands of Peroxisome Proliferator-Activated Receptor gamma Inhibit Lung Cancer Cell Growth and Induce Apoptosis by Stimulation of P21 Expression. *Chest.* 2004125:134S, 2004
5. American Thoracic Society Research Policy Statement Human Embryonic Stem Cell Research, *Am J Respir Cri Care Med*, 173:1043-1045, 2006. **Roman J**, Comm member.

6. Khuri F and **Roman J**. From nihilism to individualism: the evolution of lung cancer therapy. Requested editorial, *Am J Respir Crit Care Med*, 12:1299-1300, 2008.
7. **Roman J**. Creating a culture of discovery through clinical and translational research. *Am J Med Sci*, 337:155, 2009.
8. Raghu and IPFNET Investigators. Improving the standard of care for patients with idiopathic pulmonary fibrosis requires participation in clinical trials. *Chest*, 136:330-333, 2009.
9. **Roman J**. Moving away from PPARs – EGFR signaling and the anti-cancer effects of thiazolidinediones. Research Highlight, *Cell Research*, 19:669-671, 2009.
10. Ahmad F and **Roman J**. Treating refractory asthma with antibodies against Interleukin-5 – Is it ready for prime time? *Expert Review in Respiratory Medicine*, 3:227-230, 2009.
11. **Roman J** and Koval MH. Control of lung epithelial growth by a nicotinic acetylcholine receptor: the other side of the coin. *Am J Pathol*, 175:1799-1801, 2009.
12. **Roman J**. Getting trainees ‘hooked’ on academic medicine. *Am J Med Sci*, 338:436-437, 2009.
13. **Roman J**. The future of ILD treatment rests in research. *Louisville Medicine*, 57:20-21, 2010.
14. Thannickal V and **Roman J**. Challenges in Translating Pre-Clinical Studies to Effective Drug Therapies in Idiopathic Pulmonary Fibrosis? *Am J Respir Crit Care Med*, 181:532-533, 2010.
15. **Roman J**. Southern Society for Clinical Investigation – Is it time for evolution? *Am J Med Sci*, 340:3-4, 2010.
16. Perez RL and **Roman J**. Idiopathic Pulmonary Fibrosis – An enigmatic disease in search for a cause and a cure. *Lung Health Professional*, <http://lunghealthprofessional.org/p-37>, 2010.
17. IPFnet Investigators. The IPFnet strategy: Creating a Comprehensive Approach in the Treatment of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med*, 181:527-528, 2010.
18. Kubiak N, Guidot DM, Trimm RF, Kamen DL, **Roman J**. Recruitment and retention in academic medicine – What junior faculty and trainees want department chairs to know. *Am J Med Sci*, 344:24-27, 2012
19. Reddy RC, Rehan VK, **Roman J**, Sime PJ. PPARs: Regulators and translational targets in the lung. *PPAR Research*, 2012;2012:342924. Doi: 10.1155/2012/342924.

20. **Roman J**, Brown KK, Olson A, Corcoran BM, Williams KJ; ATS Comparative Biology Working Group. An Official American Thoracic Society Workshop Report: Comparative Pathobiology of Fibrosing Lung Disorders in Humans and Domestic Animals. *Ann Thorac Soc* 10:S224-S229, 2013.
21. **Roman J**. Chronic alcohol ingestion and predisposition to lung ‘cirrhosis’. *Alcoholism Clinical & Experimental Research*, 297:670-700, 2014.
22. **Roman J**. 2014 Southern Society for Clinical Investigation Founders’ Medal Acceptance: An academic career – it takes a village. *Am J Med Sci*, 2014 (Epub ahead of print).
23. Celedon JC, **Roman J**, Schraufnagel DE, Thomas A, Samet J; a working group of the Health Equality Sub-Committee of the American Thoracic Society. Respiratory Health Equality in the United States: the American Thoracic Society Perspective. *Ann Am Thorac Soc*, 11:473-479, 2014.
24. White ES, Brown KK, Collard HR, Conoscenti CS, Cosgrove GP, Eu JP, Flaherty KR, Leff JA, Martinez FJ, **Roman J**, Rose D, Violette S, Kaminski N. Open-Access Biorepository for Idiopathic Pulmonary Fibrosis: The way forward. *Annals Am Thorac Soc*. 11:1171-1175, 2014.
25. **Roman J**. The Puerto Rico Health Crisis. *Annals of the American Thoracic Society*, 12:1760-1763, 2015.
26. Burnham EL and **Roman J**. Composition of the Sepsis Definitions Task Force. *JAMA* 316:460-461, 2016.
27. **Roman J** and Cribbs SK. Presentation of 2017 SSCI Founders Medal. *Am J Med Sci*. 354:75-77, 2017.
28. **Roman J**. On the ‘TRAIL’ of a killer: MMP12 in lung cancer. *Am J Respir Crit Care Med*. 196:262-264, 2017.
29. Celedon JC, Burchard EG, Schraufnagel D, Castillo-Salgado C, Schenker M, Balmes J, Neptune E, Cummings KJ, Holguin F, Riekert KA, Wisnivesky JP, Garcia JGN, **Roman J**, Kittles R, Ortega VE, Redine S, Mathias R, Thomas A, Samet J, Ford JG; on behalf of the American Thoracic Society and the National Heart, Lung and Blood Institute. An American Thoracic Society/National Heart, Lung, and Blood Institute Workshop Report: Addressing respiratory health equality in the United States. *Annals ATS*. 14:814-826, 2017.
30. **Roman J**. Hurricane Maria: a humanitarian and healthcare disaster unveiling the Puerto Rican dilemma. *Ann Am Thorac Soc*. 15:293-295, 2018.
31. **Roman J**, Viegi G, Schenker M, Ojeda VD, Perez-Stable E, Nemery B, Annesi-Maesano I, Patel SR, La Grutta S, Holguin F, Moughrabieh A, Bime C, Lindberg A, Migliori GB, de

- Vries G, Ramirez J, Aliberti S, Feldman C, Celedon JC. An American Thoracic Society and European Respiratory Society Workshop Report: Research Needs on Respiratory Health in Migrant and Refugee Populations. *Ann Am Thorac Soc*, Accepted for publication.
32. **Roman J** and Mutsaers SE. Epigenetic control of CXC10: regulating the counterregulator in IPF. *Am J Respir Cell Mol Biol*, 58:419-420, 2018.
  33. Gupta E, Jacobs MD, George G, **Roman J**. Beyond the ICU – Frailty and post-ICU disability, nursing home admission, and mortality; healthcare utilization and costs in ARDS survivors; and increased healthcare facility use after severe sepsis. *Am J Respir Crit Care Med*, accepted for publication.
  34. **Roman J**. Update on pulmonary fibrosis: Great advances, but still searching for answers. *Am J Med Sci* 357:357-358, 2019.
  35. Barnes T, Brown KK, Corcoran B, Glassberg MK, Kervitsky DJ, Limper AH, McGuire K, Williams K, **Roman J**, for the Comparative Biology of Pulmonary Fibrosis Working Group. 357:399-404, 2019.
  36. **Roman J**, Barnes TR, Kervitsky DJ, Cosgrove GP, Doherty DE, Tager AM, Richeldi L, White ES, Brenner DA, Schnapp LM, Hewitson TD, Jugdutt BI, McKinsey TA, Tosi JD, Crane S, Brown KK, for the Fibrosis Across Organs Symposium Working Group. *Am J Med Sci* 357: 405-410, 2019.
  37. Perez RL, **Roman J**. Granulomatous inflammation and the lymphatic system – Perhaps a new target for intervention in tuberculosis and sarcoidosis. *BioEssays*, 2019. Nov;41(11):e1900167. doi: 10.1002/bies.201900167
  38. **Roman J**. Coronavirus: Lessons learned? *Am J Med Sci*. 360(3):313. doi: 10.1016/j.amjms.2020.06.002.
  39. Perez RL and **Roman J**. Coronavirus pandemic: At the beginning of the learning curve. *Am J Med Sci*. 2020 Jun 3:S0002-9629(20)30244-5. doi: 10.1016/j.amjms.2020.06.002.
  40. Perez T, Perez RL, **Roman J**. Conducting clinical trials in the era of COVID-19. *Am J Med Sci*. 2020 Jun 10:S0002-9629(20)30253-6. doi: 10.1016/j.amjms.2020.06.011.
  41. Venkata-Subramani M and **Roman J**. India’s coronavirus response: World’s largest lockdown. *Am J Med Sci*. 2020 Aug 5:S0002-9629(20)30351-7. doi: 10.1016/j.amjms.2020.08.002
  42. Thakur N, Lovinsky-Desair S, Appell D, Bime C, Castro L, Celedon J, Ferreira J, George M, Mageto Y, mainous Iii AG, Pakhale S, Riekert KA, **Roman J**, Ruvalcaba E, Sharma S, Shete P, Wisnivesky JP, Holguin F. An official American thoracic Society Research Statement: Enhancing recruitment and retention of minority populations for clinical research in Pulmonary, Critical Care and Sleep Medicine. *Am J Respir Crit Care Med*, 204: e26-e50, 2021.

43. **Roman J.** A tribute to the gang. *The Lancet Respiratory*, 2021; 9:345-346.
44. **Roman J** and Chiba H. B-cells in idiopathic pulmonary fibrosis - Targeting immune cells with antifibrotic agents. *Am J Respir Cell Mol Biol.* 64:652-654, 2021.
45. Downey GP, Rivera MP, Schnapp L, Petrache I, **Roman J**, Collishaw K. Be the Change: Advancing Lung Health and Closing the Global Health Care Gap. *Am J Respir Crit Care Med.* 206:667-669, 2022.
46. Downey G, Petrache I, **Roman J**, Schnapp L. Considerations in Selecting Venues for the ATS International Conference: Balancing Competing Priorities of the Society's Diverse Membership. *Ann Am Thorac Soc.* 2023. Accepted.
47. **Roman J.** First, do no harm – The Puerto Rican saga continues. *Medicina y Salud Publica.* April 10, 2023. [First, Do No Harm – The Puerto Rican Saga Continues \(medicinaysaludpublica.com\)](https://www.medicinaysaludpublica.com)
48. Atabai K, Badr MS, Costello J, Ridge K, Rounds S, Turenne M, White ES, **Roman J.** The American Thoracic Society Research Program (ATSRP) – Twenty years of driving discovery in respiratory medicine. *Am J Respir Crit Care Med*, online ahead of print, 2024.

### Book chapters

1. Senior KM, Griffin GL, **Roman J**, Hinek A, Crouch EC, Mecham RP. Extracellular matrix components as mediators of inflammation. In PM Henson, RC Murphy (eds.), *Handbook of Inflammation*, vol. 6. Amsterdam/New York: Elsevier, 1989, pp. 339-59.
2. **Roman J**, McDonald JA. Fibronectin in lung. In Crystal, West, Barnes, Cherniak, Weibel (eds.), *The Lung: Scientific Foundations*. NY: Raven Press, pp. 399-411, 1991.
3. **Roman, J.** Cell-cell and cell-matrix interactions and development of lung vasculature. In: *Growth and development of the lung*. Ed. J. A. McDonald. Marcel Dekker, Inc., New York 1997; pp. 365-399.
4. **Roman, J.** and McDonald, J. A. Fibronectin and fibronectin receptors in lung development, injury and repair. In Crystal, West, Barnes, Cherniak, Weibel (eds.), *The Lung: Scientific Foundations (second edition)*. NY: Raven Press, 1997.
5. **Roman, J.** Extracellular matrix and lung inflammation. *Immunologic Research* , 15:163-178, 1996.
6. Guidot, D.M., **Roman, J.** and Francis, P.B.: Pulmonary Diagnostic Techniques. The Emory University Comprehensive Board Review in Internal Medicine. Stein, S.F. and Kokko, J.P. ed. McGraw-Hill, New York, 1997, 1998, 1999, and 2000 versions.

7. **Roman, J.** Cellular and molecular mechanisms of lung development. Pulmonary Textbook: *Pulmonary Diseases and Disorders*, A. P. Fishman, (Ed), Third Edition; McGraw Hill, York, 1998; pp:73-90.
8. **Roman, J.** Extracellular matrices in interstitial lung disease. In: *Interstitial Lung Disease*. M Schwarz and T King (Eds). B. C. Decker, Inc., London; Third Edition., pp:207-227.
9. Tomic R, **Roman J.** Hypersensitivity Pneumonitis, Contributions to *Encyclopedic Reference of Molecular Mechanisms of Disease*, Ed. F Lang, Springer Publications, Springer-Verlag Heidelberg, 2003.
10. **Roman, J.** Extracellular matrices in lung injury and repair. In: *Interstitial Lung Disease*. M Schwarz and T King (Eds). B. C. Decker, Inc., London; Fourth Edition; p: 276-299, 2003.
11. **Roman J**, Hart CM, Han S. *Peroxisome proliferator activated receptors (PPAR)*. In: Encyclopedia of Respiratory Medicine (Eds: Laurent and Shapiro), Elsevier Ltd, Oxford, UK. 2006. pp. 327-331.

**Contributions to Cecil's Essentials in Internal Medicine, 7<sup>th</sup> Edition, Ed. Andreoli.  
Chapters related to the Pulmonary Disease Section:**

12. **Roman J** and Brigham KL. The lung in health and disease. Cecil's Essentials in Internal Medicine, Ed. Andreoli, 7<sup>th</sup> Edition, 193-195, 2007
13. Slovis B, **Roman J** and Brigham KL. General approach to patients with respiratory disorders. Cecil's Essentials in Int Medicine, Ed. Andreoli, 7<sup>th</sup> Edition, 196-200, 2007.
14. Slovis B, **Roman J** and Brigham KL. Evaluating lung structure and function. Cecil's Essentials in Internal Medicine, Ed. Andreoli, 7<sup>th</sup> Edition, 201-213, 2007
15. **Roman J** and Brigham KL. Obstructive lung disease. Cecil's Essentials in Internal Medicine, Ed. Andreoli, 7<sup>th</sup> Edition, 214-223, 2007
16. **Roman J** and Brigham KL. Interstitial lung disease. Cecil's Essentials in Internal Medicine, Ed. Andreoli, 7<sup>th</sup> Edition, 224-237, 2007
17. **Roman J** and Brigham KL. Pulmonary vascular disease. Cecil's Essentials in Internal Medicine, Ed. Andreoli, 7<sup>th</sup> Edition, 238-241, 2007.
18. **Roman J** and Brigham KL. Disorders of respiratory control. Cecil's Essentials in Internal Medicine, Ed. Andreoli, 7<sup>th</sup> Edition, 242-243, 2007
19. **Roman J** and Brigham KL. Disorders of the pleura, chest wall and mediastinum. Cecil's Essentials in Internal Medicine, Ed. Andreoli, 7<sup>th</sup> Edition, 244-248, 2007

20. **Roman J** and Brigham KL. Infectious diseases of the lung. Cecil's Essentials in Internal Medicine, Ed. Andreoli, 7<sup>th</sup> Edition, 249-252, 2007
21. **Roman J** and Brigham KL. Critical care medicine. Cecil's Essentials in Internal Medicine, Ed. Andreoli, 7<sup>th</sup> Edition, 253-258, 2007
22. **Roman J** and Brigham KL. Neoplastic disorders of the lung. Cecil's Essentials in Internal Medicine, Ed. Andreoli, 7<sup>th</sup> Edition, 259-263, 2007.

**Book Chapters (continuation):**

23. Han SW, Wongtrakool CW, **Roman J**. Nicotine and lung cancer: Mechanisms and implications for early detection and treatment. Chapter 6 in *Progress in Cell Growth Process Research*; Editor: T Hayashi; Nova Science Publishers, Inc., 2008. pp. 149-165.
24. Han SW, Ritzenthaler JD, **Roman J**. PPAR $\beta/\delta$  promotes lung carcinoma cell proliferation through PGE2 receptor EP4. In: *Methods in Molecular Medicine*. F Columbus, Editor-In-Chief, requested review.
25. Mora A and **Roman J**. Viral pathogenesis of interstitial lung disease. In: *Interstitial Lung Disease*. M Schwarz and T King (Eds). B. C. Decker, Inc., London; Fifth Edition., requested review, 2011.
26. Han SW, Ritzenthaler JD, **Roman J**. Fibronectin – a matrix glycoprotein with roles in lung carcinoma cell growth and progression. *Oncogene Proteins: New Research*. Editor: F. Columbus; Nova Science Publishers, Inc., Hauppauge, NY.
27. Han SW and **Roman J**. Apoptosis and lung cancer. Apoptosis. Editor: Victor R. Preedy Publisher: Science Publishers, Enfield, NH, USA, 2010. Pp. 263-276.
28. **Roman J** and Sueblingvon V. Progenitor cells and cell-matrix adhesion. In: *Stem Cells in the Respiratory System*. Editor: M. Rojas. Springer. 1<sup>st</sup> Edition, 2010. Pp. 77-96.
29. Olson A, Schwarz M, **Roman J**. Interstitial Lung Disease. In: *Breathing in America: Diseases, Progress, and Hope*. Editor: Dean E. Schraufnagel, American Thoracic Society. pp 99-108, 2010.
30. **Roman J**. Remodeling of the matrix in the aging lung. *Molecular Aspects of Aging: Understanding Lung Aging*. Editors: Rojas, Seiner, Le Saux.. Publisher: Wiley Blackwell. June 2014.
31. Arteel G, Ritzenthaler JD, **Roman J**. Alcohol in liver and lung disease. Publication expected for 2015.
32. Matthes SA, Hadley R, **Roman J**, White ES. Comparative biology of the normal lung extracellular matrix. In: Parent, RA (Ed), *Comparative biology of the normal lung*, pp. 387-402, 2015.

33. George G, Ramirez MI, **Roman J.** Lung mesenchyme. Murray & Nadel's Textbook of Respiratory Medicine – 7<sup>th</sup> Edition. Publisher: Elsevier. Eds: Broaddus, Ernst, King, Lazarus, Sarmiento, Schnapp, Stapleton, and Gotway. 2021: pp. in press
34. **Roman J.** Hermansky Pudlak Syndrome. Pathobiology of Rare Lung Diseases. Publisher: Elsevier. Eds: McCarthy C and Bonella F. 2022. Requested and pending

**Other publications - Manuals, videos, computer programs and other teaching aids:**

- 2002 WILD (World of Interstitial Lung Disease), Publication that educates the public about ILD the Emory ILD Center.
- 1995 Roman J and Bailey F. Pulmonary Function Testing and Imaging Techniques. Emory Board Review Course Book
- 1997 Roman J and Aranson R. Critical Care Issues, Emory Board Review Course Book
- 1997 Asthma Pathophysiology Review, Asthma Workshop, Chateau Elan, GA. Sponsored by Georgia Thoracic Society
- 1998 Oxygen Therapy Review, Annual COPD Workshop, Sponsored by GA Thor Society.

**Selected Advocacy Efforts, Community Engagement, and Other Activities**

- 2003 Helped organize American Lung Association of Georgia Asthma Walk (May)
- 2004 Visited U.S. Congress and met with several representatives to advocate for research in respiratory disorders and the use of oxygen on airplanes.

**Selected Advocacy Efforts, Community Engagement, and Other Activities (continuation)**

- 2001-05 Served on the American Thoracic Society Research Advocacy Committee
- 2007-09
- 2009 Testimony offered to U.S. Congress House Military Construction/VA Appropriations Subcommittee on behalf of the American Thoracic Society (Apr)
- 2010 Discussion on 'Clinical Trials', *State of Affairs*, National Public Radio (Mar)
- 2010 Discussion on 'Clinical Trials', *WAVE3 Listens*, WAVE3 TV Station (Apr)
- 2011 Clinical Research Education Day, Presentation on Phase 1 and 2 trials; NIA Center, West Louisville (Jun)



- 2011 Speaker and panelist, *Festival of Faiths*, Lecture: Biomass burning and global health. Louisville, KY
- 2012-17 Member, *Pulmonary Fibrosis Advocates*, a non-profit organization involved in work related to pulmonary fibrosis.
- 2012 Participant and Speaker, Pulmonary Fibrosis Fund Raising Dinner, Chicago (Oct)
- 2013 Participant and Speaker, Pulmonary Fibrosis Fund Raising dinner, Chicago (Dec)
- 2015-17 Established the ANCHOR Partnership (Academic and Community Partnership in Idiopathic Pulmonary Fibrosis). With funds from BI, we established a monthly meeting where cases of IPF and related ILDs are presented and discussed amongst participants including academic and community pulmonologists, pathologists, rheumatologists, respiratory therapists and nurses.
- 2016 Presented two lectures to HPS Patient Support Groups in Puerto Rico (Feb)
- 2016 Participant, Meeting of Hermanski Pudlak Association (Mar), Long Island, NY
- 2016 Chair, Committee for development of Puerto Rico Center for Pulmonary Fibrosis. Created a coalition of doctors, hospitals, advocacy organizations, and patients to establish this center at the Mayaguez Medical Center in Puerto Rico in partnership with the University of Louisville and the Ponce School of Medicine and endorsed by the Hermansky Pudlak Syndrome Network, the Pulmonary Fibrosis Foundation, and the American Lung Association-Midland States.
- 2016 Established *Puerto Rico Center for Pulmonary Fibrosis* in Mayaguez Medical Center, Mayaguez, Puerto Rico (Aug).

**Selected Advocacy Efforts, Community Engagement, and Other Activities (continuation)**

- 2016-pres Assist with consultation on patients suspected of or diagnosed with pulmonary fibrosis in Puerto Rico. Traveling to PR monthly.
- 2018 Member of delegation visiting Puerto Rico Sub-Secretary of Health in efforts to advocate for ‘catastrophic’ health insurance coverage for HPS patients in the island.
- 2018-pres Assisted in opening of first Multidisciplinary Hermansky Pudlak Syndrome Clinic in Puerto Rico. Clinics held Nov 2018 and Feb 2019.
- 2020 Interview, Publication: *Medicina y Salud Publica* (for Latin America). Topics: Lung Cancer (July) and Pneumococcal pneumonia (September)

2020	“COVID-19 en fibrosis pulmonary” (COVID-19 in pulmonary fibrosis). Videoconference in Spanish sponsored by the Pulmonary Fibrosis Foundation.
2022	Panelist: Clinical trials. American Thoracic Society Virtual Educational Meeting for patients.

## Grant Support

### Active Support (Federal funds):

Years	Source	Title	Role*	Amount
2020-2024	1R01HL147088 NIH/NHLBI	Early life exposures and chronic lung dz	PI	\$1,000,000 (NCE)
2016-2023	1P500AA024337 (Project #3) NIH/NIAAA PI Overall project: McClain Roman is PI of Project #3	Alcohol in lung injury Nutrition & alcohol in organ injury	PI total	\$750,000 (NCE) \$7,660,000

### Pending Support (applications submitted):

Years	Source	Title	Role*	Amount
2024-29	R01 NIH	$\alpha$ 4 nAChRs and ETOH liver disease	PI	\$1,000,000
2024-29	R01 NIH	$\alpha$ 4 nAChRs and LPS related lung injury	PI	\$1,000,000

### Active industry-sponsored clinical trials & registries

2022-pres 1305-0014	Fibroner Clinical Trial – Fibroner Clinical Trial – A double blind, randomize, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with idiopathic pulmonary fibrosis. (Sponsor: Boehringer Ingelheim; site PI: Roman)
2022-pres 1305-0023	Fibroner Clinical Trial – A double blind, randomize, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with progressive fibrosing interstitial lung disease. (Sponsor: Boehringer Ingelheim; site PI: Roman)
2021-pres	A phase III study to assess the safety and efficacy of the investigational drug, PRM151 vs. placebo, given IV over a period of 52 weeks to subjects with a

diagnosis of IPF. (Sponsor: F. Hoffmann –La Roach Ltd; site PI: Perez; Roman is co-I)

- 2021 CaTT Study (UM1 AI109565-07). Use of anti-CD14 for the treatment of COVID-19. (Sponsor: NIH/NIAID; site PI: Roman). *NOTE: Study terminated due to insufficient recruitment.*
- 2021-pres Clinical trial evaluating the long-term safety, efficacy and pharmacokinetics of open-label PRM-151 in patients with idiopathic pulmonary fibrosis (IPF). (Sponsor: F. Hoffmann –La Roach Ltd; site PI: Perez; Roman is co-I)
- 2021-pres *STRIVE-IPF*. Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF), NIH through UAB; Site PI: Summer; Co-I: Roman)
- 2021-pres Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis. (Sponsor: Horizon Therapeutics Ireland DAC; site PI: Summer; Co-I: Roman)
- 2018-pres *Galapagos Isabela IPF*. Randomized, double-blind, parallel-group, placebo-controlled, 52-week, Phase IIb study to assess efficacy and safety of GLPG1690 on top of pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis (IPF). Protocol GLPG1690-CL-203. (Sponsor: Galapagos; Site PI: Ross Summer; Collaborator: Roman J)
- 2019-pres *Galecto Biotech AB, Galactic-1*. Randomized, double-blind, multicenter, parallel, placebo-controlled Phase 2b study in subjects with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of TD139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler over 52 weeks. (Sponsor: Syneos Health; Site PI: Roman)
- 2019-pres *IPF/ILD – PRO*. Multicenter registry of subjects with IPF and other interstitial lung diseases. (Sponsor: Boehringer Ingelheim; Site PI: Roman)
- 2019-pres *PULSE-PHPF-001*. Multicenter randomized clinical trial evaluating the role of inhaled nitric oxide (iNO) the management of IPF. (Sponsor: Bellerophon Therapeutics; Site PI: George; Site Co-investigator: Roman)
- 2019-pres *FGCL-3019-091*. A phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of Pamrevlumab in subjects with IPF. (Sponsor: Fibrogen; Site PI: Perez; Site Coinvestigator: Roman)

**Previous Support:**

Years	Source	Title	Role	Amount
-------	--------	-------	------	--------

2020-2022	Chan Zuckerberg Initiative Rare As One Network	HPS Network	1° Clinician	\$450,000
2020-2022	Foundation Sarcoidosis Research	Tissue remodeling in sarcoidosis.	Co-I	\$25,000
2012-2018	R01 AA019953 NIH/NIAAA	Ethanol receptors and lung injury	PI	\$1,125,000
2013-2018	U01 HL121807-01 NIH/NHLBI	Lung complications in HIV (Multi-PI with Ramirez)	PI	\$1,125,000
2014-2018	R01 AA021978-01 NIH	ECM/inflammation in alcohol liver & lung dz (with Arteel)	Co-I	\$1,000,000
2014-2018	5I01 BX000216-02 Merit Review Department of Veterans Affairs	Nicotine, nAChRs lung injury/repair	PI	\$628,500
2015-2017	Academic and Community Partnership in Idiopathic Pulmonary Fibrosis (AnChor Parntership); Boehringer Ingelheim – (PI: Roman) - \$58,000			
2011-2017	R25-CA134283 NIH/NCI (PI: Hein)	UofL Cancer Education Program	Preceptor	\$1,543,610
2015-17	No number VA Cancer Research Program	Lung cancer	Mentor Mentee: Rivas	\$25,000
2015-17	Young Investigator Res Grant	Stem cell vaccine In lung cancer	Mentor Mentee: Yaddanapudi	

**Previous Support (continuation):**

Years	Source	Title	Role	Amount
2008-2014	R01 CA116812 NIH/NCI	Lung ECM and tumors	PI	\$1,250,000
2013-2015	No number Kentucky Lung Cancer Res Prog	miRNAs in lung cancer	Co-PI	\$150,000
2011-2013	R21 AG038652, NIH/NIA	Aging & lung injury	PI	\$275,000
2009-2014	5I01 BX000216-02 Merit Review Department of Veterans Affairs	Nicotine and lung injury/repair	PI	\$628,500

2010-2013	R01 HL096508-01 NIH/NHLBI	Oxidant stress and IPF	PI	\$451,250
2005-2014	U10 HL080543-01 NIH/NHLBI (NCE)	Clinical Research Center in IPF	PI	\$663,643
2011-2013	K08 HL077533 06 NIH (PI: Ramirez)	TGF $\beta$ in OB	Mentor	\$500,000
2009-2014	1P50 AA013757 (PI:Guidot) NIAAA, NIH (Roman; PI Project 3) <i>Declined in 2009 because of transfer</i>	Fibronectin in the alcoholic lung	PI	\$750,000
2009-2014	T32 HL076118-06 NRSA NHLBI, NIH <i>Transferred to another PI after move</i>	Training in Academic pulmonary medicine	PI	\$949,589
2006-2011	R01 AA012197 (PI: Brown) NIH/NIAAA	Ethanol and mitochondrial dysfunction	Coll	\$1,200,000
2008-2013	R01 AA016348 (PI: Gauthier)	Alveolar and <i>in utero</i> ethanol	Coll	\$1,000,000
2006-2011	PO1 CA116676-01A NCI, NIH (Khuri - PI) <i>Transferred to another PI because of move</i>	Targeting cell signaling in lung cancer	Coll	11,000,000
2008-2011	K22CA123104-01A2 (ShouWei Han-PI) Transferred to another institution	ILK and lung cancer	Mentor	\$350,000

**Previous Support (continuation):**

Years	Source	Title	Role	Amount
2005-2009	K08 Award from NIH (Cherry Wongtrakool-PI) <i>Transferred to another mentor due to move</i>	Nicotine, remodeling & lung development	Mentor	\$500,000
2007-2009	K08 Award from NIH (Allan Ramirez-PI) <i>Transferred to another mentor due to move</i>	Matrices and bronchiolitis obliterans	Mentor	\$500,000
2008-2013	Merit Review Department of Veterans Affairs <i>Declined-overlap with other grant</i>	Nicotinic, fibronectin, and lung cancer	PI	\$625,000

2003-2009	K12-RR017643-03 NIH, NCR (Henry Blumberg – PI)	Emory Mentored Clinical Scholars Program	Mentor	2,435,000
2008-2013	T32 AA13528-01 NIAAA, NIH (David Guidot – PI)	Alcohol Training Grant	Mentor	1,276,323
2006-2009	Roche Organ Transplantation Research Foundation	PPAR $\gamma$ in obliterative bronchiolitis	Collab	\$225,000 (Ramirez – PI)
2006-2009	Woodruff Foundation	Biomarkers of lung disease	PI	\$275,000
2007-2009	Woodruff Health Sci Center Emory University	Emory Center for Respiratory Health	Director	\$3,100,000
2007-2009	Coulter Foundation (Baker –PI)	Fibrin and lung fibrosis	Co-PI	\$200,000
2004-2009	T32 HL076118-06 NRSA NHLBI, NIH	Training in Academic pulmonary medicine	PI	\$949,589
2005-08	PR043305 Department of Defense	Nicotine & asthma	PI	\$550,000
2003-08	P50AA013757 (PI: Guidot) NIAAA, NIH (Roman; PI Project 3)	Fibronectin in the alcoholic lung	PI	\$750,000
2007-08	Am Found for Aging Research (Rojas- PI)	Stem Cells, ECM, fibrosis	Co-PI	\$43,000

**Previous Support (continuation):**

Years	Source	Title	Role	Amount
2007-2008	Georgia Research Alliance	Vaccine development in TB	Co-PI	\$100,000
2002-07	Merit Review Department of Veterans Affairs	Nicotinic receptors and fibronectin in lung	PI	\$625,000
2001-06	R01-HL68543-01 NHLBI, NIH	Host response genes in TB	PI	\$1,000,000
2002-06	DAMD17-02-1-0179 Department of Defense	Ethanol and fibronectin in lung injury	PI	725,000
2004-05	GlaxoSmithKline Corp	Preceptorship in COPD	PI	17,000

2001-04	R01-HL62316-01A1 NHLBI, NIH	Fibronectin in lung vasculogenesis	PI	600,000
2000-04	R01 NIH (LA Brown, PI)	AT II cells and matrix	Co-PI	100,000 to Roman Lab
2002-04	V247P-0097, Scarce Med. Contract Department of Veterans Affairs	Methodological Experts	PI	1,005,507
1998-02	Established Investigator Award American Heart Association	Gelatinases in lung	PI	300,000
2003-05	GlaxoSmithKline	Inhaled steroids in COPD	Co-PI	
2003-05	Wyeth	Embrel in treatment of IPF	Co-PI	
2000-02	Research Grant, ALA Am Lung Assoc, (RL Perez, PI)	Tissue remodeling in sarcoidosis	Co-PI	40,000
2001-02	Potts Memorial Foundation	MMP-9 in TB	PI	30,000
1999-02	Merit Review Type II Department of Veterans Affairs (CA Rivera, PI)	Virulence genes in tuberculosis	Mentor	360,000
2001-02	Research Grant Sepracor, Inc.	Albuterol and tissue remodeling	PI	30,000
1998-01	Research Grant (renewal) Department of Veterans Affairs	Galectin in lung development	PI	225,000

**Previous Support (continuation):**

Years	Source	Title	Role	Amount
1997-00	R01-AI 37937, NIAID, NIH	Differential cloning of mycobacteria virulence factors	PI	346,578
1994-99	Merit Review, Veterans Affairs	Integrins in lung Development	PI	512,500
1993-99	RO1-HL51639-NHLBI, NIH	Fibronectin in tuberculosis	PI	621,408
1997-99	American Lung Association	Signal transduction via $\alpha 5\beta 1$	Mentor	35,000

1997-99	NRSA, NIH	Tissue remodeling in transplants	Mentor	105,000
1996-98	American Lung Association	Fibrin matrices in lung	Co-PI	50,000
1997-98	Allens Hansbury Fellow Award	Expression of fibronectin	Mentor	35,000
1995-98	Merit Review, Veterans Affairs	Galectin in lung development	PI	180,000
1992-95	AHA Grant-In-Aid American Heart Association	Extracellular matrices in lung development	PI	120,000
1993-94	NRSA, NIH	Cell-matrix interactions	Mentor	35,000
1992-94	Research Award American Lung Association	Signal transduction via fibronectin receptors. III.	PI	50,000
1992-93	Research Adv. Group Award Veterans Affairs	Matrix receptors in lung development	PI	80,000
1991-92	Research Grant American Lung Association	Signal transduction via fibronectin receptors. II.	PI	35,000
1990-93	Minority Med. Faculty Dev. Robert Wood Johnson Foundation	Signal transduction via fibronectin receptors. I.	PI	300,000
1990	BRSA, Washington Univ. St. Louis, MO	Matrix and matrix receptors in lung development	PI	10,000
1988	Research Fellowship Award American Lung Association	Fibronectin in lung injury and repair. I.	PI	17,500

### Completed Clinical Trials

2021	A phase II/III seamless, randomized, double-blind, placebo-controlled, parallel-group, group-sequential study to evaluate efficacy, safety, and tolerability of BI 767551 for the treatment of symptomatic, non-hospitalized adults with mild to moderate COVID-19. Trial prematurely discontinued. (Sponsor: BI (1487-0001); Coordinating investigator: Roman)
2020	GC/Pamrevlumab in the treatment of severe COVID-19. (Sponsor: FibroGen; Site PI: Perez; Co-I: Roman)
2020	Convalescent plasma treatment to COVID-19. (Sponsor: Department; PI: Baram; Co-I: Roman)



2020	Outcomes in severe COVID-19 with or without administration of Tocilizumab. (Sponsor: Department; PI: Roman)
2020	Aviptadil in the management of severe COVID-19. (Sponsor: NeuroRX, Inc.; Site PI: Summer; co-I: Roman)
2020	BVH-3500/CGRP in the treatment of hospitalized patients with COVID-19. (Sponsor: Biohaven Pharmaceuticals, Inc.; Site PI: Baram; Co-I: Roman)
2020-pres	<i>PEARL</i> . Investigator-driven open-label 52-week trial, Phase II, to assess efficacy and safety of Pirfenidone in Hermansky-Pudlak Syndrome-related interstitial lung disease. (Sponsor: Genentech; PI: Roman J); terminated early because of COVID
No number 2013-pres	Symphony: A study of Macitentan in pulmonary arterial hypertension to validate the PAH-SYMPACT instrument. (Site PI: Smith; Co-I: Roman).
Aspire 2012-pres	Treatment of Pulmonary Arterial Hypertension; United Therapeutics (PI: Smith, Sub-I: Roman)
Symphony 2013-pres	Treatment of Pulmonary Arterial Hypertension; Actelion (PI: Smith, Sub-I: Roman)
Queri Trial 2013-pres	Pulmonary Arterial Hypertension; Actelion (PI: Smith, Sub-I: Roman)
FG-3019	“A Phase 2a, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 for Treatment of Subjects with Idiopathic Pulmonary Fibrosis.” Role in project: Site principal investigator. FibroGen, Inc.
BEAT 2014-pres	The BEAT trial in pulmonary arterial hypertension; Lung Biotechnology (PI: Smith, Sub-I: Roman)

**Completed Clinical Trials (continuation):**

BRAVE3 2014-16	Role of cryobiopsy in evaluation of interstitial lung disease; Veracyte (PI: Perez, Sub-I: Roman)
PIPF 016 2012-14	A randomized, double-blind, placebo-controlled, phase 3 study of the efficacy and safety of pirfenidone in patients with IPF (The Ascend Trial; Intermune) (Site PI: Perez; Co-PI: Roman)
<i>ESCAPE</i>	“ <i>ESCAPE</i> [Extended Steroid (in) CAP(e)] A Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of Methylprednisolone in Hospitalized Veterans with Severe Community-Acquired Pneumonia.” Role in project: Site Co-investigator. VA Cooperative Study No. 574. 2011-16.

- PIPF 012  
2013-14 Idiopathic Pulmonary Fibrosis; Intermune (PI: Perez, Sub-I: Roman)
- PIPF 031 Idiopathic Pulmonary Fibrosis; Intermune (PI: Perez, Sub-I: Roman)
- RAINIER A phase 2, randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of GS-6624 in subjects with idiopathic pulmonary fibrosis. Protocol GS-US-322-0207; Gilead (Site PI: Perez, Co-I: Roman).
- LPA Safety and efficacy of a lysophosphatidic acid receptor antagonist in IPF:  
2013-15 A multicenter, randomized, double-blind, placebo-controlled, phase 2 study of the safety and efficacy of BMS-986020 in subjects with IPF. Protocol: IM136003; Bristol Myers Squibb (Site PI: Roman).
- PANTHER  
2012-14 Phase 3 trial. Prednisone, azathioprine, and N-acetylcysteine in the treatment of IPF. *NIH sponsored IPFnet*. (Site PI: Roman).
- IW001  
2012-2013 A phase 1, open label, multi-dose study to evaluate the safety, tolerability, and Biologic effects of three doses of IW001 in patients with IPF (Role of bovine derived collagen in the treatment of IPF). Sponsored by ImmuneWorks. (Site PI: Roman)
- IM136003 Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of BMS-986020 in Subjects with Idiopathic Pulmonary Fibrosis. (Site PI: Roman).
- ACE Phase 3 trial. Anticoagulation with Coumadin in the treatment of idiopathic pulmonary fibrosis. *NIH IPF Clinical Research Network (IPFnet)* 2010-2011. (Site PI: Roman)

**Completed Clinical Trials (continuation):**

- STEP Phase 3 trial. Sildenafil treatment in exercise tolerance in advanced idiopathic pulmonary fibrosis. *NIH IPF Clinical Research Network (IPFnet)* 2007-2009. (Site PI: Roman; IPFnet Steering Comm. member; Co-chair, Publications Committee)
- AC-052-321 Phase 3 trial. “Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequential, phase III study.” (BUILD 3) Role in project: Site Co-PI, *Actelion Pharmaceuticals Ltd*. 2007-2009. (Site PI: Perez; Co-PI: Roman).

- GIPF-007 Phase 3 trial. “A double-blind, parallel, placebo-controlled, randomized study of the efficacy and safety of Interferon- $\gamma$  in patients with Idiopathic Pulmonary Fibrosis”. *Intermune*. 2004-2007 (Site PI: Roman)
- PIPF-002 Phase 3 trial. “An Open-Label Phase II Study of the Safety and Efficacy of Oral Pirfenidone in Patients with Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis” *Intermune*. 2005-09 (Site PI: Roman)
- PIPF-006 Phase 3 trial. “A double-blind, parallel, placebo-controlled, randomized study of the efficacy and safety of Pirfenidone in patients with Idiopathic Pulmonary Fibrosis”. *Intermune*. 2007-2009 (Site PI: Roman).
- PIPF-012 Open label extension study of the long term safety of pirfenidone in patients with IPF. *Intermune Pharmaceuticals* (Site PI: Roman)
- Novartis Phase 1 trial. “Open label, multi-center study with a single IV dose of QAX576 to determine IL-13 production in patients with Idiopathic Pulmonary Fibrosis” *Novartis*, 2007-09 (Site PI: Roman)

**Consultant/membership in national and other federal committees/agencies and international**

- 2023 *Ad hoc* member of the NIAAA/NIH Board of Scientific Counselors (BSC)
- 2023- Member, HPS Registry Advisory Board, Hermansky-Pudlak Syndrome Network
- 2021-25 Full Member, Clinical Trials Review Committee (Study Section), NHLBI, NIH
- 2021 Member, Network Management Core - Pulmonary Trials Cooperative, ZHL1 CSR-I(M2); NIH/NHLBI
- 2020 VA ORD Lung Precision Oncology Program (LPOP) Review, Department of VA
- 2020 Special Emphasis Panel, E-cigarettes-basic mechanisms of health effects, ZRG1 CVRS-H 50R, NIH
- 2020 Application Reviewer, Hope for the Breathless Charity related to IPF
- 2019 Special Emphasis Panel, Tobacco Regulatory Science, NIH-FDA
- 2018 Special Emphasis Panel, Tobacco Regulatory Science, ZRG1 BST-T [55], NIH-FDA
- 2018 Grant Reviewer, National Children’s Research Centre, Ireland.

**Consultant/membership in national and other federal committees/agencies and international (continuation)**

- 2017, 2018 Study Section, FPA-Pulmonary Fibrosis; FY17 PRMRP Department of Defense Congressionally Directed Med. Research Program
- 2017,18 Reviewer, JB Barnwell and WS Middleton Awards, Biomedical Laboratory R&D Service, Department of Veterans Affairs
- 2016 Reviewer, Department of Defense Congressionally Directed Med. Research Program Pre-applications, Constrictive Bronchiolitis, FY16
- 2016 Reviewer, NCAT Conference Grant Applications, NCATS, NIH
- 2015 Chair, Study Section, FPA-Pulmonary Fibrosis; FY15 PRMRP Department of Defense Congressionally Directed Med. Research Program

2015-16 Study Section Member, National VA ORD, Pulmonary Medicine  
 2015 Reviewer, NIH/NCI Special Emphasis Panel, 10 ZCA1 SRB-L  
 2015 Reviewer, Ministry of Science, Technology and Space, State of Israel  
 2014-pres Steering Committee, IPF-PRO National Registry, BI Pharmaceuticals  
 2014 Reviewer, CDMRP – PRMRP – Discovery – Respiratory Health  
 2014-17 Council Member (Treasurer), Association of Professors of Medicine  
 2014-17 Member, Finance Committee, Alliance Academic Internal Medicine  
 2014-pres NIH, INHALD Network on Pulmonary Complications in HIV.  
 Member, Steering Committee, Bronchoalveolar Lavage Analysis  
 Committee, and CT/Imaging Committee; PI on one project  
 2014-17 Chair, Medical Advisory Committee, Pulmonary Fibrosis Foundation  
 2014 Reviewer, Special Emphasis Panel, Rare Diseases Clinical Research Consortia  
 (U54), National Center for Advancing Translational Sci, NIH  
 2013-17 Member, Board of Directors, Association of Professors of Medicine  
 2013-16 Grant Reviewer for Chest Foundation, Am College of Chest Physicians  
 2013 Reviewer, 2013 Clinical Trials, NHLBI, NIH (PAR-10-096, PA-11-260, PAR-10-005, R34)  
 2013-14 Member, Intermune Research Steering Committee  
 2012-14 Member, Board of Directors, American Thoracic Society  
 2018 Reviewer, Research Grants Council of Hong Kong, China  
 2012-17 Member, Board of Directors, American Lung Association / Midland States  
 2012-17 Diversity Committee, Alliance of Academic Internal Medicine  
 2012 Reviewer, Stage 1, NIH Director’s Early Independence Award (DP5)  
 2012-14 Chair, Respiratory Cell & Mol. Biol. Assembly, Am. Thor. Society  
 2011-12 Chair, Task Force on Research Development, ATS Research Foundation  
 2011-15 Chair, Data Safety & Monitoring Board, Phase II NIH trial in IPF  
 2011-14 Chair, Pulmonary Fibrosis Foundation Research Advisory Committee  
 2011 *Ad hoc* reviewer, LIRR Study Section, National Institutes of Health (Oct)  
 2010-12 Member, Diversity Committee of Assoc. Professors of Medicine (APM)  
 2010 Reviewer, Cancer Research Study Section, United Kingdom  
 2010-12 Chair, American Thoracic Society Scientific Advisory Committee  
 2010 Reviewer, Grants for NIH ZRG1 VH-D, Director’s Opportunity 5 Themes  
 2009-13 Full Member, VA Oncology Study Section, Depart. of Veterans Affairs  
 2009 Reviewer, Canadian Cancer Society Grants  
 2009 Reviewer, NIH Director’s Pioneer Awards, National Institutes of Health

**Consultant/membership in national and other federal committees/agencies and international (continuation)**

2008-09,12 Steering Committee, Division Director’s Group, Am Thoracic Society  
 2008 Reviewer, Research Projects for American Thoracic Society  
 2008, 12,14 Reviewer, Abstracts and Awards for Southern Soc. Clinical Investigation  
 2008 Reviewer, *Raine Medical Research Foundation*; Univ. Western Australia  
 2008 Reviewer for *NSFC/RGC 2 JRS*, Research Grants Council, Hong Kong  
 2008 NHLBI Special Emphasis Panel, RFA, Grants for Lung Tissue Research  
 2008-09 Member, Research Advocacy Committee, American Thoracic Society  
 2008-10 Member, Scientific Advisory Committee, American Thoracic Society  
 2008 Reviewer, Ad Hoc Study Section for Program Project Grant, NHLBI, NIH

- 2007 Reviewer, Ad-Hoc Study Section for K22 review, NIH
- 2007 Chair, Ad-Hoc Study Section for LIRR (ZRG1 RES-B 02 M), NIH
- 2007 Reviewer, NIH Director's Pioneer Awards, National Institutes of Health
- 2006-14 Member, Program Project Review Committee, ZHL1-SRC-(99), NHLBI  
 NIH Idiopathic Pulmonary Fibrosis Network Clin & Res Network (IPFnet)  
 Member, IRB Committee and Steering Committee  
 Chair, Education and Cowlin Research Fellowship Committees  
 Co-chair, Publications Committee  
 Member, Early Treatment Protocol Committee
- 2006-07 Program Chair, RCMB Assembly, American Thoracic Society
- 2005 Member, NHLBI-NIH Working Group: New Directions in Genetics of TB
- 2003-07 Full Member, Lung Injury, Repair and Remodeling Study Section (LIRR), National Institutes of Health (NIH).
- 2003 Lung Biology and Pathology Study Section, NIH
- 2005 Grant Reviewer, Am Soc Cancer / *Union Internationale de Cancer Control*
- 2003-04 American Thoracic Society Program Review Committee
- 2003 Ad Hoc Reviewer for Study Section, NHLBI, NIH  
 RFA: Coordination of Lung Vasculogenesis, June 5-6
- 2002 Ad Hoc Reviewer for Lung Biology and Pathology Study Section, NHLBI, NIH, Washington D.C., October 7 and 8.
- 2002 Member Ad Hoc Study Section for NHLBI, NIH  
 RFA: Tissue Engineering of Lung, Washington, D.C., July 10-11
- 2002-03 Planning Committee, Respiratory Cell Molecular Biology Assembly, ATS
- 2002-03 Member, Nominating Committee, American Thoracic Society
- 2002-03 Program Committee, Respiratory Cell Molecular Biology Assembly, ATS
- 2001 Ad hoc reviewer for Merit Review Applications,  
 Respiration Review Board, Department of Veterans Affairs
- 2001-05 Member, Research Advocacy Committee, American Thoracic Society
- 2001 Reviewer, California Tobacco-Related Disease Research Program
- 2001 Ad hoc reviewer for VA Career Development Program, DVA
- 1998-00 Member, Review Panel, Research Career Scientist Program  
 Department of Veterans Affairs
- 1998-00 Member, Scientific Review Committee, National Am Lung Association
- 1994-98 Member, Aids-Related Research Study Section 5 (ARRE, AHR Q1), NIH

**Consultant/membership in national and other federal committees/agencies and international (continuation)**

- 1996 Review Committee for SCOR applications (Lung Development), NIH
- 1996-97 Co-chair, Subsection on Cardio-Respiratory Health of Minorities, ACCP
- 1995 Special Emphasis Panel on Tuberculosis & Aids, NHLBI, NIH
- 1994 Ad Hoc Study Section (ARRB, AHR M1), NIH 1995-97
- 1995 Ad Hoc Reviewer, British Columbia Lung Association,  
 Vancouver, British Columbia, Canada
- 1995-96 American Thoracic Society Membership Committee
- 1994-00 External Advisory Committee, Indiana University  
 Pulmonary Program for Minority Students (T35M)

1992-95 Secretary of Association of Respiratory Health of Minorities  
 1993 Clinical Investigator Development Award, NHLBI, NIH  
 1991-93 Advisory Group on Respiratory Health of Minorities, NHLBI, NIH

**Regional and State**

2010-pres Member, External Advisory Committee; Chair (2010-12; 2015-pres)  
 Puerto Rico Clinical & Translational Research Consortium  
 2011 Reviewer, Louisiana Board of Regents' Research Program  
 2011-17 Chair, Fund Raising Committee, Southern Society of Clinical Investig.  
 2010-17 Member, Executive Advisory Board, Southern Soc. Clinical Investigation  
 2010-13 Chair, Nominations Committee, Southern Soc. For Clinical Investigation  
 2009-10 President, Southern Society for Clinical Investigation  
 Reviewer, Young Investigator Awards, Southern Soc Clin Investigation  
 2003-08 Councilor of the Southern Society for Clinical Investigation  
 2001-03 President, Georgia Thoracic Society  
 2001-04 Member, Executive Committee, American Lung Association of Georgia  
 2001 Ad hoc reviewer for the MBRs Program, Morehouse School of Medicine  
 1996-97 Chair, Scientific Review Committee, GA Lung Assoc/GA Thoracic Soc  
 Member, Scientific Review Committee, Ga Thor Society  
 1999-01 President-Elect, Georgia Thoracic Society

**Institutional - *Thomas Jefferson University***

2023-pres Member, Department DEI Advisory Council  
 2019-2020 Member, Departmental Review Committee, Surgery  
 2020-2020 Chair, Departmental Review Committee, Oral & Maxillofacial Surgery  
 2020 Member, Operations Committee, Jefferson Service Lines  
 2018 Clinical Research Council, Department of Medicine,  
 2018-pres Member, Cancer Screening Program Committee  
 2018-pres Lung Transplantation Initiative Committee  
 2018-2020 Member, Respiratory Therapy Advisory Group  
 2021-2022 Member, Search for Chair Department of Medical Oncology

***University of Louisville***

2018-pres Member, Oncology Coordinating Council, SKMC Cancer Center  
 2017 Member, UofL/UMC Joint Planning & Integration Committee  
 2017 Co-leader Affinity Group for Faculty of Color, School of Medicine  
 2017 Member, JB Cancer Center Leadership Council  
 2016-17 Member, Search Committee, Med. Director, JGB Cancer Center/Assoc VP  
 2016-17 Board Member, KMRRRG (Malpractice Plan of Physician Practice)  
 2016-17 Member, Diversity Steering Committee, University of Louisville, KY  
 2015-17 Member, Transplantation Executive Committee, KentuckyOne Health  
 2014-15 Member, Steering Committee, Strategic Planning, UofL Sch of Medicine  
 2013-17 Chair, VA Research & Development Committee, VAMC

2013 Member, KentuckyOne Health Integration Committee  
 2013 Member, SOM Strategic Planning Steering Committee  
 2013 Chair, SOM Strategic Planning Committee on Education  
 2012 Member, Faculty Advisory Committee, Exec VP for Research/Innovation  
 2012 Member, LCME Task Force  
 2012 Member, Chief of Staff for Executive Vice-President Search Committee  
 2011-12 Member, Academic Health Center Committee, KY Statewide Network  
 2010-12 Member, Compliance Committee, U of L Medical School Fund, Inc.  
 2010-11 Member, Search Committee for Executive Vice-President/Research, UofL  
 2010-11 Chair, Search Committee, Chair of Urology  
 2010 Chair, Task Force, Assistant Dean for Research & Clinical Trials Position  
 2010-17 Member, Internal Advisory Committee, Cardiology Program Project Grant  
 2010-17 Member, Compensation Committee, University Physician Associates, PSC  
 2010 Member, Task Force on Academic Affiliation  
 2003-08 Councilor of the Southern Society for Clinical Investigation  
 2001-04 President, Georgia Thoracic Society  
 2001-04 Member, Executive Committee, American Lung Association of Georgia  
 2001 Ad hoc reviewer for the MBRS Program, Morehouse School of Medicine  
 1996-97 Chair, Scientific Review Committee, GA Lung Assoc/GA Thoracic Soc  
 1999-01 Member, Scientific Review Committee, Ga Thor Society  
 1999-02 President-Elect, Georgia Thoracic Society  
 2009-17 Board Member, University Physicians Associates, PSC  
 2009-14 President and Board Chairman, University Medical Associates, PSC  
 2009-17 Medical Council Member, School of Medicine, University of Louisville  
 2009-17 Member, Research & Development Committee, Louisville VAMC  
 2009 Member, Search Committee, Center for Predictive Medicine, U of L  
 2009-11 Member, Allergy/Immunology Task Force  
 2009-11 Chair, Internal Advisory Comm., UofL NCI SPORE Grant / Lung Cancer  
 2009-12 Member, Board of Directors, University Health Care, Inc.  
 2009-12 Member, Governance Committee and Practice Plan Task Force, UPA  
 2009-12 Member, Finance Committee, University Physician Associates, PSC

***Emory University***

2009-pres Member, Executive Committee, University Physician Associates, PSC  
 2009-pres Member, UofL School of Medicine Fund Committee  
 2009-12 Member, Single Point Contracting Executive Committee, UPA  
 2008-09 Reviewer, Seed Grant Program, Emory Children's Research Center  
 2008-09 Member, Search for Critical Care Center Director, Emory Healthcare  
 2008-09 Member, Emory Critical Care Ad Hoc Charter Committee  
 2007-09 Member, Woodruff Health Sciences Ctr Research Advocacy Committee  
 2007-09 Member, Clinical Integration Committee, Emory Healthcare  
 2007-09 Emory Healthcare Hospital - Northlake: Director, Respiratory Care

	Services & PFT Lab; Member, Professional Services Comm.; Medical Practice Comm.; Pharmacy & Therapeutics Comm.; Ethics Comm.
2007	Member, Interdisciplinary Center and Future Diagnostics Committee
2006	Member, Search Committee, Chief of Neonatology Division, Pediatrics
2006	Member, Emory Lung Center Implementation Committee
2006-08	Member, Executive Committee, Department of Medicine
2005	Member, Search Committee, Chair of Rehabilitation Medicine
2005	Member, Medical Science Discovery Committee, Emory Sch. Of Medicine
2005/08	Member, Faculty Development Committee, Department of Medicine
2005	Member, Search Committee, Director of Pediatric Pulmonology Division
2003-04	Member, Pulmonary Division Clinical Enterprise Committee
2004	Member, Emory University Opportunity Committee
2003-04	Member, Critical Care Committee, EmoryHealthcare
2002	Member, Standing Nominations Committee, Emory School of Medicine
2002	Member, Adult Cystic Fibrosis Program Steering Committee, Emory
2001-02	Member, Search Committee for Endocrinology Division Director, Emory
2000-02	Chair, Research and Development Committee, VA Med Center
2000	Member, Strategic Planning Steering Committee, Department of Medicine
1992-97	Chair, Committee on Long Term Oxygen Therapy, VA Med Center
1993-95, 00-04	Member, Research and Development Committee, VA Medical Center
1994-96	Member, Cancer Committee, Atlanta VA Medical Center
1994-95	Member, Peer Review Committee, Atlanta VA Medical Center
1993-94	Clinical Preceptor, Nursing Training Program, Emory University
1993-94	Member, Research Equipment Committee, Atlanta VA Medical Center

## **Prior Clinical Service Contributions**

### *University of Louisville*

2009-pres	Attending in Interstitial Lung Disease Clinic, U of L (weekly)
2009-pres	Attending physician, Pulm. Consults and MICU, Louisville VA
2009-2010	Attending physician, MICU, University of Louisville Hospital

### *Emory University*

2002-09	Attending in Interstitial Lung Disease Clinic at The Emory Clinic
2003-04	Member, Critical Care Committee, EmoryHealthcare
2002	Established the Emory Interstitial Lung Disease Center
2002	Helped establish the combined Neurology/Pulmonary Emory Sleep Center
2002	Helped establish the Emory Adult Cystic Fibrosis Program
2002	Helped establish the Allergy Program at The Emory Clinic and Grady
1998	Helped establish the Atlanta Sarcoidosis Center (VAMC and Emory)
1992	Ad Hoc Committee on Chronic Ventilator Dependent Unit, VAMC
1991-00	Member, Medical Intensive Care Unit Committee, VA Medical Center





00, 03	
1993-94	Clinical Preceptor, Nursing Training Program Nursing School, Emory University, Atlanta, GA
2002-04	Professor Rounds, Grady Memorial Hospital (~3 times per year)
1991-pres	Instructor in various seminars provided to housestaff
1999-2000	Clinical Preceptor in the Primary Care Curriculum
1999-2001	Weekly participation in Morning Report, Atlanta VAMC
2007, 08	Speaker, Idiopathic Pulmonary Fibrosis Patient Support Program, Atlanta
2005	Speaker, Interstitial Lung Disease, McKelvey Center Conference, Atlanta
2004	Speaker, Pulmonary Topics, Board Review for Family Med, Atlanta
2004	Director and Speaker, Glaxo Preceptorship Program at Emory
2004	Speaker, Pfizer Preceptorship Program at Emory
2002	Established the weekly Pulmonary Research Conference at Emory
1999-01	Organizer of the Annual Roland H. Ingram Honorary Lecture, Emory
2002	Lecturer, Respiratory Faculty Development Forum, March 23-24, Chateau Elan, Georgia. Sponsored by AstraZeneca.
1991-94, 1998-05	Lecturer, Internal Medicine Board Review Course, Emory University
1997-03	Speaker in <i>Annual Asthma Workshop</i> (Chateau Elan, GA; sponsored by Emory; provided to general practitioners, nurses, and respiratory therapists)
1999-02	Speaker in <i>Annual Advances in Pulmonary Medicine Course</i> (San Destin, FL, provided to Pulmonary/Critical Care practitioners; sponsored by Emory)
1998, 99	Speaker in <i>Annual COPD Workshop</i> (Chateau Elan, GA; sponsored by Emory, provided to general practitioners, nurses, and respiratory therapists)
1991-98	Organizer of Monthly Pulmonary Research Conference, Emory University

## Supervisory Teaching

### Masters Degree students supervised

Period	Name	Current Position	Funding for Training*
2007-08	Megan C. Lofton	Department of Bioengineering Member, Thesis Committee	Bioengineering Georgia Tech
2010-12	Daniel Fioret	Mentor, Medical Student Chair, Thesis Committee	Pharm/Toxicol UofL SOM

**PhD students directly supervised**

Period	Name	Current Position	Funding for Training*
2011-12	Veronica Massey Mentor: Arteel	Masters Student Member, Thesis Committee	Pharm/Toxicol UofL SOM
2010-12	Glenn Vicary	Masters Student Chair, Thesis Committee	Pharm/Toxicol
2011-15	John Greenwell	Masters Student Chair, Thesis Committee	Pharm/Toxicol
2014-16	Lauren Pool Mentor: Arteel	Masters Student Member, Thesis Committee	Pharm/Toxicol
2015-17	Zimple Kurlawala Mentor: Beverly	Masters Student Member, Thesis Committee	Pharm/Toxicol
2013-16	Jeffrey Marshall Mentors: Potempa/Roman	Co-mentor, Master Student Member, Thesis Committee	UofL Sch of Dentistry
2015-15	Cierra N. Sharp	Master's Defense Committee	UofL
2015-17	Douglas Saforo	Dissertation Committee MD/PhD Student	UofL SOM
2013-16	Christopher J. Flemming	MD/PhD student Member, Dissertation Thesis	UofL SOM
2012-16	Glenn Vicary	Pre-doctoral Student Department Pharm/Tox University of Louisville	Pharm/Toxicology NIH R01, T35

**PhD students directly supervised (continued)**

Period	Name	Current Position	Funding for Training*
2015-17	John Greenwell	Pre-doctoral Student Department of Pharm/Tox University of Louisville	Pharm/Toxicol
2015-18	Ryan McAllister	Pre-doctoral student Department of Pharm/Tox University of Louisville	

2016-2020	Yuxuan Zheng	Pre-doctoral student Department of Pharm/Tox University of Louisville	
1991-92	Young June-Jeon, MD	Associate Professor Department of Medicine, Keimyung University, Taegu, Korea	Korean Gov.
1991-95	Rafael L. Perez, MD	Professor Department of Medicine University of Louisville, KY	ALA Emory
1992-94	Karen L. Graves, MD	Private Practice Nashville, TN	NRSA, NIH Emory
1994-95	Cynthia Sundell, Ph.D.	Research Assistant Professor Department of Medicine Emory Univ Sch of Medicine Atlanta, GA	MR
1995-96	Kathleen Cannella, Ph.D.	Clinical Nurse Coordinator VAMC in Atlanta	DVA
1996-99	Bonnie Boles, MD	Private Practice Georgia	Emory, ALA, NRSA, Glaxo
1999-00	Manuel Lois, MD Co-mentor with Dr. Guidot	Private Practice Texas	Emory
1998-99	Jeffrey Michaelson, MD	Private Practice Georgia	Emory
1999	David G. Dillard, MD (co-mentor)	Private Practice Georgia	ENT Division Emory

**PhD students directly supervised (continued)**

Period	Name	Current Position	Funding for Training*
2000-01	Alcides Gil-Acosta, MD	Private Practice Indiana	AHA, Emory
1997-2002	Carlos A. Rivera, PhD	Assistant Research Professor Department of Biochemistry Emory University	MR Type II, DVA, Emory

2000	Howard Silverboard, MD	Private Practice Atlanta, Georgia	Emory
2000-01	Rabih Bechara, MD Co-sponsor with Dr. Guidot	Assistant Professor Department of Medicine Emory University, Atlanta, GA	Emory
2001-02	Theresa Jarmuz, MD	ENT Practice Atlanta, GA	ENT Division, Emory
2002-05	Sumita Katri, MD	Assistant Professor Pulmonary Division Cleveland Clinic	NIH K-12
2002-03	Shari Lydi, PhD	Senior Research Associate Centers for Disease Control, Atlanta	NIH
2002-09 2011-13	Allan Ramirez, MD	Associate Professor Pulmonary Division University of Louisville, KY	McKelvey Ctr. Foundation KO8
2003-04	Rade Tomic, MD	Private Practice, Winsconsin	
2004-2009	Cherry Wongtrakool, MD	Assistant Professor Pulmonary Division Emory University, Atlanta	NIH-K08 ATS Award
2005-07	Basel Ramadan, MD	Private Practice	Foundation Funds
2005-06	Mubina Gaffar, MD	Private Practice Oklahoma	Division Funds
2005-06	Anitra Graves, MD	Private Practice after a year on faculty	NIH T32; VA

**PhD students directly supervised (continued)**

Period	Name	Current Position	Funding for Training*
2005-07	Corey Kershaw, MD	Assistant Professor, Dallas, TX	NIH T32
2005-07	Annette Esper, MD	Assistant Professor Department of Medicine at Emory	NIH T32
2006-07	Seth Clemens, MD	Assistant Professor Department of Medicine at Emory	NIH T32

2007-09	Helen Ward, MD	Private Practice Atlanta, Georgia	NIH T32
2007-09	Sushma Cribbs, MD	Assistant Professor Pulmonary Med Emory, Atlanta, GA	NIH T32
2008-09	Gloria Wesley, MD	Associate Professor in Pulmonary Med Morehouse School of Medicine	
2008-10	Faisal Ahmad, MD	Private Practice Atlanta, GA	Schild Found.
2008-10	Carter Co, MD (co-mentor)	Fellow in Pulmonary Medicine Department of Medicine at Emory	NIH T32
2007-09	Yeng Zheng, MD, PhD	Postdoctoral Fellow Tianjin Medical University Tianjin Lung Cancer Institute, China	NIH R01
2009-11	Zhong, XiaoRong, MD, PhD	Postdoctoral Fellow Tianjin Medical University Tianjin Lung Cancer Institute, China	
2009-10	Sun, XiaoJuan, MD, PhD	Postdoctoral Fellow Huhan Medical University, China	K22
2009-11	Wang, Ke, MD, PhD	Postdoctoral Fellow Sichuan University First Univ. Hospital, China	VA Merit
2009-12	Zhang, WenJin, MD, PhD	Postdoctoral Fellow Sichuan University 2 <sup>nd</sup> University Hospital, China	VA Merit

**PhD students directly supervised (continued)**

Period	Name	Current Position	Funding for Training*
2009-12	Fan, Yu MD, PhD.	Postdoctoral fellow Tianjin Medical University	VA Merit
2009-10	Karla Tarfur, MD	Pulmonary Fellow Universidad Cayetano Heredia, Peru	Cayetano
2014-16	Karim El-Kersh, MD	Fellow	Divisional funds

		UofL Pulmonary Division	
2014-pres	Hiram Rivas-Perez, MD	Assistant Professor UofL Pulmonary Division	Divisional funds
2016-18	Sally Sulliman, MD	Pulmonary Fellow UoL Pulmonary Division	Divisional funds
2018-pres	M. Venkata Subramini, MD	Pulmonary Fellow Thomas Jefferson U	Division funds
2019-pres	Pooja Pandit, MD	Pulmonary Fellow Thomas Jefferson U	Divisional funds
2021-23	Andrea Oh, MD	PFF Scholar	Pulm Fibrosis Found

### Residency program

Period	Name	Current Position	Funding for Training*
1994-95-96 (summers)	John Millstine	Unknown	MR
1992-93 (summer)	Sidney Jones, MD	Private Practice	Emory
1995 (summer)	Lena Dutta, MD	Unknown	Emory
1999	Silpa Reddy, MD	Private Practice	Private Foundation
2000 (summer)	Nikiva Bernard, MD	Resident, Internal Medicine Emory University	ALA

### Residency program (continuation)

Period	Name	Current Position	Funding for Training*
2001 (2 months)	Charles Lassiter, MD	Private Practice Georgia	Emory
2003 (2 mo)	Shrinine Allam, MD	Assistant Professor Pulmonary Medicine, Emory	Emory
2004 (1 mo)	Ashish Mehta, MD	Fellow in Pulmonary/CCM	Emory

		Department of Medicine	
2005 (1 mo)	Alex Guzman, MD	Fellow in Pulmonary/CCM Department of Medicine	Emory
2010 (1 mo)	Tanmay Panchabhai, MD	Resident UofL Department of Medicine	UofL

### Medical Students

Period	Name	Current Position	Funding for Training*
2011-11	Justin Choi	Medical Student University of Louisville	UofL
2012-12	Sean T. Butterbaugh	Undergraduate Student University of Louisville	UofL
2013	Matthew Cook R25(Summer)	Undergraduate Student Emory University	NCI
2016	Javier Otero	Medical Student Ponce Health Sciences Ctr, PR	UofL
2021- 21	Brian Im	Medical Student 1 Sidney Kimmel Col Med	
2021-21	Marco Dispagna	Medical Student 1 <sup>st</sup> year Sidney Kimmel Coll Med	
2021-22	Roy Samuel	Medical Student 1 <sup>st</sup> year Sidney Kimmel Coll Med	

\* NRSA: National Research Service Award; NIH: National Institutes of Health; MR: Merit Review; DVA: Department of Veterans Affairs; ALA: American Lung Association; AHA: American Heart Association)

### Consultantships

2024-pres	Member, Data Safety Monitoring Board (DSMB), CONQUEST Trial testing anti-fibrotic agents in Scleroderma (Sponsor: Scleroderma Research Foundation).
2022-pres	Member, Independent Oversight Committee (IOC) for ENDCOVI Clinical Trial evaluating the effect of nintedanib in COVID related lung fibrosis (Sponsor: BI)
2020-21	Coordinator, COVID-19 clinical trials for Boehringer Ingelheim, Inc.



- 2021-22 Chair, IDMC, Interleukin-22 and COVID-19 (IL-2-COVID-19) clinical trial. Evive Biotech. Studied closed due to poor recruitment.
- 2021- pres Member, Clinical Trials Review Committee (NIH, NHLBI) (starting 6/2021)
- 2021-pres Member, Data Safety Monitoring Board (DSMB), Phase 2 trial, Saracatinib in IPF. STOP-IPF ; 3UH3TR002445; NCT04598919). AstraZeneca and NIH
- 2020-pres Member, Data Monitoring Committee (DMC). Generon GC-625-04 : A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22:IgG2 Fusion Protein) in Patients with Moderate to Severe COVID-19. *Medpace, Inc.*
- 2020-pres Member, Data Safety Monitoring Board (DSMB), Clinical trial of saracatinib in the treatment of idiopathic pulmonary fibrosis. HS-32-1, NCATS
- 2019-pres Member, Adjudication Committee, Clinical trial, *Novartis*
- 2018-21 Member, DSMB, Phase 2 trial, VAY736A2101, *Novartis*
- 2017-20 Chair, Data Safety Monitoring Board (DSMB), Phase 2 trial, Pirfenidone in RA-related ILD, *Genentech*
- 2015-pres Consultant, *Best Doctors*
- 2018 Consultant, *Theravance Biopharma*
- 2012-15 Chair, Data Safety Monitoring Board (DSMB), Phase 1 trial in IPF, *National Institutes of Health*
- 2012-14 Chair, Adjudication Committee, IPF Phase 3 trial, *Boehringer Ingelheim*
- 2012 Consultant, *Moerae Matri, Inc.*
- 2011-12 Chair, Data Safety Monitoring Board (DSMB), Phase I trial – IPF, *Celgene*
- Consultantships (continuation)**
- 2007-08 Consultant, *Cyclacel Pharmaceuticals, Inc.*
- 2007-08 Steering Committee Member, Phase II Clinical Study, *Novartis*
- 2006-08 Data Safety Monitoring Board, Phase I Clinical Study, *Genzyme*
- 2005 Postgraduate Institute of Medicine Grand Rounds Program on COPD

- 2003-09 External Advisory Committee; Univ. of Indiana Training Program in Molecular Physiology and Clinical Mechanisms of Lung Disease
- 2003-17 Medical Advisory Board (Chair, 2015-17), *Pulmonary Fibrosis Foundation*
- 2003-pres Scientific Advisory Committee & Grant Reviewer, *Pulmonary Fibrosis Foundation*
- 2002 US Consultancy Meeting, COPD and Asthma, *AstraZeneca*
- 2000 Member COPD Advisory Board in Georgia, *GlaxoSmithKline, Inc.*
- 2000 Member Advisory Board for Educational Website entitled: Asthma Educ. of Hispanic Communities in the US, Health Alliances, Inc.

## Summary

Dr. Jesse Roman is a physician-scientist who serves as the Ludwig Kind Professor of Medicine and Pharmacology & Experimental Therapeutics, Founding CEO of the Jane & Leonard Korman Respiratory Institute, and Enterprise Leader for Respiratory Medicine of Jefferson Health at Thomas Jefferson University, Philadelphia, PA. For over three decades, Dr. Roman has played leadership roles in regional/national/international professional organizations and has served on important posts in academic institutions in the U.S. including Georgia (Emory University, 1991-2009), Kentucky (University of Louisville, 2009-2018), and Pennsylvania (Thomas Jefferson University, 2018-pres). He also served as staff physician in the Department of Veterans Affairs

for 30 years. He has served as division director of three successful pulmonary & critical care medicine divisions as well as department chair and institute director. Dr. Roman has also served as a full-time member of study sections of the federal government (e.g., National Institutes of Health [currently on the Clinical Trials Study Section], Department of Veterans Affairs, and Department of Defense) and private organizations (e.g., American Thoracic Society, American Lung Association, and currently on the Pulmonary Fibrosis Foundation). Dr. Roman's basic, translational, and clinical research has generated over 250 publications and 30 book chapters. His basic research focuses on fibroblast biology and lung tissue remodeling and has been continuously funded since 1989, having served as principal investigator or collaborator on multiple federal (e.g., NIH, VA, DOD) and foundation grants attracting over 35 million dollars in direct costs over his career. He has also participated in over 32 clinical trials and has served on Data Safety Monitoring Boards and Adjudication Committees of multi-center and multi-national clinical trials. Dr. Roman has been actively engaged in efforts to promote diversity including his role as founding chair of the Diversity and Inclusion Committee of the American Thoracic Society and he currently serves on the department's DEI Advisory Council. He also serves as the first Treasurer of the American Thoracic Society (2022-pres) and Editor-in-Chief of the American Journal for the Medical Sciences (2017-pres). Regarding education, he was the PI of an NIH T32 Institutional Training Grant (2004-2009), served as preceptor on several others, and recently served as fellowship program director at Jefferson (2018-2023). More recently, he engaged in efforts to improve the care of patients with pulmonary fibrosis and Hermansky Pudlak Syndrome in the island of Puerto Rico through infrastructure building in collaboration with the HPS Network. Dr. Roman has delivered over 180 invited lectures in the US and abroad and has won several awards. However, he is most proud of the over 150 faculty he has helped recruit into academic medicine and the more than 70 students, residents, fellows, and junior faculty he mentored consistent with his stated mission of using his laboratory and clinic as a classroom for those interested in developing careers as clinician investigators in academic medicine. Today, at least 11 of Dr. Roman's mentees (4 Assistant Professors, 6 Associate Professors, 1 Professor) are in leadership roles as section chiefs or leading programs in lung transplantation, sarcoidosis, pulmonary hypertension, and interstitial lung disease, among others.